PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12N 15/24, 21/02, C07K 13/00, C12N 15/62, 1/61, A61K 37/02

A2

(11) International Publication Number: WO 94/12638

(43) International Publication Date: 9 June 1994 (09.06.94)

(21) International Application Number: PCT/US93/11197

(22) International Filing Date: 22 November 1993 (22.11.93)

(30) Priority Data:
07/981,044 24 November 1992 (24.11.92) US

(60) Parent Application or Grant
(63) Related by Continuation
US 07/981,044 (CIP)
Filed on 24 November 1992 (24.11.92)

(71) Applicants *(for all designated States except US)*: G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). THE MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63166 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BAUER, S., Christopher [US/US]; Box 108A, RR #1, New Haven, MO 63068 (US). ABRAMS, Mark, Allen [US/US]; 7723 Blackberry Avenue, St. Louis, MO 63130 (US). BRAFORD-GOLDBERG, Sarah, Ruth [US/US]; 4111 West Pine #10, St. Louis, MO 63108 (US). CAPARON, Maire, Helena [US/US]; 109 Beechwood Court, Chesterfield, MO 63017 (US). EASTON, Alan, Michael [US/US]; 2317 Seven Pines Drive #7, Maryland Heights, MO 63146 (US). KLEIN, Barbara, Kure [US/US]; 12917 Topping Estates, Town and Country, MO 63131 (US). MCKEARN, John, Patrick [US/US]; 1430 Highway C., Glencoe, MO 63038 (US). OLINS, Peter, O. [US/US]; 17507 Summit View, Glencoe, MO 63038 (US). PAIK, Kumnan [US/US]; 1021 Alpine Ridge, Ballwin, MO 63021 (US). THOMAS, John, Warren [US/US]; 13426 Mason Valley Court, Town & Country, MO 63131 (US).

(74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: INTERLEUKIN-3 (IL-3) MULTIPLE MUTATION POLYPEPTIDES

(57) Abstract

The present invention relates to a recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids 119 to 133 have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				

INTERLEUKIN-3 (IL-3) MULTIPLE MUTATION POLYPEPTIDES

This is a continuation-in-part of United States Application Serial No. 07/981,044 filed November 24, 1992 which is incorporated herein by reference.

Field of the Invention

The present invention relates to mutants or variants of human interleukin-3 (hIL-3) which contain multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. These hIL-3 multiple mutation polypeptides retain one or more activities of native hIL-3 and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with native hIL-3.

Background of the Invention

Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.

Because of its ability to stimulate the proliferation of a number of different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic

treatments such as radiation and chemotherapy.

Interleukin-3 (IL-3) is a hematopoietic growth factor which has the property of being able to promote the survival, growth and differentiation of hematopoietic cells. Among the biological properties of IL-3 are the ability (a) to support the growth and differentiation of progenitor cells committed to all, or virtually all, blood cell lineages; (b) to interact with early multipotential stem cells; (c) to sustain the growth of pluripotent precursor cells; (d) to stimulate proliferation of chronic myelogenous leukemia (CML) cells; (e) to stimulate proliferation of mast cells, eosinophils and basophils; (f) to stimulate DNA synthesis by human acute myelogenous leukemia (AML) cells; (g) to prime cells for production of leukotrienes and histamines; (h) to induce leukocyte chemotaxis; and (i) to induce cell surface molecules needed for leukocyte adhesion.

Mature human interleukin-3 (hIL-3) consists of 133 amino acids. It has one disulfide bridge and two potential glycosylation sites (Yang, et al., CELL 47:3 (1986)).

Murine IL-3 (mIL-3) was first identified by Ihle, et al., J. IMMUNOL. 126:2184 (1981) as a factor which induced expression of a T cell associated enzyme, 20 - hydroxysteroid dehydrogenase. The factor was purified to homogeneity and shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells.

In 1984, cDNA clones coding for murine IL-3 were isolated (Fung, et al., NATURE 307:233 (1984) and Yokota, et al., PROC. NATL. ACAD. SCI. USA 81:1070 (1984)). The murine DNA sequence coded for a polypeptide of 166 amino acids including a putative signal peptide.

The gibbon IL-3 sequence was obtained using a gibbon cDNA expression library. The gibbon IL-3 sequence was then used as a probe against a human genomic library to obtain a human IL-3 sequence.

Gibbon and human genomic DNA homologues of the murine IL-3 sequence were disclosed by Yang, et al., CELL 47:3 (1986). The human sequence reported by Yang, et al. included a serine residue at position 8 of the mature protein sequence. Following this finding, others reported isolation of Pro^8 hIL-3 cDNAs having proline at position 8 of the protein sequence. Thus it appears that there may be two allelic forms of hIL-3.

Dorssers, et al., GENE 55:115 (1987), found a clone from a human cDNA library which hybridized with mIL-3. This hybridization was the result of the high degree of homology between the 3' noncoding regions of mIL-3 and hIL-3. This cDNA coded for an hIL-3 (Pro^8) sequence.

U.S. 4,877,729 and U.S. 4,959,454 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

Clark-Lewis, et al., SCIENCE 231:134 (1986) performed a functional analysis of murine IL-3 analogues synthesized with an automated peptide synthesizer. The authors concluded that the stable tertiary structure of the complete molecule was required for full activity. A study on the role of the disulfide bridges showed that replacement of all four cysteines by alanine gave a molecule with 1/500th the activity as the native molecule. Replacement of two of the four Cys residues by Ala(Cys^{79}, Cys^{140} -> Ala^{79}, Ala^{140}) resulted in an increased activity. The authors concluded that in murine IL-3 a single disulfide bridge is required between cysteines 17 and 80 to get biological activity that approximates physiological levels and that this structure probably stabilizes the tertiary structure of the protein to give a conformation that is optimal for function. (Clark-Lewis, et al., PROC. NATL. ACAD. SCI. USA 85:7897 (1988)).

International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser^8 -> Pro^8 replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge,

and to replace one or more amino acids at the glycosylation sites.

EP-A-0275598 (WO 88/04691) illustrates that Ala^1 can be deleted while retaining biological activity. Some mutant hIL-3 sequences are provided, e.g., two double mutants, Ala^1 -> Asp^1, Trp^{13} -> Arg^{13} (pGB/IL-302) and Ala^1 -> Asp^1, Met^3 -> Thr^3 (pGB/IL-304) and one triple mutant Ala^1 -> Asp^1, Leu^9 -> Pro^9, Trp^{13} -> Arg^{13} (pGB/IL-303).

WO 88/05469 describes how deglycosylation mutants can be obtained and suggests mutants of $Arg^{54}Arg^{55}$ and $Arg^{108}Arg^{109}Lys^{110}$ might avoid proteolysis upon expression in Saccharomyces cerevisiae by KEX2 protease. No mutated proteins are disclosed. Glycosylation and the KEX2 protease activity are only important, in this context, upon expression in yeast.

WO 88/06161 mentions various mutants which theoretically may be conformationally and antigenically neutral. The only actually performed mutations are Met^2 -> Ile^2 and Ile^{131} -> Leu^{131}. It is not disclosed whether the contemplated neutralities were obtained for these two mutations.

WO 91/00350 discloses nonglycosylated hIL-3 analog proteins, for example, hIL-3 ($Pro^8Asp^{15}Asp^{70}$), Met^3 rhuI-3 ($Pro^8Asp^{15}Asp^{70}$); Thr^4 rhuL-3 ($Pro^8Asp^{15}Asp^{70}$)and Thr^6 rhuIL-3 ($Pro^8Asp^{15}Asp^{70}$). It is said that these protein compositions do not exhibit certain adverse side effects associated with native hIL-3 such as urticaria resulting from infiltration of mast cells and lymphocytes into the dermis. The disclosed analog hIL-3 proteins may have N termini at Met^3, Thr^4, or Thr^6.

WO 91/12874 discloses cysteine added variants (CAVs) of IL-3 which have at least one Cys residue substituted for a naturally occurring amino acid residue.

Summary of the Invention

The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at either/or both the N- and C- termini. Preferably, these mutant polypeptides of the present invention contain four or more amino acids which differ from the amino acids found at the corresponding positions in the native hIL-3 polypeptide. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins, DNA coding for the muteins, and methods for using the muteins. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems.

The present invention includes mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus, and in which multiple amino acid substitutions have been made. Preferred muteins of the present invention are those in which amino acids 1 to 14 have been deleted from the N-terminus, amino acids 126 to 133 have been deleted from the C-terminus, and which also contain from about four to about twenty-six amino acid substitutions in the polypeptide sequence. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile, i.e., some muteins may have a better therapeutic index than native hIL-3. The present invention also provides muteins which may function as IL-3 antagonists or as discrete antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols. In addition to the use of the hIL-3 multiple mutation polypeptides of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and

blood cell activation and growth before infusion into patients.

Antagonists of hIL-3 would be particularly useful in blocking the growth of certain cancer cells like AML, CML and certain types of B lymphoid cancers. Other conditions where antagonists would be useful include those in which certain blood cells are produced at abnormally high numbers or are being activated by endogenous ligands. Antagonists would effectively compete for ligands, presumably naturally occurring hemopoietins including and not limited to IL-3, GM-CSF and IL-5, which might trigger or augment the growth of cancer cells by virtue of their ability to bind to the IL-3 receptor complex while intrinsic activation properties of the ligand are diminished. IL-3, GM-CSF and/or IL-5 also play a role in certain asthmatic responses. An antagonist of the IL-3 receptor may have the utility in this disease by blocking receptor-mediated activation and recruitment of inflammatory cells.

Brief Description of the Drawings

Figure 1 is the human IL-3 gene for E. coli expression (pMON5873), encoding the polypeptide sequence of natural (wild type) human IL-3 [SEQ ID NO:128], plus an initiator methionine, as expressed in E. coli, with the amino acids numbered from the N-terminus of the natural hIL-3.

Figure 2: ClaI to NsiI Replacement Fragment. Figure 2 shows the nucleotide sequence of the replacement fragment used between the ClaI and NsiI sites of the hIL-3 gene. The codon choice used in the fragment corresponds to that found in highly expressed E. coli genes (Gouy and Gautier, 1982). Three new unique restriction sites, EcoRV, XhoI and PstI were introduced for the purpose of inserting synthetic gene fragments. The portion of the coding sequence shown encodes hIL-3 amino acids 20-70.

Figure 3 shows the nucleotide and amino acid sequence of the gene in pMON5873 with the sequence extending from NcoI through HindIII. The codon choices used to encode amino acids 1-14 and 107-133 correspond to that found in

highly expressed E. coli genes.

Figure 4 shows the construction of the plasmid vector pMON5846 which encodes [Met-(1-133) hIL-3 (Arg^{129})].

Figure 5 shows the construction of the plasmid vector pMON5847 (ATCC 68912) which encodes [Met-(1-133) hIL-3 (Arg^{129})].

Figure 6 shows the construction of plasmid vector pMON5853 which encodes [Met-(15-133) hIL-3 (Arg^{129})].

Figure 7 shows the construction of the plasmid vector pMON5854 which encodes [Met-(1-133) hIL-3 (Arg^{129})].

Figure 8 shows the DNA sequence and resulting amino acid sequence of the LamB signal peptide.

Figure 9 shows the construction of the plasmid vector pMON5978 which encodes Met-Ala-(15-125)hIL-3.

Figure 10 shows the construction of the plasmid vector pMON5988 which encodes Met-Ala(15-125)hIL-3.

Figure 11 shows the construction of the plasmid vector pMON5887 which encodes Met-(1-125)hIL-3.

Figure 12 shows the construction of pMON6457 which encodes (15-125)hIL-3; it contains the araBAD promoter and the LamB signal peptide fused to the variant hIL-3 amino acids 15-125.

Figure 13 shows the construction of pMON6458; it contains the araBAD promoter and the LamB signal peptide fused to the variant hIL-3 amino acids 15-125.

Figure 14 shows the construction of pMON13359.

Figure 15 shows the construction of pMON13352.

Figure 16 shows the construction of pMON13360.

Figure 17 shows the construction of pMON13363.

Figure 18 shows the construction of pMON13364.

Figure 19 shows the construction of pMON13365.

Figure 20 shows the construction of pMON13287.

Figure 21 shows the construction of pMON13288.

Figure 22 shows the construction of pMON13289.

Figure 23 shows the construction of pMON5723.

Figure 24 shows the construction of pMON13438.

Detailed Description of the Invention

The present invention relates to muteins of human interleukin-3 (hIL-3) in which amino acid substitutions have been made at four or more positions in amino acid sequence of the polypeptide and to muteins which have substantially the same structure and substantially the same biological activity. Preferred muteins of the present invention are (15-125)hIL-3 deletion mutants which have deletions of amino acids 1 to 14 at the N-terminus and 126 to 133 at the C-terminus and which also have four or more amino acid substitutions in the polypeptide and muteins having substantially the same structure and substantially the same biological activity. Among the preferred muteins are those having twenty-six amino acid substitutions. As used herein human interleukin-3 corresponds to the amino acid sequence (1-133) as depicted in Figure 1 and (15-125) hIL-3 corresponds to the 15 to 125 amino acid sequence of the hIL-3 polypeptide. Naturally occurring variants of hIL-3 polypeptide amino acids are also included in the present invention (for example, the allele in which proline rather than serine is at position 8 in the hIL-3 polypeptide sequence) as are variant hIL-3 molecules which are modified post-translationally (e.g. glycosylation).

The present invention also includes the DNA sequences which code for the mutant polypeptides, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the muteins of the invention only due to the degeneracy of the genetic code.

Included in the present invention are novel mutant human interleukin-3 polypeptides comprising a polypeptide having the amino acid sequence of native human interleukin-3 wherein amino acids 126 to 133 have been deleted from the C-terminus of the native human interleukin-3 polypeptide and amino acids 1 to 14 have been deleted from the N-terminus of the native human interleukin-3 polypeptide and, in addition, polypeptides also have four or more amino acid substitutions in the polypeptide sequence.

Also included in the present invention are the DNA sequences coding for the muteins of the present invention; the oligonucleotide intermediates used to construct the mutant DNAs; and the polypeptides coded for by these oligonucleotides. These polypeptides may be useful as antagonists or as antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols.

The mutant hIL-3 polypeptides of the present invention may also have methionine, alanine, or methionine-alanine residues inserted at the N-terminus.

The present invention includes human interleukin-3 mutant polypeptide Formula I:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:15]
125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;
Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;
Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;
Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;
Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp, Leu, or Val;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn, or Ala;
Xaa at position 40 is Leu, Trp, or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;
Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,

Gln, Arg, Thr, Gly or Ser;
Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;
Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;
Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;
Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;
Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;
Xaa at position 57 is Asn or Gly;
Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;
Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;
Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, Asp, or Ile;
Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;
Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;
Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly,

or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His,

Ala,
or Pro;
Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys,
Ser, Ala, Trp, Phe, Ile, or Tyr;
Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;
Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;
Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr,
Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,
Gly, Ser, Phe, or His;
Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln,
or Pro;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,
Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;
Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
Xaa at position 103 is Asp, or Ser;
Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,
Gln, Lys, Ala, Phe, or Gly;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,
Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala
or Pro;
Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;
Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser,
Ala, or Trp;
Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,
Lys, Leu, Ile, Val or Asn;
Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,
Trp, or Met;
Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,
Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;
Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.

Included in the present invention are human interleukin-3 mutant polypeptide of the Formula II:

```
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1               5                  10                  15

Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa
                20                  25                  30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa
                35                  40                  45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa
                50                  55                  60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
                65                  70                  75

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa
                80                  85                  90
```

Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa
95 100 105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:16]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 20 is Ile or Pro;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Phe, Gly, Arg, or Ala;
Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 29 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp or Leu;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn or Ala;
Xaa at position 41 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;

Xaa at position 47 is Ile, Val, or His;

Xaa at position 49 is Met, Asn, or Asp;

Xaa at position 50 is Glu, Thr, Ala, Asn, Ser or Asp;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn or Gly;

Xaa at position 53 is Leu, Met, or Phe;

Xaa at position 54 is Arg, Ala, or Ser;

Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;

Xaa at position 59 is Glu, Tyr, His, Leu, or Arg;

Xaa at position 60 is Ala, Ser, Asn, or Thr;

Xaa at position 61 is Phe or Ser;

Xaa at position 62 is Asn, Val, Pro, Thr, or Ile;

Xaa at position 63 is Arg, Tyr, Lys, Ser, His, or Val;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val, Thr, Leu, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Phe, Val, Gly, Asn, Ile, or His;

Xaa at position 68 is Leu, Val, Ile, Phe, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 70 is Asn or Pro;

Xaa at position 71 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;

Xaa at position 74 is Ile or Met;

Xaa at position 75 is Glu, Gly, Asp, Ser, or Gln;

Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, or Leu;

Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, or Val;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, or Met;

Xaa at position 85 is Leu or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala, Arg, or Trp;

Xaa at position 89 is Thr, Asp, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Asp, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;

Xaa at position 92 is Pro or Ser;

Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;

Xaa at position 96 is Pro or Tyr;

Xaa at position 97 is Ile, Val, or Ala;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Leu, Arg, Gln,
Glu, lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 99 is Ile, Leu, Val, or Phe;

Xaa at position 100 is Lys, Leu, His, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;

Xaa at position 102 is Gly, Glu, Lys, or Ser;

Xaa at position 104 is Trp, Val, Tyr, Met, or Leu;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, or Gly;

Xaa at position 108 is Arg, Ala, Gln, Ser or Lys;

Xaa at position 109 is Arg, Thr, Glu, Leu, Ser, or Gly;

Xaa at position 112 is Thr, Val, Gln, Glu, His, or Ser;

Xaa at position 114 is Tyr or Trp;

Xaa at position 115 is Leu or Ala;

Xaa at position 116 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;

Xaa at position 117 is Thr, Ser, or Asn;

Xaa at position 119 is Glu, Ser, Pro, Leu, Thr, or Tyr;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.

Included in the present invention are human interleukin-3 mutant polypeptide of the Formula III:

```
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1               5                  10                  15

Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa
                20                  25                  30

Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa
                35                  40                  45

Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa
                50                  55                  60

Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu
                65                  70                  75

Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala
                80                  85                  90

Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa
                95                 100                 105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa
```

110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:17]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 19 is Met or Ile;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, or Leu;
Xaa at position 25 is Thr, His, Gln, or Ala;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln, Asn, or Val;
Xaa at position 30 is Pro, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 37 is Phe, Ser, Pro, or Trp;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 54 is Arg or Ala;
Xaa at position 54 is Arg or Ala;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;

Xaa at position 60 is Ala or Ser;
Xaa at position 62 is Asn, Pro, Thr, or Ile;
Xaa at position 63 is Arg or Lys;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 66 is Lys or Arg;
Xaa at position 67 is Ser, Phe, or His;
Xaa at position 68 is Leu, Ile, Phe, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 71 is Ala, Pro, or Arg;
Xaa at position 72 is Ser, Glu, Arg, or Asp;
Xaa at position 73 is Ala or Leu;
Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 83 is Pro or Thr;
Xaa at position 85 is Leu or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;
Xaa at position 96 is Pro or Tyr;
Xaa at position 97 is Ile or Val;
Xaa at position 98 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 99 is Ile, Leu, or Val;
Xaa at position 100 is Lys, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 104 is Trp or Leu;
Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu or Gly;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr, Val, or Gln;
Xaa at position 114 is Tyr or Trp;
Xaa at position 115 is Leu or Ala;
Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 35 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3.

Included in the present invention arehuman interleukin-3 mutant polypeptide of the Formula IV:

Ala	Pro	Met	Thr	Gln	Thr	Thr	Ser	Leu	Lys	Thr	Ser	Trp	Val	Asn	
1				5				10						15	

Cys	Xaa	Xaa	Met	Ile	Asp	Glu	Xaa	Ile	Xaa	Xaa	Leu	Lys	Xaa	Xaa	
				20				25						30	

Pro	Xaa	Pro	Xaa	Xaa	Asp	Phe	Xaa	Asn	Leu	Asn	Xaa	Glu	Asp	Xaa	
				35				40						45	

Xaa	Ile	Leu	Met	Xaa	Xaa	Asn	Leu	Arg	Xaa	Xaa	Asn	Leu	Glu	Ala	
				50				55						60	

Phe	Xaa	Arg	Xaa	Xaa	Lys	Xaa	Xaa	Xaa	Asn	Ala	Ser	Ala	Ile	Glu	

65 70 75

Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala
80 85 90

Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa
95 100 105

Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:18]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 25 is Thr, His, or Gln;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln or Asn;
Xaa at position 30 is Pro or Gly;
Xaa at position 32 is Leu, Arg, Asn, or Ala;
Xaa at position 34 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met;
Xaa at position 35 is Leu, Ala, Asn, or Pro;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 45 is Gln, Val, Met, Leu, Ala, Asn, Glu, or Lys;
Xaa at position 46 is Asp, Phe, Ser, Gln, Glu, His, Val or Thr;
Xaa at position 50 is Glu Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Pro, Thr, or His;
Xaa at position 55 is Arg, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 62 is Asn, Pro, or Thr;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;

Xaa at position 67 is Ser or Phe;
Xaa at position 68 is Leu or Phe;
Xaa at position 69 is Gln, Ala, Glu, or Arg;
Xaa at position 76 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Gly, Asn, Met, Arg, Ile, or Gly;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, or Ala;
Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 98 is His, Ile, Asn, Ala, Thr, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 99 is Ile or Leu;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 105 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr or Gln;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 122 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 123 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3.

Included in the present invention are (15-125)human interleukin-3 mutant polypeptides of the Formula V:

Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:19]
110

wherein
Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
Xaa at position 6 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;
Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, or Gly;
Xaa at position 9 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 10 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 13 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 14 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 15 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;
Xaa at position 21 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 22 is Asp, Leu, or Val;
Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 24 is Asn, or Ala;
Xaa at position 26 is Leu, Trp, or Arg;
Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met, Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, Phe, Tyr, Ile or Met;
Xaa at position 29 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;
Xaa at position 30 is Asp, Ser, Leu, Arg, Lys, Thr,Met, Trp, Glu, Asn, Gln, Ala or Pro;
Xaa at position 31 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, Ser, Ala, Ile, Glu, His or Trp;
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;
Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 34 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 39 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser,

Met, or;

Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 41 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 43 is Asn or Gly;

Xaa at position 44 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 45 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 50 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 51 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 54 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 56 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 57 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 60 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 63 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 64 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;

Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 67 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 68 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 69 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 70 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 71 is Leu, Asn, Val, or Gln;

Xaa at position 72 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 73 is Leu, Ser, Trp, or Gly;

Xaa at position 74 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 79 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 80 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro;

Xaa at position 81 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile or Tyr;

Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 83 is Ile, Val, Lys, Ala, or Asn;

Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;

Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, Pro;

Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu or Gln;

Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 89 is Asp, or Ser;

Xaa at position 90 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro;

Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 96 is Lys, Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala or Trp;
Xaa at position 97 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 98 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;
Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 101 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;
Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;
Xaa at position 103 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 104 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;
Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 106 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding native amino acids of (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Included in the present invention are (15-125)human interleukin-3 mutant polypeptides of the Formula VI:

```
Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa
 1               5                  10                  15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa
                20                  25                  30
```

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:20]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 6 is Ile or Pro;
Xaa at position 7 is Asp, or Glu;
Xaa at position 9 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Phe, Gly, Arg, or Ala;
Xaa at position 14 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 15 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;

Xaa at position 22 is Asp or Leu;

Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;

Xaa at position 24 is Asn or Ala;

Xaa at position 27 is Asn, Cys, Arg, His, Met, or Pro;

Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg;

Xaa at position 30 is Asp, or Glu;

Xaa at position 31 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn Glu, Ser or Trp;

Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;

Xaa at position 33 is Ile, Val, or His;

Xaa at position 35 is Met, Asn, or Asp;

Xaa at position 36 is Glu, Thr, Ala, Asn, Ser or Asp;

Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 38 is Asn or Gly;

Xaa at position 39 is Leu, Met, or Phe;

Xaa at position 40 is Arg, Ala or Ser;

Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;

Xaa at position 45 is Glu, Tyr, His, Leu, or Arg;

Xaa at position 46 is Ala, Ser, Asn, or Thr;

Xaa at position 47 is Phe or Ser;

Xaa at position 48 is Asn, Val, Pro, Thr, or Ile;

Xaa at position 49 is Arg, Tyr, Lys, Ser, His, or Val;

Xaa at position 50 is Ala or Asn;

Xaa at position 51 is Val, Thr, Leu, or Ser;

Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 53 is Ser, Phe, Val, Gly, Asn, Ile, or His;

Xaa at position 54 is Leu, Val, Ile, Phe, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 56 is Asn or Pro;

Xaa at position 57 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;

Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;

Xaa at position 60 is Ile or Met;

Xaa at position 61 is Glu, Gly, Asp, Ser, or Gln;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;
Xaa at position 63 is Ile, Ser, or Leu;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
Xaa at position 66 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 67 is Leu, or Val;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro, Ala, Thr, Trp, or Met;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala, Arg, or Trp;
Xaa at position 75 is Thr, Asp, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Asp, or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
Xaa at position 78 is Pro or Ser;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is Ile, Val, or Ala;
Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, Val, or Phe;
Xaa at position 86 is Lys, Leu, His, Arg, Ile, Gln, Pro or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;
Xaa at position 88 is Gly, Glu, Lys, or Ser;
Xaa at position 90 is Trp, Val, Tyr, Met, or Leu;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, Ser, Ala, or Gly;
Xaa at position 94 is Arg, Ala, Gln, Ser or Lys;
Xaa at position 95 is Arg, Thr, Glu, Leu, Ser, or Gly;
Xaa at position 98 is Thr, Val, Gln, Glu, His, or Ser;

Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr, Ser, or Asn;
Xaa at position 105 is Glu, Ser, Pro, Leu, Thr, or Tyr;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Included in the present invention are (15-125)human interleukin-3 mutant polypeptides of the Formula VII:

Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa
20 25 30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu
35 40 45

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile
50 55 60

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr
65 70 75

Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:21]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 5 is Met or Ile;
Xaa at position 7 is Asp or Glu;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, or Leu;
Xaa at position 11 is Thr, His, Gln, or Ala;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln, Asn, or Val;
Xaa at position 16 is Pro, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 23 is Phe, Ser, Pro, or Trp;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met Tyr or Arg;
Xaa at position 30 is Asp or Glu;
Xaa at position 31 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 40 is Arg or Ala;

Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;
Xaa at position 46 is Ala or Ser;
Xaa at position 48 is Asn, Pro, Thr, or Ile;
Xaa at position 49 is Arg or Lys;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 52 is Lys or Arg;
Xaa at position 53 is Ser, Phe, or His;
Xaa at position 54 is Leu, Ile, Phe, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 57 is Ala, Pro, or Arg;
Xaa at position 58 is Ser, Glu, Arg, or Asp;
Xaa at position 59 is Ala or Leu;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro or Thr;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is Ile or Val;
Xaa at position 84 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, or Val;
Xaa at position 86 is Lys, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu or Tyr;

Xaa at position 90 is Trp or Leu;
Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, or Gly;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr, Val, or Gln;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 35 of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3.

Included in the present invention are (15-125)human interleukin-3 mutant polypeptides of the Formula VIII:

```
Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa
 1               5                  10                  15

Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp
                20                  25                  30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu
                35                  40                  45

Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile
                50                  55                  60
```

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr
65 70 75

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp
80 85 90

Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:22]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 11 is Thr, His, or Gln;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln or Asn;
Xaa at position 16 is Pro or Gly;
Xaa at position 18 is Leu, Arg, Asn, or Ala;
Xaa at position 20 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, or Pro;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 31 is Gln, Val, Met, Leu, Ala, Asn, Glu or Lys;
Xaa at position 32 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;
Xaa at position 36 is Glu, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Pro, Thr, or His;
Xaa at position 41 is Arg, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 48 is Asn, Pro, or Thr;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;

Xaa at position 53 is Ser or Phe;
Xaa at position 54 is Leu or Phe;
Xaa at position 55 is Gln, Ala, Glu, or Arg;
Xaa at position 62 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Asn, Met, Arg, Ile, or Gly;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, or Ala;
Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 84 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 85 is Ile or Leu;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 91 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr or Gln;
Xaa at position 102 is Lys, Val, Trp, or Ile;
Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 108 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 109 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 26 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

The present invention includes polypeptides of the formula

1 5 10

(Met)$_m$-Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr

15 20

Ser Trp Val Asn Cys Ser Xaa Xaa Xaa Asp Glu Ile Ile

25 30 35

Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa

40 45 50

Xaa Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Xaa Glu

55 60

Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa

65 70 75

Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa

80 85

Ile Leu Xaa Asn Leu Xaa Pro Cys Xaa Pro Xaa Xaa Thr

90 95 100

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly

105 110 115

Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu

120 125

Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu

130

Ser Leu Ala Ile Phe [SEQ ID NO:129]

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile; Xaa at position 19 is Met, Ala or Ile; Xaa at position 20 is Ile, Pro or Ile; Xaa at position 23 is Ile, Ala or Leu; Xaa at position 25 is Thr or His; Xaa at position 29 is Gln, Arg, Val or Ile; Xaa at position 32 is Leu, Ala, Asn or Arg; Xaa at position 34 is Leu or Ser; Xaa at position 37 is Phe, Pro, or Ser; Xaa at position 38 is Asn or Ala; Xaa at position 42 is Gly, Ala, Ser, Asp or Asn; Xaa at position 45 is Gln, Val, or Met; Xaa at position 46 is Asp or Ser; Xaa at position 49 is Met, Ile, Leu or Asp; Xaa at position 50 is Glu or Asp; Xaa at position 51 is Asn Arg or Ser; Xaa at position 55 is Arg, Leu, or Thr; Xaa at

position 56 is Pro or Ser; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn, Val or Pro; Xaa at position 63 is Arg or His; Xaa at position 65 is Val or Ser; Xaa at position 67 is Ser, Asn, His or Gln; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser, Ala or Pro; Xaa at position 79 is Lys, Arg or Ser; Xaa at position 82 is Leu, Glu, Val or Trp; Xaa at position 85 is Leu or Val; Xaa at position 87 is Leu, Ser, Tyr; Xaa at position 88 is Ala or Trp; Xaa at position 91 is Ala or Pro; Xaa at position 93 is Pro or Ser; Xaa at position 95 is His or Thr; Xaa at position 98 is His, Ile, or Thr; Xaa at position 100 is Lys or Arg; Xaa at position 101 is Asp, Ala or Met; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg, Glu or Leu; Xaa at position 112 is Thr or Gln; Xaa at position 116 is Lys, Val, Trp or Ser; Xaa at position 117 is Thr or Ser; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; with the proviso that from four to twenty-six of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

Preferred polypeptides of the present invention are those of the formula

$(Met_m\text{-}Ala_n)_p$-Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa Ile
1 5 10

Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa
15 20

Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu Xaa Glu
25 30 35

Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa
40 45

Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
50 55 60

Ile Leu Xaa Asn Xaa Xaa Pro Cys Xaa Pro Xaa Ala Thr
65 70 75

80 85

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly
90 95 100
Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu
105 110
Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln [SEQ ID NO:130]

wherein m is 0 or 1; n is 0 or 1; p is 0 or 1; Xaa at position 4 is Asn or Ile; Xaa at position 5 is Met, Ala or Ile: Xaa at position 6 is Ile, Pro or Leu; Xaa at position 9 is Ile, Ala or Leu; Xaa at position 11 is Thr or His; Xaa at position 15 is Gln, Arg, Val or Ile; Xaa at position 18 is Leu, Ala, Asn or Arg; Xaa at position 20 is Leu or Ser; Xaa at position 23 is Phe, Pro, or Ser; Xaa at position 24 is Asn or Ala; Xaa at position 28 is Gly, Ala, Ser, Asp or Asn; Xaa at position 31 is Gln, Val, or Met; Xaa at position 32 is Asp or Ser; Xaa at position 35 is Met, Ile or Asp; Xaa at position 36 is Glu or Asp; Xaa at position 37 is Asn, Arg or Ser; Xaa at position 41 is Arg, Leu, or Thr; Xaa at position 42 is Pro or Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Asn, Val or Pro; Xaa at position 49 is Arg or His; Xaa at position 51 is Val or Ser; Xaa at position 53 is Ser, Asn, His or Gln; Xaa at position 55 is Gln or Glu; Xaa at position 59 is Ala or Gly; Xaa at position 62 is Ser, Ala or Pro; Xaa at position 65 is Lys, Arg or Ser; Xaa at position 67 is Leu, Glu, or Val; Xaa at position 68 is Leu, Glu, Val or Trp; Xaa at position 71 is Leu or Val; Xaa at position 73 is Leu, Ser or Tyr; Xaa at position 74 is Ala or Trp; Xaa at position 77 is Ala or Pro; Xaa at position 79 is Pro or Ser; Xaa at position 81 is His or Thr; Xaa at position 84 is His, Ile, or Thr; Xaa at position 86 is Lys or Arg; Xaa at position 87 is Asp, Ala or Met; Xaa at position 91 is Asn or Glu; Xaa at position 95 is Arg, Glu, Leu; Xaa at position 98 Thr or Gln; Xaa at position 102 is Lys, Val, Trp or Ser; Xaa at position 103 is Thr or Ser; Xaa at position 106 is Asn, Gln, or His; Xaa at position 109 is Ala or Glu; with the proviso that from four to twenty-six of the amino acids designated by Xaa are

different from the corresponding amino acids of native (15-125)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

"Mutant amino acid sequence," "mutant protein" or "mutant polypeptide" refers to a polypeptide having an amino acid sequence which varies from a native sequence or is encoded by a nucleotide sequence intentionally made variant from a native sequence. "Mutant protein," "variant protein" or "mutein" means a protein comprising a mutant amino acid sequence and includes polypeptides which differ from the amino acid sequence of native hIL-3 due to amino acid deletions, substitutions, or both. "Native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Human IL-3 can be characterized by its ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Human IL-3 has demonstrated an ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial levels in studies performed initially in primates and subsequently in humans (Gillio, A. P., et al. (1990); Ganser, A, et al. (1990); Falk, S., et al. (1991). Additional activities of hIL-3 include the ability to stimulate leukocyte migration and chemotaxis; the ability to prime human leukocytes to produce high levels of inflammatory mediators like leukotrienes and histamine; the ability to induce cell surface expression of molecules needed for leukocyte adhesion; and the ability to trigger dermal inflammatory responses and fever. Many or all of these biological activities of hIL-3 involve signal transduction and high affinity receptor binding. Mutant polypeptides of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to native hIL-3 or by having improved half-life or

decreased adverse side effects, or a combination of these properties. They may also be useful as antagonists. hIL-3 mutant polypeptides which have little or no activity when compared to native hIL-3 may still be useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins. Since hIL-3 functions by binding to its receptor(s) and triggering second messages resulting in competent signal transduction, hIL-3 muteins of this invention may be useful in helping to determine which specific amino acid sequences are responsible for these activities.

The novel hIL-3 mutant polypeptides of the present invention will preferably have at least one biological property of human IL-3 or of an IL-3-like growth factor and may have more than one IL-3-like biological property, or an improved property, or a reduction in an undesirable biological property of human IL-3. Some mutant polypeptides of the present invention may also exhibit an improved side effect profile. For example, they may exhibit a decrease in leukotriene release or histamine release when compared to native hIL-3 or (15-125) hIL-3. Such hIL-3 or hIL-3-like biological properties may include one or more of the following biological characteristics and in vivo and in vitro activities.

One such property is the support of the growth and differentiation of progenitor cells committed to erythroid, lymphoid, and myeloid lineages. For example, in a standard human bone marrow assay, an IL-3-like biological property is the stimulation of granulocytic type colonies, megakaryocytic type colonies, monocyte/macrophage type colonies, and erythroid bursts. Other IL-3-like properties are the interaction with early multipotential stem cells, the sustaining of the growth of pluripotent precursor cells, the ability to stimulate chronic myelogenous leukemia (CML) cell proliferation, the stimulation of proliferation of mast cells, the ability to support the

growth of various factor-dependent cell lines, and the ability to trigger immature bone marrow cell progenitors. Other biological properties of IL-3 have been disclosed in the art. Human IL-3 also has some biological activities which may in some cases be undesirable, for example the ability to stimulate leukotriene release and the ability to stimulate increased histamine synthesis in spleen and bone marrow cultures and in vivo.

Biological activity of hIL-3 and hIL-3 mutant proteins of the present invention is determined by DNA synthesis by human acute myelogenous leukemia cells (AML). The factor-dependent cell line AML 193 was adapted for use in testing biological activity.

One object of the present invention is to provide hIL-3 muteins and hIL-3 deletion muteins with four or more amino acid substitutions in the polypeptide sequence which have similar or improved biological activity in relation to native hIL-3 or native (15-125)hIL-3.

The present invention includes mutant polypeptides comprising minimally amino acids residues 15 to 118 of hIL-3 with or without additional amino acid extensions to the N-terminus and/or C-terminus which further contain four or more amino acid substitutions in the amino acid sequence of the polypeptide. It has been found that the (15-125)hIL-3 mutant is more soluble than is hIL-3 when expressed in the cytoplasm of E. coli, and the protein is secreted to the periplasm in E. coli at higher levels compared to native hIL-3.

When expressed in the E. coli cytoplasm, the above-mentioned mutant hIL-3 polypeptides of the present invention may also be constructed with Met-Ala- at the N-terminus so that upon expression the Met is cleaved off leaving Ala at the N-terminus. These mutant hIL-3 polypeptides may also be expressed in E. coli by fusing a signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. Secretion in E. coli can be used to obtain the correct amino acid at the N-terminus (e.g., Asn^{15} in the

(15-125) hIL-3 polypeptide) due to the precise nature of the signal peptidase. This is in contrast to the heterogeneity often observed at the N-terminus of proteins expressed in the cytoplasm in E. coli.

The hIL-3 mutant polypeptides of the present invention may have hIL-3 or hIL-3-like activity. For example, they may possess one or more of the biological activities of native hIL-3 and may be useful in stimulating the production of hematopoietic cells by human or primate progenitor cells. The hIL-3 muteins of the present invention and pharmaceutical compositions containing them may be useful in the treatment of conditions in which hematopoietic cell populations have been reduced or destroyed due to disease or to treatments such as radiation or chemotherapy.

hIL-3 muteins of the present invention may also be useful as antagonists which block the hIL-3 receptor by binding specifically to it and preventing binding of the agonist.

One potential advantage of the (15-125) hIL-3 muteins of the present invention, particularly those which retain activity similar to or better than that of native hIL-3, is that it may be possible to use a smaller amount of the biologically active mutein to produce the desired therapeutic effect. This may make it possible to reduce the number of treatments necessary to produce the desired therapeutic effect. The use of smaller amounts may also reduce the possibility of any potential antigenic effects or other possible undesirable side effects. For example, if a desired therapeutic effect can be achieved with a smaller amount of polypeptide it may be possible to reduce or eliminate side effects associated with the administration of native IL-3 such as the stimulation of leukotriene and/or histamine release. The hIL-3 muteins of the present invention may also be useful in the activation of stem cells or progenitors which have low receptor numbers. Pharmaceutical compositions containing (15-125) hIL-3 muteins of the present invention can be administered

parenterally, intravenously, or subcutaneously.

As another aspect of the present invention, there is provided a novel method for producing the novel family of human IL-3 muteins. The method of the present invention involves culturing a suitable cell or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of a novel hIL-3 mutant polypeptide. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 [Yanish-Perron, et al. (1985)] and MON105 [Obukowicz, et al. (1992)]. Various strains of B. subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in: Kaufman, R. J. (1987) High level production of proteins in mammalian cells, in Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, California) can be used. The eukaryotic secretion signal peptide coding region can be from the hIL-3 gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al. (1987) Proc. Natl. Acad. Sci. USA 84, 2638-2642). After construction of the vector containing the hIL-3 variant gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The

hIL-3 variant secreted into the media can be recovered by standard biochemical approaches following transient expression 24 - 72 hours after transfection of the cells or after establishment of stable cell lines following selection for neomycin resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5(7):1750-1759 (1985) or Howley et al., U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E. (1987) - A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, California) can be used. After construction of the vector carrying the hIL-3 variant gene, two micrograms of this DNA is cotransfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the hIL-3 variant is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kansas). The hIL-3 variant secreted into the medium can be recovered by

standard biochemical approaches.

Another aspect of the present invention provides plasmid DNA vectors for use in the method of expression of these novel hIL-3 muteins. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the hIL-3 muteins include expression vectors comprising nucleotide sequences coding for the hIL-3 muteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the hIL-3 mutant polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and capable of directing the replication and expression thereof in selected host cells.

Additional details may be found in co-filed United States Patent Application Attorney docket number 2713/1, which is hereby incorporated by reference in its entirety.

All references, patents or applications cited herein are incorporated by reference in their entirety.

The present invention also includes the construction and expression of (15-125)human interleukin-3 muteins having four or more amino acid substitutions in secretion vectors that optimize accumulation of correctly folded, active polypeptide. While many heterologous proteins have been secreted in E. coli there is still a great deal of unpredictability and limited success (Stader and Silhavy 1990). Full-length hIL-3 is such a protein, where attempts to secrete the protein in E. coli resulted in low secretion levels. Secretion of the variant (15-125) hIL-3 mutant polypeptides of the present invention as a fusion with a signal peptide such as LamB results in correctly folded

protein that can be removed from the periplasm of E. coli by osmotic shock fractionation. This property of the variant (15-125) hIL-3 muteins allows for the direct and rapid screening for bioactivity of the secreted material in the crude osmotic shock fraction, which is a significant advantage. Furthermore, it provides a means of using the (15-125)hIL-3 muteins to conduct structure activity relationship (SAR) studies of the hIL-3 molecule. A further advantage of secretion of (15-125) hIL-3 muteins fused to the LamB signal peptide is that the secreted polypeptide has the correct N-terminal amino acid (Asn) due to the precise nature of the cleavage of the signal peptide by signal peptidase, as part of the secretion process.

The (15-125)hIL-3 muteins of the present invention may include hIL-3 polypeptides having Met-, Ala- or Met-Ala- attached to the N-terminus. When the muteins are expressed in the cytoplasm of E. coli, polypeptides with and without Met attached to the N-terminus are obtained. The methionine can in some cases be removed by methionine aminopeptidase.

Amino terminal sequences of hIL-3 muteins made in E. coli were determined using the method described by Hunkapillar et al., (1983). It was found that hIL-3 proteins made in E. coli from genes encoding Met-(15-125)hIL-3 were isolated as Met-(15-125) hIL-3. Proteins produced from genes encoding Met-Ala-(15-125) hIL-3 were produced as Ala-(15-125) hIL-3. The N-termini of proteins made in the cytoplasm of E. coli are affected by posttranslational processing by methionine aminopeptidase (Ben-Bassat et al., 1987) and possibly by other peptidases.

One method of creating the preferred hIL-3 (15-125) mutant genes is cassette mutagenesis [Wells, et al. (1985)] in which a portion of the coding sequence of hIL-3 in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites. In a similar manner amino acid substitutions could be made in the full-length hIL-3 gene, or genes encoding variants of hIL-3 in

which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus. When properly assembled these oligonucleotides would encode hIL-3 variants with the desired amino acid substitutions and/or deletions from the N-terminus and/or C-terminus. These and other mutations could be created by those skilled in the art by other mutagenesis methods including; oligonucleotide-directed mutagenesis [Zoller and Smith (1982, 1983, 1984), Smith (1985), Kunkel (1985), Taylor, et al. (1985), Deng and Nickoloff (1992)] or polymerase chain reaction (PCR) techniques [Saiki, (1985)].

Pairs of complementary synthetic oligonucleotides encoding portions of the amino terminus of the hIL-3 gene can be made and annealed to each other. Such pairs would have protruding ends compatible with ligation to NcoI at one end. The NcoI site would include the codon for the initiator methionine. At the other end of oligonucleotide pairs, the protruding (or blunt) ends would be compatible with a restriction site that occurs within the coding sequence of the hIL-3 gene. The DNA sequence of the oligonucleotide would encode sequence for amino acids of hIL-3 with the exception of those substituted and/or deleted from the sequence.

The NcoI enzyme and the other restriction enzymes chosen should have recognition sites that occur only once in the DNA of the plasmid chosen. Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with mutant hIL-3 genes.

One example of a restriction enzyme which cleaves within the coding sequence of the hIL-3 gene is ClaI whose recognition site is at codons 20 and 21. The use of ClaI to cleave the sequence of hIL-3 requires that the plasmid

DNA be isolated from an E. coli strain that fails to methylate adenines in the DNA at GATC recognition sites. This is because the recognition site for ClaI, ATCGAT, occurs within the sequence GATCGAT which occurs at codons 19, 20 and 21 in the hIL-3 gene. The A in the GATC sequence is methylated in most E. coli host cells. This methylation prevents ClaI from cleaving at that particular sequence. An example of a strain that does not methylate adenines is GM48.

Interpretation of activity of single amino acid mutants in IL-3 (15-125)

As illustrated in Tables 6 and 9, there are certain positions in the IL-3 (15-125) molecule which are intolerant of substitutions, in that most or all substitutions at these positions resulted in a considerable decrease in bioactivity. There are two likely classes of such "down-mutations": mutations that affect overall protein structure, and mutations that interfere directly with the interaction between the IL-3 molecule and its receptor. Mutations affecting the three-dimensional structure of the protein will generally lie in the interior of the protein, while mutations affecting receptor binding will generally lie on the surface of the protein. Although the three-dimensional structure of IL-3 is unknown, there are simple algorithms which can aid in the prediction of the structure. One such algorithm is the use of "helical wheels" (Kaiser, E.T. & Kezdy, F.J., Science, 223:249-255 (1984)). In this method, the presence of alpha helical protein structures can be predicted by virtue of their amphipathic nature. Helices in globular proteins commonly have an exposed hydrophilic side and a buried hydrophobic side. As a broad generalization, in globular proteins, hydrophobic residues are present in the interior of the protein, and hydrophilic residues are present on the surface. By displaying the amino acid sequence of a protein on such a "helical wheel" it is possible to derive a model for which amino acids in alpha helices are exposed

and which are buried in the core of the protein. Such an analysis of the IL-3 (15-125) molecule predicts that the following helical residues are buried in the core:

M19, I20, I23, I24, L27, L58, F61, A64, L68, A71, I74, I77, L78, L81, W104, F107, L111, Y114, L115, L118.

In addition, cysteine residues at positions 16 and 84 are linked by a disulfide bond, which is important for the overall structure or "folding" of the protein. Finally, mutations which result in a major disruption of the protein structure may be expressed at low level in the secretion system used in our study, for a variety of reasons: either because the mis-folded protein is poorly recognized by the secretion machinery of the cell; because mis-folding of the protein results in aggregation, and hence the protein cannot be readily extracted from the cells; or because the mis-folded protein is more susceptible to degradation by cellular proteases. Hence, a block in secretion may indicate which positions in the IL-3 molecule which are important for maintenance of correct protein structure.

In order to retain the activity of a variant of IL-3, it is necessary to retain both the structural integrity of the protein, and retain the specific residues important for receptor contact. Hence it is possible to define specific amino acid residues in IL-3 (15-125) which must be retained in order to preserve biological activity.

Residues predicted to be important for interaction with the receptor: D21, E22, E43, D44, L48, R54, R94, D103, K110, F113.

Residues predicted to be structurally important: C16, L58, F61, A64, I74, L78, L81, C84, P86, P92, P96, F107, L111, L115, L118.

The hIL-3 muteins of the present invention may be useful in the treatment of diseases characterized by a decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs and of infection or hemorrhage. Therapeutic treatment of leukopenia with these hIL-3 mutant polypeptides of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The hIL-3 muteins of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.

Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, and diuretics. The hIL-3 muteins of the present invention may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of treatment for renal disease or renal failure, e.g., dialysis. The hIL-3 muteins of the present invention may be useful in treating such hematopoietic deficiency.

The treatment of hematopoietic deficiency may include administration of the hIL-3 mutein of a pharmaceutical composition containing the hIL-3 mutein to a patient. The hIL-3 muteins of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the muteins of the present invention prior to injecting the cells into a patient.

Various immunodeficiencies e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the hIL-3 mutant polypeptides of the present invention. Immunodeficiencies may be the result of viral infections e.g. HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The hIL-3 mutant polypeptides of the present invention may also be employed, alone or in combination with other hematopoietins, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are in the treatment of patients recovering from bone marrow transplants in vivo and ex vivo, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the hIL-3 muteins of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of

the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g. the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2 - 150 μg/kg of non-glycosylated IL-3 protein per kilogram of body weight. This dosage regimen is referenced to a standard level of biological activity which recognizes that native IL-3 generally possesses an EC_{50} at or about 10 picoMolar to 100 picoMolar in the AML proliferation assay described herein. Therefore, dosages would be adjusted relative to the activity of a given mutein vs. the activity of native (reference) IL-3 and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of IL-3 mutein would be adjusted higher or lower than the range of 10 - 200 micrograms per kilogram of body weight. These include co-administration with other CSF or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated IL-3 mutein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate hematopoietins, CSFs and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, CSF-1, G-CSF, Meg-CSF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, LIF, B-cell growth factor, B-cell differentiation factor and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to compensate

for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.

Materials and methods for hIL-3 Mutein Expression in E. coli

Unless noted otherwise, all specialty chemicals were obtained from Sigma Co., (St. Louis, MO). Restriction endonucleases, T4 poly-nucleotides kinase, E. coli DNA polymerase I large fragment (Klenow) and T4 DNA ligase were obtained from New England Biolabs (Beverly, Massachusetts).

Escherichia coli strains

Strain JM101: delta (pro lac), supE, thi, F'(traD36, rpoAB, lacI-Q, lacZdeltaM15) (Messing, 1979). This strain can be obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, accession number 33876. MON 105 (W3110 rpoH358) is a derivative of W3110 (Bachmann, 1972) and has been assigned ATCC accession number 55204. Strain GM48: dam-3, dcm-6, gal, ara, lac, thr, leu, tonA, tsx (Marinus, 1973) was used to make plasmid DNA that is not methylated at the sequence GATC.

Genes and plasmids

The gene used for hIL-3 production in E. coli was obtained from British Biotechnology Incorporated, Cambridge, England, catalogue number BBG14. This gene is carried on a pUC based plasmid designated pP0518.

The plasmids used for production of hIL-3 in E. coli contain genetic elements whose use has been described (Olins et al., 1988; Olins and Rangwala, 1990). The replicon used is that of pBR327 (Covarrubias, et al., 1981) which is maintained at a copy number of about 100 in the cell (Soberon et al., 1980). A gene encoding the beta-lactamase protein is present on the plasmids. This protein confers ampicillin resistance on the cell. This resistance serves as a selectable phenotype for the presence of the plasmid in the cell.

For cytoplasmic expression vectors the transcription

promoter was derived from the recA gene of E. coli (Sancar et al., 1980). This promoter, designated precA, includes the RNA polymerase binding site and the lexA repressor binding site (the operator). This segment of DNA provides high level transcription that is regulated even when the recA promoter is on a plasmid with the pBR327 origin of replication (Olins et al., 1988) incorporated herein by reference.

In secretion expression plasmids the transcription promoter was derived from the *ara B, A,* and *D* genes of *E. coli* (Greenfield *et al.*, 1978). This promoter is designated p*Ara*BAD and is contained on a 323 base pair *SacII, BglII* restriction fragment. The *LamB* secretion leader (Wong *et al.*, 1988, Clement *et al.*, 1981) was fused to the N-terminus of the hIL-3 gene at the recognition sequence for the enzyme *NcoI* (5'CCATGG3'). The hIL-3 genes used were engineered to have a *HindIII* recognition site (5'AAGCTT3') following the coding sequence of the gene.

These hIL-3 variants were expressed as a fusion with the LamB signal peptide shown in Figure 8, operatively joined to the araBAD promoter (Greenfield, 1978) and the g10-L ribosome binding site (Olins et al. 1988). The processed form was selectively released from the periplasm by osmotic shock as a correctly folded and fully active molecule. Secretion of (15-125) hIL-3 was further optimized by using low inducer (arabinose) concentration and by growth at 30°C. These conditions resulted in lower accumulation levels of unprocessed LamB signal peptide (15-125) hIL-3 fusion, maximal accumulation levels of processed (15-125) hIL-3 and selective release of (15-125) hIL-3 by osmotic shock fractionation. The use of a tightly regulated promoter such as araBAD from which the transcription level and hence the expression level can be modulated allowed for the optimization of secretion of (15-125) hIL-3.

The ribosome binding site used is that from gene 10 of phage T7 (Olins et al., 1988). This is encoded in a 100 base pair (bp) fragment placed adjacent to precA. In the

plasmids used herein, the recognition sequence for the enzyme NcoI (CCATGG) follows the g10-L. It is at this NcoI site that the hIL-3 genes are joined to the plasmid. It is expected that the nucleotide sequence at this junction will be recognized in mRNA as a functional start site for translation (Olins et al., 1988). The hIL-3 genes used were engineered to have a HindIII recognition site (AAGCTT) downstream from the coding sequence of the gene. At this HindIII site is a 514 base pair RsaI fragment containing the origin of replication of the single stranded phage f1 (Dente et al., 1983; Olins, et al., 1990) both incorporated herein by reference. A plasmid containing these elements is pMON2341. Another plasmid containing these elements is pMON5847 which has been deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 under the accession number ATCC 68912.

Synthesis of Oligonucleotides

Oligonucleotides were synthesized on Nucleotide Synthesizer model 380A or 380B from Applied Biosystems, Inc. (Foster City, California). Oligonucleotides were purified by polyacrylamide gel electrophoresis at concentrations from 12 - 20% (19:1 crosslinked) in 0.5 x Tris borate buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA) followed by passage through a Nensorb column obtained from New England Nuclear (Boston, Massachusetts) using a PREP Automated Sample Processor obtained from DuPont, Co. (Wilmington, Delaware).

Quantitation of synthetic oligonucleotides

Synthetic oligonucleotides were resuspended in water and quantitated by reading the absorbance at 260nm on a Beckman DU40 Spectrophotometer (Irvine, California) using a one centimeter by one millimeter quartz cuvette (Maniatis, 1982). The concentration was determined using an extinction coefficient of 1 X 10^4 (Voet et al., 1963; Mahler and Cordes, 1966). The oligonucleotides were then diluted to a desired concentration.

Quantitation of synthetic DNA fragments can also be achieved by adding 10 to 100 picomoles of DNA to a solution

containing kinase buffer (25 mM Tris pH 8.0, 10 mM $MgCl_2$, 10 mM DTT and 2 mM spermidine). To the reaction mix is added ATP to 20 micromolar, ATP radiolabeled at the gamma phosphate (5000-10,0000 dpm/pmol) and 5 units of T4 polynucleotide kinase. Radiolabelled material is obtained from New England Nuclear (Boston, Massachusetts). The 10 microliter mixture is incubated at 37°C for one hour. A 1 microliter aliquot of the mixture was chromatographed on DEAE paper (Whatman) in 0.3 M ammonium bicarbonate. The counts that remained at the origin were used to determine the concentration of the synthetic DNA.

Recombinant DNA methods

Isolation of plasmid DNA from E. coli cultures was performed as described (Birnboim and Doly, 1979). Some DNAs were purified by Magic™ columns, available from Promega (Madison, Wisconsin).

Purified plasmid DNA was treated with restriction endonucleases according to manufacturer's instructions. Analysis of the DNA fragments produced by treatment with restriction enzymes was done by agarose or polyacrylamide gel electrophoresis. Agarose (DNA grade from Fisher, Pittsburgh PA.) was used at a concentration of 1.0% in a Tris-acetate running buffer (0.04 M Tris-acetate, 0.001M EDTA). Polyacrylamide (BioRad, Richmond CA.) was used at a concentration of 6% (19:1 crosslinked) in 0.5 X Tris-borate buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA), hereafter referred to as PAGE.

DNA polymerase I, large fragment, Klenow enzyme was used according to manufacturers instructions to catalyze the addition of mononucleotides from 5' to 3' of DNA fragments which had been treated with restriction enzymes that leave protruding ends. The reactions were incubated at 65°C for 10 minutes to heat inactivate the Klenow enzyme.

The synthetic oligonucleotides were made without 5' or 3' terminal phosphates. In cases where such oligonucleotides were ligated end to end, the oligonucleotides were treated at a concentration of

10 picomoles per microliter with T4 polynucleotide kinase in the following buffer: 25 mM Tris, pH 8.0, 10 mM $MgCl_2$, 10 mM dithiothreitol, 2 mM spermidine, 1 mM rATP. After incubation for 30 minutes at 37°C, the samples were incubated at 65°C for five minutes to heat inactivate the kinase.

Synthetic gene assembly

The (15-125) hIL-3 gene was divided into four regions separated by five convenient restriction sites. In each of the four regions synthetic oligonucleotides were designed so that they would anneal in complementary pairs, with protruding single stranded ends, and when the pairs were properly assembled would result in a DNA sequence that encoded a portion of the hIL-3 gene. Amino acid substitutions in the hIL-3 gene were made by designing the oligonucleotides to encode the desired substitutions. The complementary oligonucleotides were annealed at concentration of 1 picomole per microliter in ligation buffer plus 50mM NaCl. The samples were heated in a 100 ml beaker of boiling water and permitted to cool slowly to room temperature. One picomole of each of the annealed pairs of oligonucleotides were ligated with approximately 0.2 picomoles of plasmid DNA, digested with the appropriate restriction enzymes, in ligation buffer (25 mM Tris pH 8.0, 10 mM $MgCl_2$, 10 mM dithiothreitol, 1 mM ATP, 2mM spermidine) with T4 DNA ligase obtained from New England Biolabs (Beverly, Massachusetts) in a total volume of 20 µl at room temperature overnight.

DNA fragments were isolated from agarose gels by intercepting the restriction fragments on DEAE membranes from Schleicher and Schuell (Keene, New Hampshire) and eluting the DNA in 10 mM Tris, 1 mM EDTA, 1 M NaCl at 55°C for 1 hour, according to manufacturer's directions. The solutions containing the DNA fragment were concentrated and desalted by using Centricon 30 concentrators from Amicon (W.R. Grace, Beverly MA.) according to the manufacturer's directions. Ligations were performed at 15°C overnight, except as noted, in ligation buffer.

Polymerase Chain Reaction

Polymerase Chain Reaction (hereafter referred to as PCR) techniques (Saiki, 1985) used the reagent kit and thermal cycler from Perkin-Elmer Cetus (Norwalk, CT.). PCR is based on a thermostable DNA polymerase from *Thermus aquaticus*. The PCR technique is a DNA amplification method that mimics the natural DNA replication process in that the number of DNA molecules doubles after each cycle, in a way similar to in vivo replication. The DNA polymerase mediated extension is in a 5' to 3' direction. The term "primer" as used herein refers to an oligonucleotide sequence that provides an end to which the DNA polymerase can add nucleotides that are complementary to a nucleotide sequence. The latter nucleotide sequence is referred to as the "template", to which the primers are annealed. The amplified PCR product is defined as the region comprised between the 5′ ends of the extension primers. Since the primers have defined sequences, the product will have discrete ends, corresponding to the primer sequences. The primer extension reaction was carried out using 20 picomoles (pmoles) of each of the oligonucleotides and 1 picogram of template plasmid DNA for 35 cycles (1 cycle is defined as 94 degrees C for one minute, 50 degrees C for two minutes and 72 degrees for three minutes.). The reaction mixture was extracted with an equal volume of phenol/chloroform (50% phenol and 50% chloroform, volume to volume) to remove proteins. The aqueous phase, containing the amplified DNA, and solvent phase were separated by centrifugation for 5 minutes in a microcentrifuge (Model 5414 Eppendorf Inc, Fremont CA.). To precipitate the amplified DNA the aqueous phase was removed and transferred to a fresh tube to which was added 1/10 volume of 3M NaOAc (pH 5.2) and 2.5 volumes of ethanol (100% stored at minus 20 degrees C). The solution was mixed and placed on dry ice for 20 minutes. The DNA was pelleted by centrifugation for 10 minutes in a microcentrifuge and the solution was removed from the pellet. The DNA pellet was washed with 70%

ethanol, ethanol removed and dried in a speedvac concentrator (Savant, Farmingdale, New York). The pellet was resuspended in 25 microliters of TE (20mM Tris-HCl pH 7.9, 1mM EDTA). Alternatively the DNA was precipitated by adding equal volume of 4M NH_4OAc and one volume of isopropanol [Treco *et al.*, (1988)]. The solution was mixed and incubated at room temperature for 10 minutes and centrifuged. These conditions selectively precipitate DNA fragments larger than ~ 20 bases and were used to remove oligonucleotide primers. One quarter of the reaction was digested with restriction enzymes [Higuchi, (1989)] an on completion heated to 70 degrees C to inactivate the enzymes.

Recovery of recombinant plasmids from ligation mixes

E. coli JM101 cells were made competent to take up DNA. Typically, 20 to 100 ml of cells were grown in LB medium to a density of approximately 150 Klett units and then collected by centrifugation. The cells were resuspended in one half culture volume of 50 mM $CaCl_2$ and held at 4°C for one hour. The cells were again collected by centrifugation and resuspended in one tenth culture volume of 50 mM $CaCl_2$. DNA was added to a 150 microliter volume of these cells, and the samples were held at 4°C for 30 minutes. The samples were shifted to 42°C for one minute, one milliliter of LB was added, and the samples were shaken at 37°C for one hour. Cells from these samples were spread on plates containing ampicillin to select for transformants. The plates were incubated overnight at 37°C. Single colonies were picked, grown in LB supplemented with ampicillin overnight at 37°C with shaking. From these cultures DNA was isolated for restriction analysis.

Culture medium

LB medium (Maniatis et al., 1982) was used for growth of cells for DNA isolation. M9 minimal medium supplemented with 1.0% casamino acids, acid hydrolyzed casein, Difco

(Detroit, Michigan) was used for cultures in which recombinant hIL-3 was produced. The ingredients in the M9 medium were as follows: 3g/liter KH_2PO_4, 6g/l Na_2HPO_4, 0.5 g/l NaCl, 1 g/l NH_4Cl, 1.2 mM $MgSO_4$, 0.025 mM $CaCl_2$, 0.2% glucose (0.2% glycerol with the AraBAD promoter), 1% casamino acids, 0.1 ml/l trace minerals (per liter 108 g $FeCl_3 \cdot 6H_2O$, 4.0 g $ZnSO_4 \cdot 7H_2O$, 7.0 $CoCl_2 \cdot 2H_2O$, 7.0 g $Na_2MoO_4 \cdot 2H_2O$, 8.0 g $CuSO_4 \cdot 5H_2O$, 2.0 g H_3BO_3, 5.0 g $MnSO_4 \cdot H_2O$, 100 ml concentrated HCl). Bacto agar was used for solid media and ampicillin was added to both liquid and solid LB media at 200 micrograms per milliliter.

DNA sequence analysis

The nucleotide sequencing of plasmid DNA was determined using a Genesis 2000 sequencer obtained from DuPont (Wilmington, Delaware) according to the methods of Prober et al. (1987) and Sanger et al. (1977).Some DNA sequences were performed using Sequenase™ polymerase (U.S. Biochemicals, Cleveland, Ohio) according to manufacturer's directions.

Production of recombinant hIL-3 muteins in E. coli with vectors employing the recA promoter

E. coli strains harboring the plasmids of interest were grown at 37°C in M9 plus casamino acids medium with shaking in a Gyrotory water bath Model G76 from New Brunswick Scientific (Edison, New Jersey). Growth was monitored with a Klett Summerson meter (green 54 filter), Klett Mfg. Co. (New York, New York). At a Klett value of approximately 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, nalidixic acid (10mg/ml) in 0.1 N NaOH was added to a final concentration of 50 µg/ml. The cultures were shaken at 37°C for three to four hours after addition of nalidixic acid. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. The cells were examined under a light microscope for the

presence of refractile bodies (RBs). One milliliter aliquots of the culture were removed for analysis of protein content.

Production of recombinant hIL-3 proteins from the pAraBAD promoter in *E. coli*

E. coli strains harboring the plasmids of interest were grown at 30°C with shaking in M9 medium plus casamino acids and glycerol. Growth was monitored with a Klett Summerson colorimeter, using a green 54 filter. At a Klett value of about 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, 20% arabinose was added to a final concentration of 0.05%. The cultures were shaken at 30°C for three to four hours after addition of arabinose. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. One milliliter aliquots of the culture were removed for analysis of protein content.

Secretion and osmotic shock

Three hour post induction samples were fractionated by osmotic shock [Neu and Heppel (1965)]. The optical density (Klett value) of the cultures was determined and 1 ml of cells were centrifuged in a Sigma microcentrifuge (West Germany) model 202MK in 1.5 mls snap top microcentrifuge tubes for 5 minutes at 10,000 rpm. The cell pellet was resuspended very gently by pipeting in a room temperature sucrose solution (20% sucrose w/v, 30mM Tris-Hcl pH7.5, 1mM EDTA), using 1µl/1 Klett unit. Following a 10 minute incubation at room temperature, the cells were centrifuged for 5 minutes at 10,000 rpm. The sucrose fraction was carefully removed from the cell pellet. The cell pellet was then resuspended very gently by pipeting in ice cold distilled water, using 1µl/1 Klett unit. Following a 10 minute incubation on ice, the cells were centrifuged for 5 minutes at 12,000 rpm. The water fraction was carefully removed. Equal volumes of the sucrose and water fractions were pooled and aliquoted to provide samples for activity screening.

Analysis of protein content of E. coli cultures producing hIL-3 mutant polypeptides

Bacterial cells from cultures treated as described above were collected from the medium by centrifugation. Aliquots of these cells were resuspended in SDS loading buffer (4X: 6 g SDS, 10 ml beta-mercaptoethanol, 25 ml upper Tris gel stock (0.5 M Tris HCl pH 6.8, 0.4% SDS) brought to 50 ml with glycerol, 0.2% bromophenol blue was added) at a concentration of one microliter per Klett unit. These samples were incubated at 85°C for five minutes and vortexed. Five or ten microliter aliquots of these samples were loaded on 15% polyacrylamide gels prepared according to the method of Laemmli (1970). Protein bands were visualized by staining the gels with a solution of acetic acid, methanol and water at 5:1:5 ratio (volume to volume) to which Coomassie blue had been added to a final concentration of 1%. After staining, the gels were washed in the same solution without the Coomassie blue and then washed with a solution of 7% acetic acid, 5% methanol. Gels were dried on a gel drier Model SE1160 obtained from Hoeffer (San Francisco, California). The amount of stained protein was measured using a densitometer obtained from Joyce-Loebl (Gateshead, England). The values obtained were a measure of the amount of the stained hIL-3 protein compared to the total of the stained protein of the bacterial cells.

Western blot analysis of hIL-3 muteins made in E. coli

In some E. coli cultures producing hIL-3, the level of accumulation of the hIL-3 protein is lower than 5% of total bacterial protein. To detect hIL-3 produced at this level, Western blot analysis was used. Proteins from cultures induced with nalidixic acid or arabinose were run on polyacrylamide gels as described above except that volumes of sample loaded were adjusted to produce appropriate signals. After electrophoresis, the proteins were electroblotted to APT paper, Transa-bind, Schleicher and Schuell (Keene, New Hampshire) according to the method of Renart et al. (1979). Antisera used to probe these blots

had been raised in rabbits, using peptides of the sequence of amino acids 20 to 41 and 94 to 118 of hIL-3 as the immunogens. The presence of bound antibody was detected with Staphylococcal protein A radiolabeled with ^{125}I, obtained from New England Nuclear (Boston, Massachusetts).

Fractionation of E. coli cells producing hIL-3 proteins in the cytoplasm

Cells from E. coli cultures harboring plasmids that produce hIL-3 muteins were induced with nalidixic acid. After three hours, the hIL-3 muteins accumulated in refractile bodies. The first step in purification of the hIL-3 muteins was to sonicate cells. Aliquots of the culture were resuspended from cell pellets in sonication buffer: 10 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl and 0.1 mM PMSF. These resuspended cells were subjected to several repeated sonication bursts using the microtip from a Sonicator cell disrupter, Model W-375 obtained from Heat Systems-Ultrasonics Inc. (Farmingdale, New York). The extent of sonication was monitored by examining the homogenates under a light microscope. When nearly all of the cells had been broken, the homogenates were fractionated by centrifugation. The pellets, which contain most of the refractile bodies, are highly enriched for hIL-3 muteins.

Methods: Extraction, Refolding and Purification of Interleukin-3 (IL-3) Muteins Expressed as Refractile Bodies in E. coli.

Extraction of refractile bodies (RB's):

For each gram of RB's (and typically one gram is obtained from a 300 ml E. coli culture), 5 ml of a solution containing 6M guanidine hydrochloride (GnHCl), 50 mM 2-N-cyclohexylaminoethanesulfonic acid (CHES) pH 9.5 and 20 mM dithiothreitol (DTT) was added. The RB's were extracted with a Bio-Homogenizer for 15-30 seconds and gently rocked for 2 hours at 5 degrees centigrade (5°C) to allow the protein to completely reduce and denature.

Refolding of the IL-3 muteins

The protein solution was transferred to dialysis tubing (1000 molecular weight cut-off) and dialyzed against at least 100 volumes of 4M GnHCl - 50 mM CHES pH 8.0. The dialysis was continued overnight at 5°C while gently stirring. Subsequently dialysis was continued against at least 100 volumes of 2M GnHCl - 50 mM CHES pH 8.0 and dialyzed overnight at 5°C while gently stirring.

Purification of the IL-3 muteins

The protein solution was removed from the dialysis tubing and acidified by the addition of 40% acetonitrile (CH_3CN) - 0.2% trifluoroacetic acid (TFA) to a final concentration of 20% CH_3CN - 0.1% TFA. This was centrifuged (16,000 x g for 5 minutes) to clarify and the supernatant was loaded onto a Vydac C-18 reversed phase column (10x250 mm) available from Vydac (Hesperia, California) previously equilibrated in 20% CH_3CN - 0.1% TFA. The column was eluted with a linear gradient (0.2% CH_3CN/minute) between 40 - 50% CH_3CN - 0.1% TFA at a flow rate of 3 ml/minute while collecting 1.5 ml fractions. The fractions were analyzed by polyacrylamide gel electrophoresis (SDS-PAGE) and the appropriate fractions pooled. The pooled material was dried by lyophilization or in a Speed Vac concentrator. The dry powder was reconstituted with 10 mM ammonium bicarbonate pH 7.5, centrifuged (16,000 x g for 5 minutes) to clarify and assayed for protein concentration by the method of Bradford (1976) with bovine serum albumin as the standard. Such protein can be further analyzed by additional techniques such as, SDS-PAGE, electrospray mass spectrometry, reverse phase HPLC, capillary zone electrophoresis, amino acid composition analysis, and ELISA (enzyme-linked immunosorbent assay).

hIL-3 SANDWICH ELISA

IL-3 protein concentrations can be determined using a sandwich ELISA based on an affinity purified polyclonal goat anti-rhIL-3. Microtiter plates (Dynatech Immulon II)

were coated with 150 µl goat-anti-rhIL-3 at a concentration of approximately 1 µg/ml in 100 mM NaHCO3, pH 8.2. Plates were incubated overnight at room temperature in a chamber maintaining 100% humidity. Wells were emptied and the remaining reactive sites on the plate were blocked with 200 µl of solution containing 10 mM PBS, 3% BSA and 0.05% Tween 20, pH 7.4 for 1 hour at 37° C and 100% humidity. Wells were emptied and washed 4X with 150 mM NaCl containing 0.05% Tween 20 (wash buffer). Each well then received 150 µl of dilution buffer (10 mM PBS containing 0.1% BSA, 0.01% Tween 20, pH 7.4), containing rhIL-3 standard, control, sample or dilution buffer alone. A standard curve was prepared with concentrations ranging from 0.125 ng/ml to 5 ng/ml using a stock solution of rhIL-3 (concentration determined by amino acid composition analysis). Plates were incubated 2.5 hours at 37° C and 100% humidity. Wells were emptied and each plate was washed 4X with wash buffer. Each well then received 150 µl of an optimal dilution (as determined in a checkerboard assay format) of goat anti-rhIL-3 conjugated to horseradish peroxidase. Plates were incubated 1.5 hours at 37° C and 100% humidity. Wells were emptied and each plate was washed 4X with wash buffer. Each well then received 150 ul of ABTS substrate solution (Kirkegaard and Perry). Plates were incubated at room temperature until the color of the standard wells containing 5 ng/ml rhIL-3 had developed enough to yield an absorbance between 0.5-1.0 when read at a test wavelength of 410 nm and a reference wavelength of 570 nm on a Dynatech microtiter plate reader. Concentrations of immunoreactive rhIL-3 in unknown samples were calculated from the standard curve using software supplied with the plate reader.

AML Proliferation Assay for Bioactive Human Interleukin-3

The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, MD). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell

line which displayed enhanced growth in GM/CSF supplemented medium (Lange, B., et al., (1987); Valtieri, M., et al., (1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D., et al., (1987)). A cell line variant was used, AML 193 1.3, which was adapted for long term growth in IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells were then replated at $1x10^5$ cells/well in a 24 well plate in media containing 100 U/ml IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells were maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells were washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, NY) by centrifuging cell suspensions at 250 x g for 10 minutes followed by decantation of supernatant. Pelleted cells were resuspended in HBSS and the procedure was repeated until six wash cycles were completed. Cells washed six times by this procedure were resuspended in tissue culture medium at a density ranging from 2×10^5 to 5×10^5 viable cells/ml. This medium was prepared by supplementing Iscove's modified Dulbecco's Medium (IMDM, Hazleton, Lenexa, KS) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, IN) was added at 500 µg/ml; human transferrin (Boehringer-Mannheim, Indianapolis, IN) was added at 100 µg/ml; soybean lipid (Boehringer-Mannheim, Indianapolis, IN) was added at 50 µg/ml; and 2-mercaptoethanol (Sigma, St. Louis, MO) was added at 5×10^{-5} M.

Serial dilutions of human interleukin-3 or human interleukin-3 variant protein (hIL-3 mutein) were made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 µl of medium containing interleukin-3 or interleukin-3 variant protein once serial dilutions were completed. Control wells contained tissue culture

medium alone (negative control). AML 193 1.3 cell suspensions prepared as above were added to each well by pipetting 50 µl (2.5 x 10^4 cells) into each well. Tissue culture plates were incubated at 37°C with 5% CO_2 in humidified air for 3 days. On day 3, 0.5 µCi ^{3}H-thymidine (2 Ci/mM, New England Nuclear, Boston, MA) was added in 50 µl of tissue culture medium. Cultures were incubated at 37°C with 5% CO_2 in humidified air for 18-24 hours. Cellular DNA was harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, MD) using a TOMTEC cell harvester (TOMTEC, Orange, CT) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats were allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, MO or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, MD) was added. Beta emissions of samples from individual tissue culture wells were counted in a LKB Betaplate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, MD) and data was expressed as counts per minute of ^{3}H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or human interleukin-3 variant preparation was quantitated by measuring cell proliferation (^{3}H-thymidine incorporation) induced by graded concentrations of interleukin-3 or interleukin-3 variant. Typically, concentration ranges from 0.05 pM - 10^5 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or interleukin-3 variant which provides 50% of maximal proliferation [EC_{50} = 0.5 x (maximum average counts per minute of ^{3}H-thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested - background proliferation measured by ^{3}H-thymidine incorporation observed in triplicate cultures lacking interleukin-3]. This EC_{50} value is also equivalent to 1 unit of bioactivity. Every assay was performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Relative biological activities of IL-3 muteins of the present invention are shown in Table 1. The Relative Biological Activity of IL-3 mutants is calculated by dividing the EC_{50} of (1-133) hIL-3 by the EC_{50} of the mutant. The Relative Biological Activity may be the average of replicate assays.

TABLE 1

BIOLOGICAL ACTIVITY OF IL-3 MUTEINS

Plasmid Code	Polypeptide Structure	Relative* Biological Activity
Reference	(1-133)hIL-3	1
pMON13298	SEQ ID NO. 82	3
pMON13299	SEQ ID NO. 83	2
pMON13300	SEQ ID NO. 84	3
pMON13301	SEQ ID NO. 85	2
pMON13302	SEQ ID NO. 86	1.2
pMON13303	SEQ ID NO. 87	0.6
pMON13287	SEQ ID NO. 88	26
pMON13288	SEQ ID NO. 89	24
pMON13289	SEQ ID NO. 90	13
pMON13290	SEQ ID NO. 91	20
pMON13292	SEQ ID NO. 92	6
pMON13294	SEQ ID NO. 93	3
pMON13295	SEQ ID NO. 94	3
pMON13312	SEQ ID NO. 95	4
pMON13313	SEQ ID NO. 96	8
pMON13285	SEQ ID NO. 259	32
pMON13286	SEQ ID NO. 260	8
pMON13325	SEQ ID NO. 261	8
pMON13326	SEQ ID NO. 262	25
pMON13330	SEQ ID NO. 263	19
pMON13329	SEQ ID NO. 406	10
pMON13364	SEQ ID NO. 117	13

TABLE 1 (cont'd)

BIOLOGICAL ACTIVITY OF IL-3 MUTEINS

Plasmid Code	Polypeptide Structure	Relative* Biological Activity
pMON13475	SEQ ID NO. 280	7
pMON13366	SEQ ID NO. 281	38
pMON13367	SEQ ID NO. 282	36
pMON13368	SEQ ID NO. 278	1.6
pMON13369	SEQ ID NO. 283	10
pMON13370	SEQ ID NO. 284	6
pMON13373	SEQ ID NO. 285	12
pMON13374	SEQ ID NO. 286	6
pMON13375	SEQ ID NO. 287	14
pMON13376	SEQ ID NO. 288	0.4
pMON13377	SEQ ID NO. 289	0.4
pMON13379	SEQ ID NO. 291	0.9
pMON13380	SEQ ID NO. 279	0.05
pMON13381	SEQ ID NO. 293	10
pMON13382	SEQ ID NO. 313	38
pMON13383	SEQ ID NO. 294	0.5
pMON13384	SEQ ID NO. 295	0.25
pMON13385	SEQ ID NO. 292	1
pMON13387	SEQ ID NO. 308	32
pMON13388	SEQ ID NO. 296	23
pMON13389	SEQ ID NO. 297	10
pMON13391	SEQ ID NO. 298	30
pMON13392	SEQ ID NO. 299	17
pMON13393	SEQ ID NO. 300	32
pMON13394	SEQ ID NO. 301	20
pMON13395	SEQ ID NO. 302	11
pMON13396	SEQ ID NO. 303	20
pMON13397	SEQ ID NO. 304	16
pMON13398	SEQ ID NO. 305	36
pMON13399	SEQ ID NO. 306	18
pMON13404	SEQ ID NO. 307	1.3
pMON13417	SEQ ID NO. 310	24
pMON13420	SEQ ID NO. 311	19
pMON13421	SEQ ID NO. 312	0.5
pMON13432	SEQ ID NO. 313	10
pMON13400	SEQ ID NO. 317	0.09
pMON13402	SEQ ID NO. 318	20
pMON13403	SEQ ID NO. 321	0.03
pMON13405	SEQ ID NO. 267	9

TABLE 1 (cont'd)

BIOLOGICAL ACTIVITY OF IL-3 MUTEINS

Plasmid Code	Polypeptide Structure	Relative* Biological Activity
pMON13406	SEQ ID NO. 264	5
pMON13407	SEQ ID NO. 266	16
pMON13408	SEQ ID NO. 269	7
pMON13409	SEQ ID NO. 270	15
pMON13410	SEQ ID NO. 271	0.4
pMON13411	SEQ ID NO. 322	1.2
pMON13412	SEQ ID NO. 323	0.5
pMON13413	SEQ ID NO. 324	0.6
pMON13414	SEQ ID NO. 265	4
pMON13415	SEQ ID NO. 268	4
pMON13418	SEQ ID NO. 326	0.5
pMON13419	SEQ ID NO. 325	0.015
pMON13422	SEQ ID NO. 272	0.4
pMON13423	SEQ ID NO. 273	0.4
pMON13424	SEQ ID NO. 274	3
pMON13425	SEQ ID NO. 275	6
pMON13426	SEQ ID NO. 276	>0.0003
pMON13429	SEQ ID NO. 277	>0.0002
pMON13440	SEQ ID NO. 319	9
pMON13451	SEQ ID NO. 320	0.1
pMON13459	SEQ ID NO. 328	0.003
pMON13416	SEQ ID NO. 309	19.9
pMON13428	SEQ ID NO. 327	0.008
pMON13467	SEQ ID NO. 329	0.16
pMON13446	SEQ ID NO. 315	21.5
pMON13390	SEQ ID NO. 316	20

* The Relative Biological Activity of IL-3 mutants is calculated by dividing the EC_{50} of (1-133) hIL-3 by the EC_{50} of the mutant.

The following assay is used to measure IL-3 mediated sulfidoleukotriene release from human mononuclear cells.

IL-3 mediated sulfidoleukotriene release from human mononuclear cells

Heparin-containing human blood was collected and layered onto an equal volume of Ficoll-Paque (Pharmacia #

17-0840-02) ready to use medium (density 1.077 g/ml.). The Ficoll was warmed to room temperature prior to use and clear 50 ml polystyrene tubes were utilized. The Ficoll gradient was spun at 300 x g for 30 minutes at room temperature using a H1000B rotor in a Sorvall RT6000B refrigerated centrifuge. The band containing the mononuclear cells was carefully removed, the volume adjusted to 50 mls with Dulbecco's phosphate-buffered saline (Gibco Laboratories cat. # 310-4040PK), spun at 400 x g for 10 minutes at 4°C and the supernatant was carefully removed. The cell pellet was washed twice with HA Buffer [20 mM Hepes (Sigma # H-3375), 125 mM NaCl (Fisher # S271-500), 5 mM KCl (Sigma # P-9541), 0.5 mM glucose (Sigma # G-5000),0.025% Human Serum Albumin (Calbiochem # 126654) and spun at 300 x g, 10 min., 4°C. The cells were resuspended in HACM Buffer (HA buffer supplemented with 1 mM CaCl2 (Fisher # C79-500) and 1 mM MgCl2 (Fisher # M-33) at a concentration of 1 x 106 cells/ml and 180 µl were transferred into each well of 96 well tissue culture plates. The cells were allowed to acclimate at 37°C for 15 minutes. The cells were primed by adding 10 µls of a 20 X stock of various concentrations of cytokine to each well (typically 100000, 20000, 4000, 800, 160, 32, 6.4, 1.28, 0 fM IL3). The cells were incubated for 15 minutes at 37°C. Sulfidoleukotriene release was activated by the addition of 10 µls of 20 X (1000 nM) fmet-leu-phe (Calbiochem # 344252) final concentration 50nM FMLP and incubated for 10 minutes at 37°C. The plates were spun at 350 x g at 4°C for 20 minutes. The supernatants were removed and assayed for sulfidoleukotrienes using Cayman's Leukotriene C4 EIA kit (Cat. #420211) according to manufacturers' directions. Native (15-125)hIL-3 was run as a standard control in each assay.

Native hIL-3 possesses considerable inflammatory activity and has been shown to stimulate synthesis of the arachidonic acid metabolites LTC_4, LTD_4, and LTE_4; histamine synthesis and histamine release. Human clinical

trials with native hIL-3 have documented inflammatory responses (Biesma, et al., BLOOD, 80:1141-1148 (1992) and Postmus, et al., J. CLIN. ONCOL., 10:1131-1140 (1992)). A recent study indicates that leukotrienes are involved in IL-3 actions in vivo and may contribute significantly to the biological effects of IL-3 treatment (Denzlinger, C., et al., BLOOD, 81:2466-2470 (1993))

Some muteins of the present invention may have an improved therapeutic profile as compared to native hIL-3 or (15-125)hIL-3. For example, some muteins of the present invention may have a similar or more potent growth factor activity relative to native hIL-3 or (15-125)hIL-3 without having a similar or corresponding increase in the stimulation of leukotriene or histamine. These muteins would be expected to have a more favorable therapeutic profile since the amount of polypeptide which needs to be given to achieve the desired growth factor activity (e. g. cell proliferation) would have a lesser leukotriene or histamine stimulating effect. In studies with native hIL-3, the stimulation of inflammatory factors has been an undesirable side effect of the treatment. Reduction or elimination of the stimulation of mediators of inflammation would provide an advantage over the use of native hIL-3.

The pMON13288 polypeptide has demonstrated a more potent growth factor activity relative to native hIL-3 in the AML 193 cell proliferation assay (EC_{50} = 0.8 - 3.8 pM for pMON13288 and EC_{50} = 30.2 pM for native hIL-3) without demonstrating a corresponding increase in the stimulation of leukotriene C_4 (LTC_4) production and histamine release, i. e., it stimulated LTC_4 production and histamine release with a potency similar to that of native hIL-3 while having an improved ability to stimulate cell proliferation compared to native hIL-3. Thus with the pMON13288 polypeptide it would be expected that one would be able to produce a desired therapeutic response, e. g., cell proliferation, with less stimulation of the undesirable inflammatory mediators.

Some muteins of the present invention have antigenic

profiles which differ from that of native hIL-3. For example, in a competition ELISA with an affinity purified polyclonal goat anti-hIL-3 antibody, native hIL-3 significantly blocked the binding of labeled hIL-3 to polyclonal anti-hIL-3 antibody whereas the pMON13288 polypeptide failed to block the binding of hIL-3 to anti-hIL-3 antibody.

Table 2 lists the sequences of some oligonucleotides used in making the muteins of the present invention.

Table 3 lists the amino acid sequence of native (15-125)hIL-3 (Peptide #1) and the amino acid sequences of some mutant polypeptides of the present invention. The sequences are shown with the amino acid numbering corresponding to that of native hIL-3 [FIG. 1].

Table 4 lists the nucleotide sequences of some DNA sequences which encode mutant polypeptides of the present invention.

TABLE 2

OLIGONUCLEOTIDES

Oligo #1 Length: 000040

CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT [SEQ ID NO:15]

Oligo #2 Length: 000045

CTTTAAGTGA TGTATAATTT CATCGATCAT TATAGAGCAG TTAGC [SEQ ID NO:16]

Oligo #3 Length: 000036

CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCG [SEQ ID NO:17]

Oligo #4 Length: 000036

GAGGTTGTTC GGGTCCAGCA AAGGTGCAGG TGGTCT [SEQ ID NO:18]

Oligo #5 Length: 000036

CACTTAAAGA GACCACCTAA CCCTTTGCTG GACCCG [SEQ ID NO:19]

Oligo #6 Length: 000036
GAGGTTGTTC GGGTCCAGCA AAGGGTTAGG TGGTCT [SEQ ID NO:20]

Oligo #7 Length: 000036
CACTTAAAGG TTCCACCTGC ACCTTTGCTG GACAGT [SEQ ID NO:21]

Oligo #8 Length: 000036
GAGGTTGTTA CTGTCCAGCA AAGGTGCAGG TGGAAC [SEQ ID NO:22]

Oligo #9 Length: 000027
AACAACCTCA ATGCTGAAGA CGTTGAT [SEQ ID NO:23]

Oligo #10 Length: 000018
ATCAACGTCT TCAGCATT [SEQ ID NO:24]

Oligo #11 Length: 000027
AACAACCTCA ATTCTGAAGA CATGGAT [SEQ ID NO:25]

Oligo #12 Length: 000018
ATCCATGTCT TCAGAATT [SEQ ID NO:26]

Oligo #13 Length: 000022
CATGGGAACC ATATGTCAGG AT [SEQ ID NO:27]

Oligo #14 Length: 000018
ATCCTGACAT ATGGTTCC [SEQ ID NO:28]

Oligo #15 Length: 000016
TGAACCATAT GTCAGG [SEQ ID NO:29]

Oligo #16 Length: 000024
AATTCCTGAC ATATGGTTCA TGCA [SEQ ID NO:30]

Oligo #17 Length: 000020
AATTCGAACC ATATGTCAGA [SEQ ID NO:31]

Oligo #18 Length: 000020
AGCTTCTGAC ATATGGTTCG [SEQ ID NO:32]

Oligo #19 Length: 000022

ATCGAACCAT ATGTCAGATG CA [SEQ ID NO:33]

Oligo #20 Length: 000018

TCTGACATAT GGTTCGAT [SEQ ID NO:34]

Oligo #21 Length: 000036

ATCCTGATGG AACGAAACCT TCGACTTCCA AACCTG [SEQ ID NO:35]

Oligo #22 Length: 000027

AAGTCGAAGG TTTCGTTCCA TCAGGAT [SEQ ID NO:36]

Oligo #23 Length: 000036

ATCCTGATGG AACGAAACCT TCGAACTCCA AACCTG [SEQ ID NO:37]

Oligo #24 Length: 000027

AGTTCGAAGG TTTCGTTCCA TCAGGAT [SEQ ID NO:38]

Oligo #25 Length: 000024

CTCGCATTCG TAAGGGCTGT CAAG [SEQ ID NO:39]

Oligo #26 Length: 000024

CCTTACGAAT GCGAGCAGGT TTGG [SEQ ID NO:40]

Oligo #27 Length: 000024

GAGAGCTTCG TAAGGGCTGT CAAG [SEQ ID NO:41]

Oligo #28 Length: 000024

CCTTACGAAG CTCTCCAGGT TTGG [SEQ ID NO:42]

Oligo #29 Length: 000015

CACTTAGAAA ATGCA [SEQ ID NO:43]

Oligo #30 Length: 000020

TTTTCTAAGT GCTTGACAGC [SEQ ID NO:44]

Oligo #31 Length: 000015

AACTTAGAAA ATGCA [SEQ ID NO:45]

Oligo #32 Length: 000020

TTTTCTAAGT TCTTGACAGC [SEQ ID NO:46]

Oligo #33 Length: 000048

GGTGATTGGA TGTCGAGAGG GTGCGGCCGT GGCAGAGGGC AGACATGG [SEQ ID NO:47]

Oligo #34 Length: 000048

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA CCATCAAG [SEQ ID NO:48]

Oligo #35 Length: 000048

GATGATTGGA TGTCGAGAGG GTGCGGCCGT GGCAGAGGGC AGACATGG [SEQ ID NO:49]

Oligo #36 Length: 000048

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAG [SEQ ID NO:50]

Oligo #37 Length: 000018

TACGAGATTA CGAAGAAT [SEQ ID NO:51]

Oligo #38 Length: 000018

CGTAATCTCG TACCATGT [SEQ ID NO:52]

Oligo #39 Length: 000018

TTGGAGATTA CGAAGAAT [SEQ ID NO:53]

Oligo #40 Length: 000018

CGTAATCTCC AACCATGT [SEQ ID NO:54]

Oligo #41 Length: 000019

TGCCTCAATA CCTGATGCA [SEQ ID NO:55]

Oligo #42 Length: 000021

TCAGGTATTG AGGCAATTCT T [SEQ ID NO:56]

Oligo #43 Length: 000026

AATTCTTGCC AGTCACCTGC CTTGAT [SEQ ID NO:57]

Oligo #44 Length: 000016

GCAGGTGACT GGCAAG [SEQ ID NO:58]

Oligo #45 Length: 000032

AATTCCGGGA AAAACTGACG TTCTATCTGG TT [SEQ ID NO:59]

Oligo #46 Length: 000037

CTCAAGGGAA ACCAGATAGA ACGTCAGTTT TTCCCGG [SEQ ID NO:60]

Oligo #47 Length: 000032

ACCCTTGAGC ACGCGCAGGA ACAACAGTAA TA [SEQ ID NO:61]

Oligo #48 Length: 000027

AGCTTATTAC TGTTGTTCCT GCGCGTG [SEQ ID NO:62]

Oligo #49 Length: 000032

ACCCTTGAGC AAGCGCAGGA ACAACAGTAA TA [SEQ ID NO:63]

Oligo #50 Length: 000027

AGCTTATTAC TGTTGTTCCT GCGCTTG [SEQ ID NO:64]

Oligo #51 Length: 000034

GCCGATACCGCGGCATACTCCCACCATTCAGAGA [SEQ ID NO:155]

Oligo #52 Length: 000033

GCCGATAAGATCTAAAACGGGTATGGAGAAACA [SEQ ID NO:156]

Oligo #53

ATAGTCTTCCCCAGATATCTAACGCTTGAG [SEQ ID NO:157]

Oligo #54 Length: 24

CAATACCTGATGCGTTTTCTAAGT [SEQ ID NO:158]

Oligo #55 Length: 33

GGTTTCGTTCCATCAGAATGTCCATGTCTTCAG [SEQ ID NO:159]

Oligo #165 NCOECRV1.REQ Length: 000040

CATGGCTAAC TGCTCTAACA TGATCGATGA AATTATAACA [SEQ ID NO:162]

Oligo #166 NCOECRV4.REQ Length: 000045

CTTTAAGTGT GTTATAATTT CATCGATCAT GTTAGAGCAG TTAGC [SEQ ID NO:163]

Oligo #167 NCOECRV2.REQ Length: 000036

CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTC [SEQ ID NO:164]

Oligo #168 NCOECRV5.REQ Length: 000036

GAGGTTGTTG AAGTCCAGCA AAGGCAAAGG TGGCTG [SEQ ID NO:165]

Oligo #169 2D5M6SUP.REQ Length: 000027

AACAACCTCA ATGACGAAGA CATGTCT [SEQ ID NO:166]

Oligo #170 2D5M6SLO.REQ Length: 000018

AGACATGTCT TCGTCATT [SEQ ID NO:167]

Oligo #15(A) Length: 000016

TGAACCATAT GTCAGG [SEQ ID NO:168]

Oligo #16(A) Length: 000024

AATTCCTGAC ATATGGTTCA TGCA [SEQ ID NO:169]

Oligo #B1 19ALA1.REQ Length: 000040

CATGGCAAAC TGCTCTATAG CTATCGATGA AATTATACAT [SEQ ID NO:170]

Oligo #B2 19ALA4.REQ Length: 000045

CTTTAAGTGA TGTATAATTT CATCGATAGC TATAGAGCAG TTTGC [SEQ ID NO:171]

Oligo #B3 19ILE1.REQ Length: 000040

CATGGCAAAC TGCTCTATAA TCATCGATGA AATTATACAT [SEQ ID NO:172]

Oligo #B4 19ILE4.REQ Length: 000045

CTTTAAGTGA TGTATAATTT CATCGATGAT TATAGAGCAG TTTGC [SEQ ID NO:173]

Oligo #B5 49ASP1.REQ Length: 000036

ATCCTGGACG AACGAAACCT TCGAACTCCA AACCTG [SEQ ID NO:174]

Oligo #B6 49ASP4.REQ Length: 000027

AGTTCGAAGG TTTCGTTCGT CCAGGAT [SEQ ID NO:175]

Oligo #B7 49ILE1.REQ Length: 000036

ATCCTGATCG AACGAAACCT TCGAACTCCA AACCTG [SEQ ID NO:176]

Oligo #B8 49ILE4.REQ Length: 000027

AGTTCGAAGG TTTCGTTCGA TCAGGAT [SEQ ID NO:177]

Oligo #B9 49LEU1.REQ Length: 000036

ATCCTGCTGG AACGAAACCT TCGAACTCCA AACCTG [SEQ ID NO:178]

Oligo #B10 49LEU4.REQ Length: 000027

AGTTCGAAGG TTTCGTTCCA GCAGGAT [SEQ ID NO:179]

Oligo #B11 42S45V3.REQ Length: 000027

AACAACCTCA ATTCTGAAGA CGTTGAT [SEQ ID NO:180]

Oligo #B12 42S45V6.REQ Length: 000018

ATCAACGTCT TCAGAATT [SEQ ID NO:181]

Oligo #B13 18I23A5H.REQ Length: 000051

CGCGCCATGG CTAACTGCTC TATAATGATC GATGAAGCAA TACATCACTTA [SEQ ID NO:182]

Oligo #B14 2341HIN3.REQ Length: 000018

CGCGTCGATA AGCTTATT [SEQ ID NO:183]

Oligo #B15 2341NCO.REQ Length: 000018

GGAGATATAT CCATGGCT [SEQ ID NO:184]

Oligo #B16 2A5M6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGACA TGTCTTCAGC ATTGAGGTTG TT [SEQ ID NO:185]

Oligo #B17 2A5V6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGAAA CGTCTTCAGC ATTGAGGTTG TT [SEQ ID NO:186]

Oligo #B18 2D5M6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGACA TGTCTTCGTC ATTGAGGTTG TT [SEQ ID NO:187]

Oligo #B19 2D5V6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGAAA CGTCTTCGTC ATTGAGGTTG TT [SEQ ID NO:188]

Oligo #B20 2S5M6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGACA TGTCTTCAGA ATTGAGGTTG TT [SEQ ID NO:189]

Oligo #B21 2S5V6S0D.REQ Length: 000042

TCGGTCCATC AGAATAGAAA CGTCTTCAGA ATTGAGGTTG TT [SEQ ID NO:190]

Oligo #B22 100ARG3.REQ Length: 000048

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCCGT [SEQ ID NO:191]

Oligo #B23 100ARG8.REQ Length: 000026

AATTCTTGCC AGTCACCTGC ACGGAT [SEQ ID NO:192]

Oligo #B24 101MET4.REQ Length: 000016

ATGGGTGACT GGCAAG [SEQ ID NO:193]

Oligo #B25 10R01M8.REQ Length: 000026

AATTCTTGCC AGTCACCCAT ACGGAT [SEQ ID NO:194]

Oligo #B26 23ALA1.REQ Length: 000040

CATGGCTAAC TGCTCTATTA TGATCGATGA AGCAATACAT [SEQ ID NO:195]

Oligo #B27 23ALA4.REQ Length: 000045

CTTTAAGTGA TGTATTGCTT CATCGATCAT AATAGAGCAG TTAGC [SEQ ID NO:196]

Oligo #B28 29V2R4S2.REQ Length: 000036

CACTTAAAGG TACCACCTCG CCCTTCCCTG GACCCG [SEQ ID NO:197]

Oligo #B29 29V2R4S5.REQ Length: 000036

GAGGTTGTTC GGGTCCAGGG AAGGGCGAGG TGGTAC [SEQ ID NO:198]

Oligo #B30 34SER2.REQ Length: 000036

CACTTAAAGA GACCACCTGC ACCTTCCCTG GACCCG [SEQ ID NO:199]

Oligo #B31 34SER5.REQ Length: 000036

GAGGTTGTTC GGGTCCAGGG AAGGTGCAGG TGGTCT [SEQ ID NO:200]

Oligo #B32 42D45M3.REQ Length: 000027

AACAACCTCA ATGACGAAGA CATGGAT [SEQ ID NO:201]

Oligo #B33 42D45M6.REQ Length: 000018

ATCCATGTCT TCGTCATT [SEQ ID NO:202]

Oligo #B34 42D45V3.REQ Length: 000027

AACAACCTCA ATGACGAAGA CGTCGAT [SEQ ID NO:203]

Oligo #B35 42D45V6.REQ Length: 000018

ATCGACGTCT TCGTCATT [SEQ ID NO:204]

Oligo #B36 42D5M6S3.REQ Length: 000027

AACAACCTCA ATGACGAAGA CATGTCT [SEQ ID NO:205]

Oligo #B37 42D5M6S6.REQ Length: 000018

AGACATGTCT TCGTCATT [SEQ ID NO:206]

Oligo #B38 42D5V6S3.REQ Length: 000027

AACAACCTCA ATGACGAAGA CGTCTCT [SEQ ID NO:207]

Oligo #B39 42D5V6S6.REQ Length: 000018

AGAGACGTCT TCGTCATT [SEQ ID NO:208]

Oligo #B40 50ASP1.REQ Length: 000036

ATCCTGATGG ACCGAAACCT TCGACTTCCA AACCTG [SEQ ID NO:209]

Oligo #B41 50ASP4.REQ Length: 000027

AAGTCGAAGG TTTCGGTCCA TCAGGAT [SEQ ID NO:210]

Oligo #B42 50D56S1.REQ Length: 000036

ATCCTGATGG ACCGAAACCT TCGACTTAGC AACCTG [SEQ ID NO:211]

Oligo #B43 56SER5.REQ Length: 000024

CCTTACGAAG CTCTCCAGGT TGCT [SEQ ID NO:212]

Oligo #B44 82TRP2.REQ Length: 000018

CGTAATCTCT GGCCATGT [SEQ ID NO:213]

Oligo #B45 82TRP6.REQ Length: 000018

CCAGAGATTA CGAAGAAT [SEQ ID NO:214]

Oligo #B46 9E12Q6W1.REQ Length: 000032

AATTCCGGGA AAAACTGCAA TTCTATCTGT GG [SEQ ID NO:215]

Oligo #B47 9E12Q6W3.REQ Length: 000037

CTCAAGGGTC CACAGATAGA ATTGCAGTTT TTCCCGG [SEQ ID NO:216]

Oligo #B48 9E12Q6V1.REQ Length: 000032

AATTCCGGGA AAAACTGCAA TTCTATCTGG TT [SEQ ID NO:217]

Oligo #B49 9E12Q6V3.REQ Length: 000037

CTCAAGGGTA ACCAGATAGA ATTGCAGTTT TTCCCGG [SEQ ID NO:218]

Oligo #B50 S09E16V1.REQ Length: 000023

AATTCCGGGA AAAACTGACG TTC [SEQ ID NO:219]

Oligo #B51 S09E16V3.REQ Length: 000028

AACCAGATAG AACGTCAGTT TTTCCCGG [SEQ ID NO:220]

Oligo #B52 S116VD31.REQ Length: 000023

TATCTGGTTA CCCTTGAGTA ATA [SEQ ID NO:221]

Oligo #B53 SECR1D33.REQ Length: 000018

AGCTTATTAC TTCAAGGGT [SEQ ID NO:222]

Oligo #B54 S9E2Q6V1.REQ Length: 000023

AATTCCGGGA AAAACTGCAA TTC [SEQ ID NO:223]

Oligo #B55 S9E2Q6V3.REQ Length: 000028

AACCAGATAG AATTGCAGTT TTTCCCGG [SEQ ID NO:224]

Oligo #B56 Ent338.Lo Length: 61

CGATCATTAT AGAGCAGTTA GCCTTGTCAT CGTCGTCCTT GTAATCAGTT TCTGGATATG C [SEQ ID NO:225]

Oligo #B57 Ent338.UP Length: 63

CATGGCATAT CCAGAAACTG ATTACAAGGA CGACGATGAC AAGGCTAACT GCTCTATAAT GAT SEQ ID NO:226]

09L2Q6S1.REQ Length: 000032

AATTCCGGCT TAAACTGCAA TTCTATCTGT CT [SEQ ID NO:227]

09L2Q6S3.REQ Length: 000037

CTCAAGGGTA GACAGATAGA ATTGCAGTTT AAGCCGG [SEQ ID NO:228]

117S2.REQ Length: 000032

TCTCTTGAGC AAGCGCAGGA ACAACAGTAA TA [SEQ ID NO:229]

19I0L3A1.REQ Length: 000040

CATGGCAAAC TGCTCTATAA TACTCGATGA AGCAATACAT [SEQ ID NO:230]

19I0L3A4.REQ Length: 000045

CTTTAAGTGA TGTATTGCTT CATCGAGTAT TATAGAGCAG TTTGC [SEQ. ID NO.:231]

20P23A1.REQ Length: 000040

CATGGCAAAC TGCTCTATAA TGCCAGATGA AGCAATACAT [SEQ. ID NO.:232]

20P23A4.REQ Length: 000045

CTTTAAGTGA TGTATTGCTT CATCTGGCAT TATAGAGCAG TTTGC [SEQ. ID NO.:233]

23L1.REQ Length: 000040

CATGGCaAAC TGCTCTATAA TGATCGATGA AactgATACAT [SEQ. ID NO.:234]

23L4.REQ Length: 000045

CTTTAAGTGA TGTATcagTT CATCGATCAT TATAGAGCAG TTtGC [SEQ. ID NO.:235]

29I4S7S2.REQ Length: 000036

CACTTAAAGA TACCACCTAA CCCTAGCCTG GACAGT [SEQ. ID NO.:236]

29I4S7S5.REQ Length: 000036

GAGGTTAGCA CTGTCCAGGC TAGGGTTAGG TGGTAT [SEQ. ID NO.:237]

38A5V6S3.REQ Length: 000027

GCTAACCTCA ATTCCGAAGA CGTCTCT [SEQ. ID NO.:238]

38A5V6S6.REQ Length: 000018

AGAGACGTCT TCGGAATT [SEQ. ID NO.:239]

50D51S1.REQ Length: 000036

ATCCTGATGG ACTCCAACCT TCGAACTCCA AACCTG [SEQ. ID NO.:240]

50D51S4.REQ Length: 000027

AGTTCGAAGG TTGGAGTCCA TCAGGAT [SEQ. ID NO.:241]

5VYWPTT3.REQ Length: 000048

GTTCCCTATT GGACGGCCCC TCCCTCTCGA ACACCAATCA CGATCAAG [SEQ. ID NO.:242]

5VYWPTT7.REQ Length: 000048

CGTGATTGGT GTTCGAGAGG GAGGGGCCGT CCAATAGGGA ACACATGG [SEQ. ID NO.:243]

62P3H5S2.REQ Length: 000024

CTCGCATTCC CACATGCTTC TAAG [SEQ. ID NO.:244]

62P63H2.REQ Length: 000024

CTCGCATTCC CACATGCTGT CAAG [SEQ. ID NO.:245]

62P63H5.REQ Length: 000024

ATGTGGGAAT GCGAGCAGGT TTGG [SEQ. ID NO.:246]

65S67Q6.REQ Length: 000020

TTTTCTAATT GCTTAGAAGC [SEQ. ID NO.:247]

67Q3.REQ Length: 000015

CAATTAGAAA ATGCA [SEQ. ID NO.:248]

67Q6.REQ Length: 00002]

TTTTCTAATT GCTTGACAGC [SEQ. ID NO.:249

76P1.REQ Length: 000021

TCAGGTATTG AGCCAATTCT T [SEQ. ID NO.:250]

76P5.REQ Length: 000019

TGGCTCAATA CCTGATGCA [SEQ. ID NO.:251]

79S2.REQ Length: 000018

TCTAATCTCC AACCATGT [SEQ. ID NO.:252]

79S6.REQ Length: 000018

TTGGAGATTA GAAAGAAT [SEQ. ID NO.:253]

9L2Q67S3.REQ Length: 000037

CTCAAGAGAA GACAGATAGA ATTGCAGTTT AAGCCGG [SEQ. ID NO.:254]

9LQS1181.REQ Length: 000043

AATTCCGGCT TAAACTGCAA TTCTATCTGT CTACCCTTTA ATA [SEQ. ID NO.:256]

9LQS1183.REQ Length: 000043

AGCTTATTAA AGGGTAGACA GATAGAATTG CAGTTTAAGC CGG [SEQ. ID NO.:257]

S9L2Q6S1.REQ Length: 000043

AATTCCGGCT TAAACTGCAA TTCTATCTGT CTACCCTTTA ATA [SEQ. ID NO.:258]

TABLE 3

POLYPEPTIDES

PEPTIDE #1; pMON5988 (Example 43); (15-125)hIL-3

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:65]
120 125

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:65]

PEPTIDE #2; pMON13344 (Example 8); (15-125)hIL-3 (18I, 25H, 29R, 32A, 37P,
42A and 45V);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:66]
120 125

PEPTIDE #3; pMON13345 (Example 9); (15-125)hIL-3 (18I, 25H, 29R, 32N, 37P,
42S and 45M);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:67]
120 125

PEPTIDE #4; pMON13346 (Example 10); (15-125)hIL-3 (18I, 25H, 29V, 32A, 37S,
42S and 45M);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:68]
120 125

PEPTIDE #5; pMON13347 (Example 12); (15-125)hIL-3 (51R, 55L, 59L, 62V,
67N and 69E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:69]
120 125

PEPTIDE #6; pMON13348 (Example 13); (15-125)hIL-3 (51R, 55L, 60S, 62V,
67N and 69E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:70]
120 125

PEPTIDE #7; pMON13349 (Example 14); (15-125)hIL-3 (51R, 55T, 59L, 62V,
67H and 69E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:71]
120 125

PEPTIDE #8; pMON13350 (Example 16); (15-125)hIL-3 (73G, 76A, 79R, 82Q, 87S,
93S, 98I, 101A and 105Q);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:72]
120 125

PEPTIDE #9; pMON13355 (Example 17); (15-125)hIL-3 (73G, 76A, 79R, 82V,
87S, 93S, 98T, 101A and 105Q);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:73]
120 125

PEPTIDE #10; pMON13352 (Example 19); (15-125)hIL-3 (109E, 116V, 120Q
and 123E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:74]
120 125

PEPTIDE #11; pMON13354 (Example 20); (15-125)hIL-3 (109E, 116V, 117S, 120H
and 123E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:75]
120 125

PEPTIDE #12; pMON13360 (Example 21); (15-125)hIL-3 (73G, 76A, 79R, 82Q,
87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ. NO:76]
120 125

PEPTIDE #13: pMON13361 (Example 22); (15-125)hIL-3 (73G, 76A, 79R, 82V,
87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:77]
120 125

PEPTIDE #14; pMON13362 (Example 23); (15-125)hIL-3 (73G, 76A, 79R, 82V,
87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E);

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:78]
120 125

PEPTIDE #15; pMON13363 (Example 24); (15-125)hIL-3 (18I, 25H, 29R, 32A,
37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N and 69E);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:79]
120 125

PEPTIDE #16; pMON13364 (Example 25); (15-125)hIL-3 (18I, 25H, 29R, 32N,
37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H and 69E);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:80]
120 125

PEPTIDE #17; pMON13365 (Example 26); (15-125)hIL-3 (18I, 25H, 29V, 32A,
37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N and 69E);

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:81]
120 125

PEPTIDE #18; pMON13298 (Example 27); Met-Ala-(15-125)hIL-3 (73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:82]
120 125

PEPTIDE #19; pMON13299 (Example 28); Met-Ala-(15-125)hIL-3 (73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:83]
120 125

PEPTIDE #20; pMON13300 (Example 29); Met-Ala-(15-125)hIL-3 (73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:84]
120 125

PEPTIDE #21; pMON13301 (Example 30); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N and 69E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:85]
120 125

PEPTIDE #22; pMON13302 (Example 31); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H and 69E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:86]
120 125

PEPTIDE #23; pMON13303 (Example 32); Met-Ala-(15-125)hIL-3 (18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N and 69E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:87]
120 125

PEPTIDE #24; pMON13287 (Example 33); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:88]
120 125

PEPTIDE #25; pMON13288 (Example 34); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:89]
120 125

PEPTIDE #26; pMON13289 (Example 35); Met-Ala-(15-125)hIL-3 (18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:90]
120 125

PEPTIDE #27; pMON13290 (Example 36); Met-Ala-(15-125)hIL-3 (18I,

25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:91]
120 125

PEPTIDE #28; pMON13292 (Example 37); Met-Ala-(15-125)hIL-3 (18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:92]
120 125

PEPTIDE #29; pMON13294 (Example 38); Met-Ala-(15-125)hIL-3 (18I,

25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:93]
120 125

PEPTIDE #30; pMON13295 (Example 39); Met-Ala-(15-125)hIL-3 (18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:94]
120 125

PEPTIDE #31; pMON13312 (Example 40); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and

123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:95]
120 125

PEPTIDE #32; pMON13313 (Example 41); Met-Ala-(15-125)hIL-3 (18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E);

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
105 110 115

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:96]
120 125

PEPTIDE #A3; pMON13285 Met-Ala-(15-125)hIL-3; (42D, 45M, 46S, 50D);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met Ser** Ile Leu Met **Asp** Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:259]
120 125

PEPTIDE #A4; pMON13286 Met-Ala-(15-125)hIL-3; (42D, 45M, 46S);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met Ser** Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:260]
120 125

PEPTIDE #A5; pMON13325 Met-Ala-(15-125)hIL-3; (42D, 45M, 46S, 116W);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met Ser** Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu **Trp** Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:261]
120 125

PEPTIDE #A6; pMON13326 Met-Ala-(15-125)hIL-3; (42D, 45M, 46S, 50D, 116W);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met Ser** Ile Leu Met **Asp** Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu **Trp** Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:262]
120 125

PEPTIDE #A7; pMON13330 Met-Ala-IL-3; (42D, 45M, 46S, 50D, 95R, 98I, 100R, 116W);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met Ser** Ile Leu Met **Asp** Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg **Arg** Pro Ile **Ile** Ile **Arg** Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu **Trp** Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:263]
120 125

PEPTIDE #A8; pMON13329 Met-Ala-(15-125)hIL-3; (42D, 45M, 46S, 98I, 100R, 116W);

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn **Asp**
30 35 40

Glu Asp **Met** **Ser** Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
45 50 55

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85

Ala Thr Ala Ala Pro Thr Arg His Pro Ile **Ile** Ile **Arg** Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu **Trp** Thr
105 110 115

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:406]
120 125

PEPTIDE #B1 Met-Ala-(15-125)hIL-3 pMON13406

Met Ala Asn Cys Ser Ile Ala Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 264]
120 125

PEPTIDE # B2 Met-Ala-(15-125)hIL-3 pMON13414

Met Ala Asn Cys Ser Ile Ile Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 265]
120 125

PEPTIDE #B3 Met-Ala-(15-125)hIL-3 pMON13407

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 266]
120 125

PEPTIDE #B4 Met-Ala-(15-125)hIL-3 pMON13405

Met Ala Asn Cys Ser Ile Ala Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 267]
120 125

PEPTIDE #B5 Met-Ala-(15-125)hIL-3 pMON13415

Met Ala Asn Cys Ser Ile Ile Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 268]
120 125

PEPTIDE #B6 Met-Ala-(15-125)hIL-3 pMON13408

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

30 35 40

Glu Asp Met Asp Ile Leu Ile Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 269]
120 125

PEPTIDE #B7 Met-Ala-(15-125)hIL-3 pMON13409

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Leu Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 270]
120 125

PEPTIDE #B8 Met-Ala-(15-125)hIL-3 pMON13410

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Asp Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 271]
120 125

PEPTIDE #B9 Met-Ala-(15-125)hIL-3 pMON13422

Met Ala Asn Cys Ser Ile Ala Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Ile Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 272]
120 125

PEPTIDE #B10 Met-Ala-(15-125)hIL-3 pMON13423

Met Ala Asn Cys Ser Ile Ile Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Ile Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 273]
120 125

PEPTIDE #B11 Met-Ala-(15-125)hIL-3 pMON13424

Met Ala Asn Cys Ser Ile Ala Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Leu Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 274]
120 125

PEPTIDE #B12 Met-Ala-(15-125)hIL-3 pMON13425

Met Ala Asn Cys Ser Ile Ile Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Leu Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 275]
120 125

PEPTIDE #B13 Met-Ala-(15-125)hIL-3 pMON13426

Met Ala Asn Cys Ser Ile Ala Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Asp Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 276]
120 125

PEPTIDE #B14 Met-Ala-(15-125)hIL-3 pMON13429

Met Ala Asn Cys Ser Ile Ile Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Val Asp Ile Leu Asp Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 277]
120 125

PEPTIDE #B15 Met-Ala-(15-125)hIL-3 pMON13368

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO: 278]
120 125

PEPTIDE #B16 Met-Ala-(15-125)hIL-3 pMON13380

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO. 279]
120 125

PEPTIDE #B17 Met-Ala-(15-125)hIL-3 pMON13475

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 280]
120 125

PEPTIDE #B18 Met-Ala-(15-125)hIL-3 pMON13366

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asn
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 281]
120 125

PEPTIDE #B19 Met-Ala-(15-125)hIL-3 pMON13367

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 282]
120 125

PEPTIDE #B20 Met-Ala-(15-125)hIL-3 pMON13369

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 283]
120 125

PEPTIDE #B21 Met-Ala-(15-125)hIL-3 pMON13370

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Met Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 284]
120 125

PEPTIDE #B22 Met-Ala-(15-125)hIL-3 pMON13378

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 285]
120 125

PEPTIDE #B23 Met-Ala-(15-125)hIL-3 pMON13374

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 286]
120 125

PEPTIDE #B24 Met-Ala-(15-119)hIL-3 pMON13375

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu [SEQ ID NO.: 287]
119

PEPTIDE #B25 Met-Asp-(15-119)hIL-3 pMON13376

Met Asp Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu [SEQ ID NO.: 288]
119

PEPTIDE #B26 Met-Ala-(15-125)hIL-3 pMON13377

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 289]
120 125

PEPTIDE #B27 Met-Asp-(15-119)hIL-3 pMON13378

Met Asp Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu [SEQ ID NO.: 290]
119

PEPTIDE #B28 Met-Ala-(15-125)hIL-3 pMON13379

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 291]
120 125

PEPTIDE #B29 Met-Ala-(15-125)hIL-3 pMON13385

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Val Pro Pro Arg Pro Ser Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 292]
120 125

PEPTIDE #B30 Met-Ala-(15-125)hIL-3 pMON13381

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Trp Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 293]
120 125

PEPTIDE #B31 Met-Ala-(15-125)hIL-3 pMON13383

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 294]
120 125

PEPTIDE #B32 Met-Ala-(15-125)hIL-3 pMON13384

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 295]
120 125

PEPTIDE #B33 Met-Ala-(15-125)hIL-3 pMON13388

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Ser Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 296]
120 125

PEPTIDE #B34 Met-Ala-(15-125)hIL-3 pMON13389

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 297]
120 125

PEPTIDE #B35 Met-Ala-(15-125)hIL-3 pMON13391

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 298]
120 125

PEPTIDE #B36 Met-Ala-(15-125)hIL-3 pMON13392

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 299]
120 125

PEPTIDE #B37 Met-Ala-(15-125)hIL-3 pMON13393

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 300]
120 125

PEPTIDE #B38 Met-Ala-(15-125)hIL-3 pMON13394

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 301]
120 125

PEPTIDE #B39 Met-Ala-(15-125)hIL-3 pMON13395

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Val Pro Pro Arg Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 302]
120 125

PEPTIDE #B40 Met-Ala-(15-125)hIL-3 pMON13396

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Arg Met Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 303]
120 125

PEPTIDE #B41 Met-Ala-(15-125)hIL-3 pMON13397

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Trp Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Arg Met Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 304]
120 125

PEPTIDE #B42 Met-Ala-(15-125)hIL-3 pMON13398

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 305]
120 125

PEPTIDE #B43 Met-Ala-(15-125)hIL-3 pMON13399

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Val Pro Pro Arg Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 306]
120 125

PEPTIDE #B44 Met-Ala-(15-119)hIL-3 pMON13404

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Val Thr
105 110 115

Leu Glu [SEQ ID NO.: 307]
119

PEPTIDE #B45 Met-Ala-(15-125)hIL-3 pMON13387

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 308]
120 125

PEPTIDE #B46 Met-Ala-(15-125)hIL-3 pMON13416

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 309]
120 125

PEPTIDE #B47 Met-Ala-(15-125)hIL-3 pMON13417

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 310]
120 125

PEPTIDE #B48 Met-Ala-(15-125)hIL-3 pMON13420

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Ser Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 311]
120 125

PEPTIDE #B49 Met-Ala-(15-125)hIL-3 pMON13421

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Ser Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.:331]
120 125

PEPTIDE #B50 Met-Ala-(15-125)hIL-3 pMON13432

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp
30 35 40

Glu Asp Met Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 312]
120 125

PEPTIDE #B51 Met-Ala-(15-125)hIL-3 pMON13382

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Gln Phe Tyr Leu Trp Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 313]
120 125

PEPTIDE #B52 Met-Asp-(15-125)hIL-3 pMON13476

Met Asp Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
30 35 40

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
45 50 55

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 314]
120 125

PEPTIDE #B53 Met-Ala-(15-125)hIL-3 pMON13446

Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys Asn
-14 -10 -5 15

Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro
20 25 30

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val
35 40 45

Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

50 55 60

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu
65 70 75

Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala
80 85 90

Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln
95 100 105

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln
110 115 120

Ala Gln Glu Gln Gln [SEQ ID NO.: 315]
125

PEPTIDE #B54 Met-Ala-(15-125)hIL-3 pMON13390

Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys Asn
-14 -10 -5 15

Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro
20 25 30

Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met
35 40 45

Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala
50 55 60

Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu
65 70 75

Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala
80 85 90

Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln
95 100 105

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln
110 115 120

Ala Gln Glu Gln Gln [SEQ ID NO.: 316]
125

PEPTIDE #C-2 Met-Ala-(15-125)hIL-3 pMON13400

Met Ala Asn Cys Ser Ile Met Pro Asp Glu Ala Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 317]
120 125

PEPTIDE #C-3 Met-Ala-(15-125)hIL-3 pMON13402

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 318]
120 125

PEPTIDE #C-10 Met-Ala-(15-125)hIL-3 pMON13440

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg Thr Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 319]
120 125

PEPTIDE #C-11 Met-Ala-(15-125)hIL-3 pMON13451

Met Ala Asn Cys Ser Ile Ile Leu Asp Glu Ala Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg Thr Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 320]
120 125

PEPTIDE #C-4 Met-Ala-(15-125)hIL-3 pMON13403

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Asp Ser Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Pro His Ala Ser Lys Gln Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 321]
120 125

PEPTIDE #C-5 Met-Ala-(15-125)hIL-3 pMON13411

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 322]
120 125

PEPTIDE #C-6 Met-Ala-(15-118)hIL-3 pMON13412

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Thr Leu
105 110 115 118

[SEQ ID NO.: 323]

PEPTIDE #C-7 Met-Ala-(15-125)hIL-3 pMON13413

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Ser
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 324]
120 125

PEPTIDE #C-8 Met-Ala-(15-125)hIL-3 pMON13419

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Asp Ser Asn Leu Leu Thr Pro Asn
45 50 55

Leu Leu Ala Phe Pro His Ala Ser Lys Gln Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Ser
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 325]
120 125

PEPTIDE #C-1 Met-Ala-(15-125)hIL-3 pMON13418

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Ser Asn Leu Gln Pro Cys Val Pro Tyr
75 80 85

Trp Thr Ala Pro Pro Ser Arg Thr Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 326]
120 125

PEPTIDE #C-9 Met-Ala-(15-125)hIL-3 pMON13428

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
15 20 25

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
30 35 40

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Ser Asn Leu Gln Pro Cys Val Pro Tyr
75 80 85

Trp Thr Ala Pro Pro Ser Arg Thr Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 327]
120 125

PEPTIDE #C-12 Met-Ala-(15-125)hIL-3 pMON13459

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Ser Asn Leu Gln Pro Cys Val Pro Tyr
75 80 85

Trp Thr Ala Pro Pro Ser Arg Thr Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 328]
120 125

PEPTIDE #C-13 Met-Ala-(15-125)hIL-3 pMON13467

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
75 80 85

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Leu Lys Leu Gln Phe Tyr Leu Ser Ser
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 329]
120 125

PEPTIDE #C-14 Met-Ala-(15-125)hIL-3 pMON13492

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His Leu
15 20 25

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser
30 35 40

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
45 50 55

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
60 65 70

Gly Ile Glu Pro Ile Leu Ser Asn Leu Gln Pro Cys Val Pro Tyr
75 80 85

Trp Thr Ala Pro Pro Ser Arg Thr Pro Ile Thr Ile Lys Ala Gly
90 95 100

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
105 110 115

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 330]
120 125

TABLE 4
DNA SEQUENCES

pMON13287

Met-Ala-(15-125)IL-3

DNA sequence #1
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:97]

pMON13290

Met-Ala-(15-125)IL-3

DNA sequence #2
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:98]

pMON13313

Met-Ala-(15-125)IL-3

DNA sequence #3
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:99]

pMON13288

Met-Ala-(15-125)IL-3

DNA sequence #4
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:100]

pMON13312

Met-Ala-(15-125)IL-3
DNA sequence #5
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:101]

pMON13294

Met-Ala-(15-125)IL-3

DNA sequence #6
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:102]

pMONM13289

Met-Ala-(15-125)IL-3

DNA sequence #7
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:103]

pMON13292

Met-Ala-(15-125)IL-3

DNA sequence #8
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:104]

pMON13295

Met-Ala-(15-125)IL-3

DNA sequence #9
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:105]

pMON13344

(15-125)IL-3

DNA sequence #10

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:106]

pMON13345

(15-125)IL-3

DNA sequence #11

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:107]

pMON13346

(15-125)IL-3

DNA sequence #12

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:108]

pMON13347

(15-125)IL-3

DNA sequence #13

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:109]

pMON13348

(15-125)IL-3

DNA sequence #14

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:110]

pMON13349

(15-125)IL-3

DNA sequence #15

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:111]

pMON13350

(15-125)IL-3

DNA sequence #16

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:112]

pMON13355

(15-125)IL-3

DNA sequence #17

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:113]

pMON13352

(15-125)IL-3

DNA sequence #18

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:114]

pMON13354

(15-125)IL-3

DNA sequence #19

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:115]

pMON13363

(15-125) IL-3 SECRETED

DNA sequence #20

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:116]

pMON13364

(15-125) IL-3 SECRETED

DNA sequence #21

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:117]

pMON13365

(15-125) IL-3 SECRETED

DNA sequence #22

AACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:118]

pMON13360

(15-125)IL-3 SECRETED

DNA sequence #23

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:119]

pMON13361

(15-125)IL-3 SECRETED

DNA sequence #24

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:120]

pMON13362

(15-125)IL-3 SECRETED

DNA sequence #25

AACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:121]

pMON13301

(15-125)IL-3 INTRACELLULAR

DNA sequence #26
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:122]

pMON13302

(15-125)IL-3 INTRACELLULAR

DNA sequence #27
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:123]

pMON13303

(15-125)IL-3 INTRACELLULAR

DNA sequence #28
ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTTCCACCTGCACCTTTG

CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCAATTGAGAGCATTCTT

AAAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAG

GACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCAG

GCTCAACAG [SEQ ID NO:124]

pMON13298

(15-125)IL-3 INTRACELLULAR

DNA sequence #29
ATGGCTAACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:125]

pMON13299

(15-125)IL-3 INTRACELLULAR

DNA sequence #30

ATGGCTAACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:126]

pMON13300

Met-Ala-(15-125)IL-3 INTRACELLULAR

DNA sequence #31

ATGGCTAACTGCTCTAACATGATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTG

CTGGACTTCAACAACCTCAATGGTGAAGACCAAGATATCCTGATGGAAAATAACCTTCGTCGTCCA

AACCTCGAGGCATTCAACCGTGCTGTCAAGTCTCTGCAGAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCGTACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCACCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTTCCCTTGAGCACGCGCAG

GAACAACAG [SEQ ID NO:127]

DNA sequence #32

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAACGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO: 160]

DNA sequence #33

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACATGGACATTTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAACGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO: 161]

DNA sequence #B1 pMON13406 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAGCTATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 332]

DNA sequence #B2 pMON13414 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAATCATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 333]

DNA sequence #B3 pMON13407 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 334]

DNA sequence #B4 pMON13405 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAGCTATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 335]

DNA sequence #B5 pMON13415 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAATGATCCATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 336]

DNA sequence #B6 pMON13408 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATCGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 337]

DNA sequence #B7 pMON13409 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGCTGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 338]

DNA sequence #B8 pMON13410 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGGACGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 339]

DNA sequence #B9 pMON13422 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAGCTATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGATCGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 340]

DNA sequence #B10 pMON13423 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAATCATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGATCGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 341]

DNA sequence #B11 pMON13424 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAGCTATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGCTGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 342]

DNA sequence #B12 pMON13425 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAATCATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGCTGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 343]

DNA sequence #B13 pMON13426 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAGCTATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTGATATCCTGGACGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 344]

DNA sequence #B14 pMON13429 Met-Ala-(15-125)IL-3

ATGGCAAACTGCTCTATAATCATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCTGAAGACGTTATATCCTGGACGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 345]

DNA sequence #B15 pMONM13368 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATTATGATCGATGAAGCAATACATCACTTAAAGGTTCCACCTGCACCTTTG
CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 346]

DNA sequence #B16 pMONM13380 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGGTTCCACCTGCACCTTTG
CTGGACAGTAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 347]

DNA sequence #B17 pMON13475 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGACGAAGACGTTTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 348]

DNA sequence #B18 pMON13366 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATAACGAAGACGTTTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 349]

DNA sequence #B19 pMON13367 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTTTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.:350]

DNA sequence #B20 pMON13369 Met-Ala-(15-125)IL-3 42D, 46S, 50D

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGACGAAGACGTTTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.:351]

DNA sequence #B21 pMON13370 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACATGTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 352]

DNA sequence #B22 pMON13373 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGACGAAGACATGTCTATTCTGATGGACCGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 353]

DNA sequence #B23 pMON13374 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO.: 354]

DNA sequence #B24 pMON13375 Met-Ala-(15-119)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG

CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA

AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAG [SEQ ID NO.: 355]

DNA sequence #B25 pMON13376 Met-Asp-(15-119)IL-3

ATGGATAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAG [SEQ ID NO.: 356]

DNA sequence #B26 pMON13377 Met-Ala-(15-119)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATTCTGATGGACCGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAG [SEQ ID NO.: 357]

DNA sequence #B27 pMON13378 Met-Asp-(15-119)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAG [SEQ ID NO.: 358]

DNA sequence #B28 pMON13379 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTTTCTATCCTGATGGACCGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 359]

DNA sequence #B29 pMON13385 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGGTACCACCTCGCCCTTCC
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 360]

DNA sequence #B30 pMON13381 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCTGGCCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 361]

DNA sequence #B31 pMON13383 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTTTCTATTCTGATGGACCGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 362]

DNA sequence #B32 pMON13384 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 363]

DNA sequence #B33 pMON13388 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGACCGAAACCTTCGACTTAGC
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 364]

DNA sequence #B34 pMON13389 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACATGGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 365]

DNA sequence #B35 pMON13391 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTCC
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 366]

DNA sequence #B36 pMON13392 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 367]

DNA sequence #B37 pMON13393 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACATGTCTATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 368]

DNA sequence #B38 pMON13394 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACATGTCTATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 369]

DNA sequence #B39 pMON13395 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGGTACCACCTCGCCCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 370]

DNA sequence #B40 pMON13396 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCCGT
ATGGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 371]

DNA sequence #B41 pMON13397 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCTGGCCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCCGT
ATGGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 372]

DNA sequence #B42 pMON13398 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 373]

DNA sequence #B43 pMON13399 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGGTACCACCTCGCCCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 374]

DNA sequence #B44 pMON13404 Met-Ala-(15-119)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGGTTACCCTTGAG [SEQ ID NO.: 375]

DNA sequence #B45 pMON13387 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGACCGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 376]

DNA sequence #B46 pMON13416 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTCGATTCTCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 377]

DNA sequence #B47 pMON13287 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGACGAAGACGTCATGTCTCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 378]

DNA sequence #B48 pMON13420 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGACCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCACTTAGC
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 379]

DNA sequence #B49 pMON13421 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACATGTCTATCCTGATGGACCGAAACCTTCGACTTAGC
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 380]

DNA sequence #B50 pMON13432 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTCC
CTGGACCCGAACAACCTCAATGACGAAGACATGTCTATCCTGATGGACCGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 381]

DNA sequence #B51 pMON13382 Met-Ala-(15-125)IL-3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGCAATTCTATCTGTGGACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 382]

DNA sequence #B52 pMON13476 Met-Asp-(15-125)IL-3

ATGGATAACTGCTCTATTATGATCGATGAAGCAATACATCACTTAAAGAGACCACCTGCACCTTTG
CTGGACCCGAACAACCTCAATGCTGAAGACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCA
AACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO.: 383]

pMON13400

Met-Ala-(15-125)IL-3

DNA sequence #C2

ATGGCTAACTGCTCTATAATGCCAGATGAAGCAATACATCACTTAAAGATACCACCTAACCCTAGC

CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:384]

pMON13402

Met-Ala-(15-125)IL-3

DNA sequence #C3

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGATACCACCTAACCCTAGC

CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:385]

pMON13440

Met-Ala-(15-125)IL-3

DNA sequence #C10

ATGGCTAACTGCTCTATTATGATCGATGAAGCAATACATCACTTAAAGATACCACCTAACCCTAGC

CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:386]

pMON13451

Met-Ala-(15-125)IL-3

DNA sequence #C11

ATGGCTAACTGCTCTATAATACTCGATGAAGCAATACATCACTTAAAGATACCACCTAACCCTAGC
CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:387]

pMON13403

Met-Ala-(15-125)IL-3

DNA sequence #C4

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGACTCCAACCTTCGAACTCCA
AACCTGCTCGCATTCCCACATGCTGTCAAGCAATTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:388]

pMON13419

Met-Ala-(15-125)IL-3

DNA sequence #C8

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGACTCCAACCTTCGAACTCCA
AACCTGCTCGCATTCCCACATGCTTCTAAGCAATTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:389]

pMON13411

Met-Ala-(15-125)IL-3

DNA sequence #C5

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTACCCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:390]

pMON13412

Met-Ala-(15-118)IL-3

DNA sequence #C6

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTACCCTTTAATA

[SEQ ID NO:391]

pMON13413

Met-Ala-(15-125)IL-3

DNA sequence #C7

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG

CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA

AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT

CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG

GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTTCTCTTGAGCAAGCGCAG

GAACAACAG [SEQ ID NO:392]

pMON13418

Met-Ala-(15-125)IL-3

DNA sequence #C1

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGCCAATTCTT
TCTAATCTCCAACCATGTGTTCCCTATTGGACGGCCCCTCCCTCTCGAACACCAATCACGATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:393]

pMON13428

Met-Ala-(15-125)IL-3

DNA sequence #C9

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTG
CTGGACCCGAACAACCTCAATTCCGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGCCAATTCTT
TCTAATCTCCAACCATGTGTTCCCTATTGGACGGCCCCTCCCTCTCGAACACCAATCACGATCAAG
GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:394]

pMON13459

Met-Ala-(15-125)IL-3

DNA sequence #C12

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGATACCACCTAACCCTAGC
CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGCCAATTCTT
TCTAATCTCCAACCATGTGTTCCCTATTGGACGGCCCCTCCCTCTCGAACACCAATCACGATCAAG
GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:395]

pMON13467

Met-Ala-(15-125)IL-3

DNA sequence #C13

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGATACCACCTAACCCTAGC
CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTT
CGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAG
GCAGGTGACTGGCAAGAATTCCGGCTTAAACTGCAATTCTATCTGTCTTCTCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:396]

pMON13492

Met-Ala-(15-125)IL-3

DNA sequence #C14

ATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGATACCACCTAACCCTAGC
CTGGACAGTGCTAACCTCAATTCCGAAGACGTCTCTATCCTGATGGAACGAAACCTTCGAACTCCA
AACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGCCAATTCTT
TCTAATCTCCAACCATGTGTTCCCTATTGGACGGCCCCTCCCTCTCGAACACCAATCACGATCAAG
GCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAG
GAACAACAG [SEQ ID NO:397]

pMON13446

Met-Ala-Tyr-Pro-Glu-Thr-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Ala (15-125)IL-3

DNA sequence #B53

ATGGCATATCCAGAAACTGATTACAAGGACGACGATGACAAGGCTAACTGCTCTATAATGATCGAT
GAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGCTGAA
GACGTCGATATCCTGATGGAACGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTC
AAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCT
GCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAA
AAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG [SEQ ID NO:404]

pMON13390

Met-Ala-Tyr-Pro-Glu-Thr-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Ala (15-125)IL-3

DNA sequence #B54

ATGGCATATCCAGAAACTGATTACAAGGACGACGATGACAAGGCTAACTGCTCTATAATGATCGAT
GAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCCGAA
GACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTC
AAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCT
GCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAA
AAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG [SEQ ID NO:405]

Polypeptides corresponding to [SEQ ID NO. 129] comprising (1-133)hIL-3 containing four or more amino acid substitutions can be made using the procedures described above and in the following examples by starting with the appropriate oligonuctiotides and then constructing the DNA encoding the polypeptide and expressing it in an appropriate host cell. In a similar manner polypeptides which correspond to [SEQ ID NO. 130] and contain four or more amino acid substitutions and wherein from 1 to 14 amino acids have been sequentially deleted from the N-terminus, or from 1 to 15 amino acids have been deleted from the C-terminus or deletions of amino acids have been made from both the N-terminus and the C-terminus can also be made by following the procedures described above and in the following examples, beginning with the appropriate starting materials.

Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1982) and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989) and references cited therein, incorporated herein by reference.

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

Amino acids are shown herein by standard one letter or three letter abbreviations as follows:

Abbreviated Designation		Amino Acid
A	Ala	Alanine
C	Cys	Cysteine
D	Asp	Aspartic acid
E	Glu	Glutamic acid
F	Phe	Phenylalanine
Abbreviated Designation		Amino Acid
G	Gly	Glycine
H	His	Histidine
I	Ile	Isoleucine
K	Lys	Lysine
L	Leu	Leucine
M	Met	Methionine
N	Asn	Asparagine
P	Pro	Proline
Q	Gln	Glutamine
R	Arg	Arginine
S	Ser	Serine
T	Thr	Threonine
V	Val	Valine
W	Trp	Tryptophan
Y	Tyr	Tyrosine

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

References

Adams, S.P., Kavka, K.S., Wykes, E.J., Holder, S.B. and Galluppi, G.R. Hindered Dialkyamino Nucleoside Phosphate reagents in the synthesis of two DNA 51-mers. J. Am. Chem. Soc., 105, 661-663 (1983).

Atkinson, T. and Smith, M., in Gait, M.J., Oligonucleotide Sythesis (1984) (IRL Press, Oxford England).

Bachmann, B., Pedigrees of some mutant strains of Escherichia coli K-12, Bacteriological Reviews, 36:525-557 (1972).

Bayne, M. L., Expression of a synthetic gene encoding human insulin-like growth factor I in cultured mouse fibroblasts. Proc. Natl. Acad. Sci. USA 84, 2638-2642 (1987).

Ben-Bassat, A., K. Bauer, S-Y. Chang, K. Myambo, A. Boosman and S. Ching. Processing of the initiating methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J. Bacteriol., 169: 751-757 (1987).

Biesma, B. et al., Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood, 80:1141-1148 (1992).

Birnboim, H. C. and J. Doly. A rapid alkaline extraction method for screening recombinant plasmid DNA. Nucleic Acids Research, 7(6): 1513-1523 (1979).

Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing

the principle of protein-dye binding, Analytical Biochemistry, 72: 248-254 (1976).

Clark-Lewis, I., L. E. Hood and S. B. H. Kent. Role of disulfide bridges in determining the biological activity of interleukin 3, Proc. Natl. Acad. Sci., 85: 7897-7901 (1988).

Clement, J. M. and Hofnung, M. Gene sequence of the receptor, an outer membrane protein of E. coli K12. Cell, 27: 507-514 (1981).

Covarrubias, L., L. Cervantes, A. Covarrubias, X. Soberon, I. Vichido, A. Blanco, Y. M. Kupersztoch-Portnoy and F. Bolivar. Construction and characterization of new cloning vehicles. V. Mobilization and coding properties of pBR322 and several deletion derivates including pBR327 and pBR328. Gene 13: 25-35 (1981).

Deng, W.P. & Nickoloff, J.A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site Anal. Biochem. 200:81 (1992).

Dente, L., G. Cesareni and R. Cortese, pEMBL: a new family of single stranded plasmids, Nucleic Acids Research, 11: 1645-1655 (1983).

Dunn, J.J. and Studier, F.W., Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J. Mol. Biol. 166:477-535 (1983).

Falk, S., G. Seipelt, A. Ganser, O. G. Ottmann, D. Hoelzer, H. J. Stutte and K. Hubner. Hematopathology 95: 355 (1991).

Fling, M. E., et al. Nucleotide sequence of the

transposon Tn7 gene encoding an aminoglycoside-modifying enzyme, 3"(9)-O-nucleotidyltransferase. Nucl. Acids Res. 13:7095-7106 (1985).

Ganser, A., A. Lindemann, G. Seipelt, O. G. Ottmann, F. Herrmann, M. Eder, J. Frisch, G. Schulz, R. Mertelsmann and D. Hoelzer. Effects of Recombinant Human Interleukin-3 in Patients With Normal Hematopoiesis and in Patients with Bone Marrow Failure, Blood 76: 666 (1990).

Gething and Sambrook, Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene, Nature, 293: 620-625 (1981).

Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick and R. J. O'Reilly. J. Clin. Invest. 85: 1560 (1990).

Gouy, M. and G. Gautier, Codon usage in bacteria: Correlation with gene expressivity, Nucleic Acids Research, 10: 7055-7074 (1982).

Greenfield, L., T. Boone, and G. Wilcox. DNA sequence of the araBAD promoter in Escherichia coli B/r. Proc. Natl. Acad. Sci. USA, 75: 4724-4728 (1978).

Higuchi, R, (1989) in *PCR Technology*, H.A. Erlich ed., Stockton Press, N.Y. chapter 2-6.

Hunkapiller, M. W., R. W. Hewick, R. J. Dreyer and L. E. Hood. High sensitivity sequencing with a gas-phase sequenator. Methods in Enzymology 153: 399-413 (1983).

Kaufman, et al., Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster

Ovary Cells, Mol. Cell. Biol., 5(7): 1750-1759 (1985).

Kaufman, R. J. High level production of proteins in mammalian cells, in Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York (1987).

Kunkel, T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA, 82: 488-492 (1985).

Laemmli, U. K., Cleavage of structural proteins during assembly of the head of bacteriophage T4, Nature, 227:680-685 (1970).

Lange, B., M. Valtieri, D. Santoli, D. Caracciolo, F. Mavilio, I. Gemperlein, C. Griffin, B. Emanuel, J. Finan, P. Nowell, and G. Rovera. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-defendent cell lines. Blood 70:192 (1987).

Mahler, H. R. and E. H. Cordes, in Biological Chemistry, p. 128, New York, Harper and Row (1966).

Maniatis, T., E. F. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory (1982).

Marinus, M. G. Location of DNA methylation genes on the Escherichia coli K-12 genetic map. Molec. Gen. Genet. 127: 47-55 (1973).

McBride, L.J. and Caruthers, M.H. An investigation of several deoxynucleoside phosphoramidites. Tetrahedron Lett., 24, 245-248 (1983).

Messing, J., A multipurpose cloning system based on the

single-stranded DNA bacteriophage M13. Recombinant DNA Technical Bulletin, NIH Publication No. 79-99, Vol. 2, No. 2, pp. 43-48 (1979).

Neu, H. C. and L. A. Heppel. The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J. Biol. Chem., 240: 3685-3692 (1965).

Obukowicz, M.G., Staten, N.R. and Krivi, G.G., Enhanced Heterologous Gene Expression in Novel rpoH Mutants of Escherichia coli. Applied and Environmental Microbiology 58, No. 5, p. 1511-1523 (1992).

Olins, P. O., C. S. Devine, S. H. Rangwala and K. S. Kavka, The T7 phage gene 10 leader RNA, a ribosome-binding site that dramatically enhances the expression of foreign genes in Escherichia coli, Gene, 73:227-235 (1988).

Olins, P. O. and S. H. Rangwala, Vector for enhanced translation of foreign genes in Escherichia coli, Methods in Enzymology, 185: 115-119 (1990).

Postmus, et al., Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J. Clin. Oncol., 10:1131-1140 (1992).

Prober, J. M., G. L. Trainor, R. J. Dam, F. W. Hobbs, C. W. Robertson, R. J. Zagursky, A. J. Cocuzza, M. A. Jensen and K. Baumeister. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 238: 336-341 (1987).

Renart J., J. Reiser and G. R. Stark, Transfer of proteins from gels to diazobenzyloxymethyl-paper and

detection with anti-sera: a method for studying antibody specificity and antigen structure, Proc. Natl. Acad. Sci. USA, 76:3116-3120 (1979).

Saiki, R.K., Schorf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N., Enzymatic Amplification of ß-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia, Science, 230: 1350-1354 (1985).

Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989).

Sancar, A., C. Stachelek, W. Konigsberg and W. D. Rupp, Sequences of the recA gene and protein, Proc. Natl. Acad. Sci., 77: 2611-2615 (1980).

Sanger, F., S. Nicklen and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 74: 5463-5467 (1977).

Santoli, D., Y. Yang, S. C. Clark, B. L. Kreider, D. Caracciolo, and G. Rovera. Synergistic and antagonistic effects of recombinant human interleukin (IL-3), IL-1 , granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139:348 (1987).

Smith, M. In vitro mutagenesis. Ann. Rev. Genet., 19:423-462 (1985).

Soberon, X., L. Covarrubias and F. Bolivar, Construction and characterization of new cloning vehicles. IV. Deletion derivatives of pBR322 and pBR325, Gene, 9: 211-223 (1980).

Stader, J. A. and T. J. Silhavy. Engineering Escherichia coli to secrete heterologous gene products, Methods in Enzymology, 185: 166-87 (1990).

Summers, M. D. and G. E. Smith. A manual of methods for Baculovirus vectors and insect cell culture procedures. Texas Agricultural Experiment Station Bulletin No. 1555 (1987).

Taylor, J.W., Ott, J. and Eckstein, F.. The rapid generation of oligonucleotide-directed mutants at high frequency using phosphorothioate modified DNA. Nucl. Acids Res., 13:8764-8785 (1985).

Treco, D.A., (1989) in *Current protocols in Molecular Biology*, Seidman et al., eds. J Wiley N.Y., unit 2.1.

Valtieri, M., D. Santoli, D. Caracciolo, B. L. Kreider, S. W. Altmann, D. J. Tweardy, I. Gemperlein, F. Mavilio, B. J. Lange and G. Rovera. Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony stimulating factor for growth. J. Immunol. 138:4042 (1987).

Voet, D., W. B. Gatzer, R. A. Cox, P. Doty. Absorption spectra of the common bases. Biopolymers 1: 193 (1963).

Wells, J.A., Vasser, M., and Powers, D.B. Cassette mutagenesis: an effective method for generation of multiple mutants at defined sites. Gene, 34:315-323 (1985).

Wong, Y. Y., R. Seetharam, C. Kotts, R. A. Heeren, B. K. Klein, S. B. Braford, K. J. Mathis, B. F. Bishop, N. R. Siegel, C. E. Smith and W. C. Tacon. Expression of secreted IGF-1 in Escherichia coli. Gene, 68: 193-203 (1988).

Yanisch-Perron, C., J. Viera and J. Messing. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119 (1985).

Zoller, M.J. and Smith, M. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acid Research, 10: 6487-6500 (1982).

Zoller, M.J. and Smith, M. Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods in Enzymology, 100:468-500 (1983).

Zoller, M.J. and Smith, M. Oligonucleotide-directed Mutagenesis: A simple method using two oligonucleotide primers and a single-stranded DNA template. DNA, 3: 479 (1984).

EXAMPLE 1

Construction of pMON 5846 (Fig. 4) which encodes [Met-(1-133)hIL-3 (Arg^{129})]

A plasmid containing the gene for the cDNA of hIL-3 cloned into pUC18 on an EcoRI to HindIII fragment was

obtained from British Biotechnology Limited (Cambridge, England). This plasmid was designated pPO518. The purified plasmid DNA was cleaved by the restriction endonucleases NheI and BamHI. Approximately 0.5 micrograms of cleaved plasmid DNA was ligated to 1.0 picomoles of a pair of annealed oligonucleotides with the following sequence:

5'-CTAGCGATCTTTTAATAAGCTTG-3' [SEQ ID NO: 1]
3'-GCTAGAAAATTATTCGAACCTAG-5' [SEQ ID NO: 2]

The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and subjected to restriction enzyme analysis. An isolate was identified in which the above oligonucleotide sequence had replaced the portion of the gene that encodes the extreme C terminus. Within the new sequence was a new stop codon, TAA, and a recognition site for the enzyme HindIII. The new plasmid was designated pMON5846.

EXAMPLE 2

(a) Construction of expression vector plasmid pMON2341

The plasmid pMON2341 was used to supply the particular replicon and expression elements used for construction of many of the plasmids used to produce hIL-3 and hIL-3 muteins in E. coli. These expression elements are described in the materials and methods section. pMON2341 is derived from pMON5515 (Olins et al., 1988) and from pMON2429. pMON2429 consists of the phage mp18 (Yanisch-Perron et al., 1985) with a BclI fragment carrying the chloramphenicol acetyl transferase (cat) gene from pBR328 (Covarrubias et al., 1981) inserted into the BamHI site. The cat gene in pMON2429 has been altered from that in pBR328 by site directed mutagenesis (Kunkel, 1985). The recognition sites for

NcoI and EcoRI which occur in the native gene were altered so that these two restriction enzymes no longer recognize these sites. The changes did not alter the protein specified by the gene. Also, an NcoI site was introduced at the N-terminus of the coding sequence so that it overlaps the codon for initiator methionine.

The steps involved in construction of pMON2341 are listed below:

(1) The DNAs of pMON5515 and pMON2429 were treated with NcoI and HindIII. The fragments were ligated and used to transform competent E. coli to ampicillin resistance. From these colonies, some were identified that were chloramphenicol resistant. From one of these colonies, plasmid DNA was isolated in which the rat atriopeptigen gene of pMON5515 had been replaced by the NcoI to HindIII fragment containing the cat gene from pMON2429. This fragment contains the recognition sites for several restriction enzymes in the portion derived from the multilinker region of mp18. The new plasmid was designated pMON2412.

(2) pMON2412 was treated with the enzyme ClaI which cleaves at one location in the pBR327 derived portion of the DNA. The protruding ends were rendered blunt by treatment with Klenow in the presence of nucleotide precursors. This DNA was mixed with an isolated 514 bp RsaI fragment derived from pEMBL8 (Dente et al., 1983). This RsaI fragment contains the origin of replication of phage f1. This ligation mixture was used to transform competent E. coli cells to ampicillin resistance. Among the plasmid DNAs isolated from these cells was pMON5578. This plasmid has the structure of pMON2412 with the f1 origin region inserted into the ClaI site. This is illustrated in the Figures and in Olins and Rangwala (1990).

(3) The DNA of pMON5578 was treated with restriction enzymes HindIII and MstII. The DNA was then treated with Klenow enzyme in the presence of nucleotide precursors to

render the ends blunt. This treated DNA was ligated and used to transform competent E. coli to ampicillin resistance. From the ampicillin resistant colonies, one plasmid was recovered from which the portion between HindIII and MstII was absent. This deletion resulted in the removal of sequences from the plasmid which are recognized by a number of restriction endonuclease sites. The new plasmid was designated pMON5582.

(4) The DNA of pMON5582 was treated with SstII and BclII and ligated in the presence of annealed oligonucleotides with the sequences shown below.

5'- GGCAACAATTTCTACAAAACACTTGATACTGTATGAGCAT-
3'-CGCCGTTGTTAAAGATGTTTTGTGAACTATGACATACTCGTA-

ACAGTATAATTGCTTCAACAGAACAGATC-3' [SEQ ID NO:3]
TGTCATATTAACGAAGTTGTCTTGT-5' [SEQ ID NO:4]

This sequence encodes the essential elements of the recA promoter of E. coli including the transcription start site and the lexA repressor binding site (the operator) (Sancar et al., 1980). The plasmid recovered from the ligation mixes contained this recA promoter in place of the one in pMON5582 (and in pMON5515). The functionality of the recA promoter was illustrated by Olins and Rangwala (1990). The new plasmid was designated pMON5594.

(5) To eliminate the single EcoRI site in pMON5594, the DNA was treated with EcoRI, then with Klenow in the presence of nucleotide precursors to render the ends blunt and then the DNA was ligated. From this ligation mix a plasmid was recovered whose DNA was not cleaved with EcoRI. This plasmid was designated pMON5630.

(6) To alter the single recognition site for PstI, plasmid pMON5630 was subjected to site directed mutagensis (Kunkel, 1985). The oligonucleotide used in this procedure has the sequence shown below.

5'-CCATTGCTGCCGGCATCGTGGTC-3' [SEQ ID NO:5]

The result of the procedure was to construct pMON2341 which differs from pMON5630 in that the PstI site in the beta-lactamase gene was altered so that PstI no longer recognizes the site. The single nucleotide change does not alter the amino acid sequence of the beta-lactamase protein.

(b) Construction of pMON5847 (Fig. 5) which encodes [Met-(1-133)hIL-3(Arg^{129})]

Plasmid pMON2341 was used to supply the replicon, promotor, ribosome binding site, transcription terminator and antibiotic resistance marker for the plasmids used to produce hIL-3 in E. coli from cDNA derived hIL-3 genes.

Plasmid pMON2341 was treated with restriction enzymes NcoI and HindIII. The restriction fragment containing the replication origin was purified. The DNA of plasmid pMON5846 was treated with NcoI and HindIII. The restriction fragment containing the hIL-3 gene was gel purified. These purified restriction fragments were mixed and ligated. The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and analyzed using restriction enzymes. pMON5847 was identified as a plasmid with the replicon of pMON2341 and the hIL-3 gene in place of the chloramphenicol acetyl transferase gene. JM101 cells harboring this plasmid were cultured in M9 medium and treated with nalidixic acid as described above. Samples of the culture were examined for protein content. It was found that this hIL-3 mutein was produced at about 6% of total cell protein as measured on Coomassie stained polyacrylamide gels.

EXAMPLE 3

Construction of pMON5854 (Fig. 7) which encodes [Met-(1-133)hIL-3(Arg^{129})]

To increase the accumulation of hIL-3 in E. coli, the coding sequence of the amino terminal portion of the protein was altered to more closely reflect the codon bias found in E. coli genes that produce high levels of proteins (Gouy and Gautier, 1982). To change the coding sequence for the amino terminal portion of the gene, a pair of synthetic oligonucleotides were inserted between the NcoI and HpaI sites within the coding sequence. About 0.5 micrograms of DNA of the plasmid pMON5847 (Example 2) was treated with NcoI and HpaI. This DNA was mixed with an annealed pair of oligonucleotides with the following sequence:

5'-CATGGCTCCAATGACTCAGACTACTTCTCTTAAGACT-
3'-CGAGGTTACTGAGTCTGATGAAGAGAATTCTGA-

TCTTGGGTT-3' [SEQ ID NO:6]
AGAACCCAA-5' [SEQ ID NO:7]

The fragments were ligated. The ligation mixture was used to transform competent JM101 to ampicillin resistance. Colonies were picked into broth. From the cultures plasmid DNA was made and examined for the presence of a DdeI site (CTNAG) which occurs in the synthetic sequence but not between the NcoI and HpaI sites in the sequence of pMON5847. The new recombinant plasmid was designated pMON5854. The nucleotide sequence of the DNA in the coding sequence of the amino terminal portion of the hIL-3 gene in pMON5854 was determined by DNA sequencing and found to be the same as that of the synthetic oligonucleotide used in ligation. Cultures of JM101 cells harboring this plasmid were grown and treated with nalidixic acid to induce production of the hIL-3 mutant protein. Analysis of the proteins on Coomassie

gels showed that the accumulation of hIL-3 mutein was about 25% of total cell protein in cultures harboring pMON5854, significantly higher than it was in cultures harboring pMON5847.

EXAMPLE 4

Construction of pMON5887 (Fig. 12) which encodes [Met-(1-125)hIL-3]

The plasmid DNA of pMON5854 (Example 3) was treated with EcoRI and HindIII and the larger fragment gel was purified. About 0.5 microgram of this DNA was ligated to 1 picomole of an annealed pair of oligonucleotides which encode amino acids 107 through 125 of hIL-3. The sequences of these oligonucleotides are shown below.

EcoRI to HindIII

5'-AATTCCGTCGTAAACTGACCTTCTATCTGAAAA-

3'-GGCAGCATTTGACTGGAAGATAGACTTTT-

CCTTGGAGAACGCGCAGGCTCAACAGTAATA-3' [SEQ ID NO:8]

GGAACCTCTTGCGCGTCCGAGTTGTCATTATTCGA-5' [SEQ ID NO:9]

After ligation, the DNA was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and plasmid DNA was isolated from each culture. Restriction analysis of the plasmid DNA showed the presence of an EcoRI to HindIII fragment smaller than that of pMON5854. The nucleotide sequence of the portion of the coding sequence between the EcoRI and HindIII sites was determined to confirm the accuracy of the replaced sequence. The new plasmid was designated pMON5887 encoding Met-(1-125)hIL-3 which has the following amino acid sequence:

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser
Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn

Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:10]

EXAMPLE 5

Construction of pMON5967 which encodes [Met-Ala-(15-125)hIL-3]

Plasmid DNA of pMON5887 isolated from E. coli GM48 (dam-) was cleaved with NcoI and ClaI and ligated to 1 picomole of an annealed pair of oligonucleotides, encoding amino acids [Met Ala (15-20)hIL-3]. The sequence of these oligonucleotides is shown below.

5'-CATGGCTAACTGCTCTAACATGAT-3'[SEQ ID NO:11]

3'-CGATTGACGAGATTGTACTAGC-5'[SEQ ID NO:12]

The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated from these cells and the size of the inserted fragment was determined to be smaller than that of pMON5887 by restriction analysis using NcoI and NsiI. The nucleotide sequence of the region between NcoI and ClaI was determined and found to be that of the synthetic oligonucleotides. The new plasmid was designated pMON5967 and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bio-assay.

EXAMPLE 6

Construction of pMON5978 which encodes [Met-Ala-(15-125)hIL-3]

Plasmid DNA of pMON5967 isolated from E. coli GM48(dam-) was cleaved with ClaI and NsiI and ligated to

1 picomole of an annealed assembly of six oligonucleotides encoding hIL-3 amino acids 20-70 (FIG. 2). This synthetic fragment encodes three unique restriction sites, EcoRV, XhoI and PstI. The sequence of these oligonucleotides is shown in Figure 2.

The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated and screened with XbaI and EcoRV for the presence of the new restriction site EcoRV. The DNA sequence of the region between ClaI and NsiI was determined and found to be the same as that of the synthetic oligonucleotides. The new plasmid was designated pMON5978, and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bio-assay.

Plasmid pMON5978 encodes [Met-Ala-(15-125)hIL-3] which has the following amino acid sequence:

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:13]

EXAMPLE 7

Construction of pMON13356

Plasmid pMON5988 DNA was digested with restriction enzymes NcoI and EcoRV, and the resulting 4190 base pair NcoI,EcoRV fragment contains the following genetic elements: beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome

binding site, lamB secretion leader and the bases encoding amino acids 47-125 of (15-125)hIL-3. The 4190 base pair NcoI,EcoRV restriction fragment from pMON5988 was ligated to the following annealed complementary oligonucleotides from Table (2).

Oligo #13 [SEQ ID NO:27]
Oligo #14 [SEQ ID NO:28]

The ligation reaction mixture was used to transform E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. In the resulting plasmid the 99 bases between the NcoI and EcoRV restriction sites in the (15-125) hIL-3 gene are replaced with 22 bases from the above mentioned oligonucleotides. This linker also contains a NdeI recognition sequence.

EXAMPLE 8

Construction of pMON13344

Plasmid pMON13356 DNA was digested with restriction enzymes NcoI and EcoRV, and the resulting 4190 base pair NcoI,EcoRV fragment contains the following genetic elements: beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 47-125 of (15-125)hIL-3. The second DNA fragment was generated by synthetic gene assembly using the following complementary oligonucleotide pairs that have overlapping ends:

Oligo #1 [SEQ ID NO:15]
Oligo #2 [SEQ ID NO:16]

Oligo #3 [SEQ ID NO:17]
Oligo #4 [SEQ ID NO:18]

Oligo #9 [SEQ ID NO:23]
Oligo #10 [SEQ ID NO:24]

The assembled oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125)hIL-3 with the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A and 45V. The codons encoding amino acids 15-46 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The 4190 base pair NcoI,EcoRV restriction fragment from pMON13356 was ligated with the pairs of annealed oligonucleotides. The ligation reaction was digested with NdeI and subsequently used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA sequence was determined to be that of the oligonucleotides. The plasmid, pMON13344, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #2

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:66]

DNA sequence #10 [SEQ ID NO:106] codes for the foregoing pMON13344 polypeptide.

EXAMPLE 9

Construction of pMON13345

The 4190 base pair NcoI,EcoRV restriction fragment from pMON13356 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #1 [SEQ ID NO:15]
Oligo #2 [SEQ ID NO:16]

Oligo #5 [SEQ ID NO:19]
Oligo #6 [SEQ ID NO:20]

Oligo #11 [SEQ ID NO:25]
Oligo #12 [SEQ ID NO:26]

The assembled oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125)hIL-3 with the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S and 45M. The codons encoding amino acids 15-46 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13345, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #3

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:67]

DNA sequence #11 [SEQ ID NO:107] codes for the foregoing pMON13345 polypeptide.

EXAMPLE 10

Construction of pMON13346

The 4190 base pair NcoI,EcoRV restriction fragment from pMON13356 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #1 [SEQ ID NO:15]
Oligo #2 [SEQ ID NO:16]

Oligo #7 [SEQ ID NO:21]
Oligo #8 [SEQ ID NO:22]

Oligo #11 [SEQ ID NO:25]
Oligo #12 [SEQ ID NO:26]

The assembled oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125)hIL-3 with the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S and 45M. The codons encoding amino acids 15-46 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at

those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth and DNA sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13346, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #4

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:68]

DNA sequence #12 [SEQ ID NO:108] codes for the foregoing pMON13346 polypeptide.

EXAMPLE 11

Construction of pMON13357

Plasmid pMON5988 DNA was digested with restriction enzymes EcoRV and NsiI, and the resulting 4218 base pair EcoRV,NsiI fragment contains the following genetic elements: beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-46 and 72-125 of (15-125)hIL-3.

The 4218 base pair EcoRV,NsiI restriction fragment from pMON5988 was ligated to the following annealed complementary oligonucleotides:

Oligo #19 [SEQ ID NO:33]
Oligo #20 [SEQ ID NO:34]

The ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth, and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. In the resulting plasmid the 71 bases between the EcoRV and NsiI restriction sites in the (15-125)hIL-3 gene are replaced with 22 bases from the above mentioned oligonucleotides. This linker also contains a NdeI recognition sequence.

EXAMPLE 12

Construction of pMON13347

The 4218 base pair EcoRV,NsiI restriction fragment from pMON13357 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #21 [SEQ ID NO:35]
Oligo #22 [SEQ ID NO:36]

Oligo #25 [SEQ ID NO:39]
Oligo #26 [SEQ ID NO:40]

Oligo #31 [SEQ ID NO:45]
Oligo #32 [SEQ ID NO:46]

The assembled oligonucleotides create EcoRV and NsiI restriction ends and the DNA sequence that encodes amino acids 47-71 of (15-125)hIL-3 with the following amino acid substitutions: 51R, 55L, 59L, 62V, 67N and 69E. The codons encoding amino acids 47-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13347, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #5

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:69]

DNA sequence #13 [SEQ ID NO:109] codes for the foregoing pMON13347 polypeptide.

EXAMPLE 13

Construction of pMON13348

The 4218 base pair EcoRV,NsiI restriction fragment from pMON13357 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #21 [SEQ ID NO:35]
Oligo #22 [SEQ ID NO:36]

Oligo #27 [SEQ ID NO:41]
Oligo #28 [SEQ ID NO:42]

Oligo #31 [SEQ ID NO:45]
Oligo #32 [SEQ ID NO:46]

The assembled oligonucleotides create EcoRV and NsiI restriction ends and the DNA sequence that encodes amino acids 47-71 of (15-125)hIL-3 with the following amino acid substitutions: 51R, 55L, 60S, 62V, 67N and 69E. The codons encoding amino acids 47-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was

that of the oligonucleotides. The plasmid, pMON13348, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #6

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:70]

DNA sequence #14 [SEQ ID NO:110] encodes the foregoing pMON13348 polypeptide.

EXAMPLE 14

Construction of pMON13349

The 4218 base pair EcoRV,NsiI restriction fragment from pMON13357 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #23 [SEQ ID NO:37]
Oligo #24 [SEQ ID NO:38]

Oligo #25 [SEQ ID NO:39]
Oligo #26 [SEQ ID NO:40]

Oligo #29 [SEQ ID NO:43]
Oligo #30 [SEQ ID NO:44]

The assembled oligonucleotides create EcoRV and NsiI restriction ends and the DNA sequence that encodes amino acids 47-71 of (15-125)hIL-3 with the following amino acid substitutions: 51R, 55T, 59L, 62V, 67H and 69E. The codons encoding amino acids 47-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth and the DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13349, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #7

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:71]

DNA sequence #15 [SEQ ID NO:111] encodes the foregoing pMON13349 polypeptide.

EXAMPLE 15

Construction of pMON13358

Plasmid pMON5988 DNA was digested with restriction enzymes NsiI and EcoRI and the resulting 4178 base pair NsiI,EcoRI fragment contains the following genetic elements: beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-71 and 106-125 of (15-125)hIL-3. The 4178 base pair NsiI,EcoRI restriction fragment from pMON5988 was ligated to the following annealed complementary oligonucleotides.

Oligo #15 [SEQ ID NO:29]

Oligo #16 [SEQ ID NO:30]

The ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth, and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. In the resulting plasmid the 111 bases between the NsiI and EcoRI restriction sites in the (15-125) hIL-3 gene are replaced with 24 bases from the above mentioned oligonucleotides. This linker also contains a NdeI recognition sequence.

EXAMPLE 16

Construction of pMON13350

The 4178 base pair NsiI,EcoRI restriction fragment from pMON13358 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #41 [SEQ ID NO:55]

Oligo #42 [SEQ ID NO:56]

Oligo #39 [SEQ ID NO:53]
Oligo #40 [SEQ ID NO:54]

Oligo #35 [SEQ ID NO:49]
Oligo #36 [SEQ ID NO:50]

Oligo #43 [SEQ ID NO:57]
Oligo #44 [SEQ ID NO:58]

The assembled oligonucleotides create NsiI and EcoRI restriction ends and the DNA sequence that encodes amino acids 72-105 of (15-125)hIL-3 with the following amino acid substitutions: 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A and 105Q. The codons encoding amino acids 72-105 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13350, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #8

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:72]

DNA sequence #16 [SEQ ID NO:112] codes for the foregoing pMON13350 polypeptide.

EXAMPLE 17

Construction of pMON13355

The 4178 base pair NsiI,EcoRI restriction fragment from pMON13358 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #41 [SEQ ID NO:55]
Oligo #42 [SEQ ID NO:56]

Oligo #37 [SEQ ID NO:51]
Oligo #38 [SEQ ID NO:52]

Oligo #33 [SEQ ID NO:47]
Oligo #34 [SEQ ID NO:48]

Oligo #43 [SEQ ID NO:57]
Oligo #44 [SEQ ID NO:58]

The assembled oligonucleotides create NsiI and EcoRI restriction ends and the DNA sequence that encodes amino acids 72-105 of (15-125)hIL-3 with the following amino acid substitutions: 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A and 105Q. The codons encoding amino acids 72-105 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine

that the sequence was that of the oligonucleotides. The plasmid, pMON13355, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #9

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:73]

DNA sequence #17 [SEQ ID NO:113] codes for the foregoing pMON13355 polypeptide.

EXAMPLE 18

Construction of pMON13359

Plasmid pMON5988 DNA was digested with restriction enzymes EcoRI and HindIII, and the resulting 4225 base pair EcoRI,HindIII fragment contains the following genetic elements: beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-105 of (15-125)hIL-3. The 4225 base pair EcoRI,HindIII restriction fragment from pMON5988 was ligated to the following annealed complementary oligonucleotides.

Oligo #17 [SEQ ID NO:31]

Oligo #18 [SEQ ID NO:32]

The ligation reaction was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth, and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. In the resulting plasmid the 64 bases between the EcoRI and HindIII restriction sites in the (15-125)hIL-3 gene are replaced with 20 bases from the above mentioned oligonucleotides. This linker also contains an NdeI recognition sequence.

EXAMPLE 19

Construction of pMON13352

The 4225 base pair EcoRI,HindIII restriction fragment from pMON13359 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #45 [SEQ ID NO:59]
Oligo #46 [SEQ ID NO:60]

Oligo #49 [SEQ ID NO:63]
Oligo #50 [SEQ ID NO:64]

The assembled oligonucleotides create EcoRI and HindIII restriction ends and the DNA sequence that encodes amino acids 106-125 of (15-125)hIL-3 with the following amino acid substitutions: 109E, 116V, 120Q and 123E. The codons encoding amino acids 106-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were

selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13352, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #10

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:74]

DNA sequence #18 [SEQ ID NO:114] codes for the foregoing pMON13352 polypeptide.

EXAMPLE 20

Construction of pMON13354

The 4225 base pair EcoRI,HindIII restriction fragment from pMON13359 was ligated with the following pairs of annealed complementary oligonucleotides:

Oligo #45 [SEQ ID NO:59]
Oligo #46 [SEQ ID NO:60]

Oligo #47 [SEQ ID NO:61]
Oligo #48 [SEQ ID NO:62]

The assembled oligonucleotides create EcoRI and HindIII

restriction ends and the DNA sequence that encodes amino acids 106-125 of (15-125)hIL-3 with the following amino acid substitutions: 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 106-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The ligation reaction was digested with NdeI and used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth, and the DNA was sequenced to determine that the sequence was that of the oligonucleotides. The plasmid, pMON13354, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #11

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:75]

DNA sequence #19 [SEQ ID NO:115] codes for the foregoing pMON13354 polypeptide.

EXAMPLE 21

Construction of pMON13360

Plasmid pMON13352 DNA was digested with restriction enzymes NsiI and EcoRI, resulting in a 4178 base pair

NsiI,EcoRI fragment. The genetic elements derived from pMON13352 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-71 and 106-125 of (15-125)hIL-3. Plasmid pMON13350 DNA was digested with NsiI and EcoRI. The resulting 111 base pair NsiI, EcoRI fragment encodes amino acids 72-105 of (15-125)hIL-3. The eluted restriction fragments were concentrated and desalted using Centricon 30 concentrators. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and analyzed by restriction analysis. Clones containing the correct insert lost a XmnI site as compared with pMON13352. Positive clones were identified by the loss of a 615 base pair XmnI fragment. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13360, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #12

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ. NO:76]

DNA sequence #23 [SEQ ID NO:119] encodes the foregoing pMON13360 polypeptide.

EXAMPLE 22

Construction of pMON13361

Plasmid pMON13352 DNA was digested with restriction enzymes NsiI and EcoRI, resulting in a 4178 base pair NsiI,EcoRI fragment. The genetic elements derived from pMON13352 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-71 and 106-125 of (15-125)hIL-3. Plasmid pMON13355 DNA was digested with NsiI and EcoRI. The resulting 111 base pair NsiI, EcoRI fragment encodes amino acids 72-105 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Clones containing the correct insert contained an additional RsaI site which results in a 1200 base pairs RsaI fragment. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13361, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #13

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:77]

DNA sequence #24 [SEQ ID NO:120] codes for the foregoing pMON13361 polypeptide.

EXAMPLE 23

Construction of pMON13362

Plasmid pMON13354 DNA was digested with restriction enzymes NsiI and EcoRI, resulting in a 4178 base pair NsiI,EcoRI fragment. The genetic elements derived from pMON13354 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-71 and 106-125 of (15-125)hIL-3. Plasmid pMON13355 DNA was digested with NsiI and EcoRI. The resulting 111 base pair NsiI, EcoRI fragment encodes amino acids 72-105 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Clones containing the correct insert contained an additional RsaI site which results in a 1200 base pairs RsaI fragment. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has

the following amino acid substitutions: 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13362, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #14

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:78]

DNA sequence #25 [SEQ ID NO:121] codes for the foregoing pMON13362 polypeptide.

EXAMPLE 24

Construction of pMON13363

Plasmid pMON13344 DNA was digested with restriction enzymes NsiI and EcoRV, resulting in a 4218 base pair NsiI,EcoRV fragment. The genetic elements derived from pMON13344 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-46 and 72-125 of (15-125)hIL-3. Plasmid pMON13348 DNA was digested with NsiI and EcoRV. The

resulting 71 base pair NsiI, EcoRV fragment encodes amino acids 47-71 of (15-125)hIL-3. The restriction fragments were ligated with T4 ligase, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Clones containing the correct insert contained an additional DdeI site which results in DdeI restriction fragments of 806 and 167 base pairs compared to 973 base pairs in pMON13344. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13363, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #15

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:79]

DNA sequence #20 [SEQ ID NO:116] codes for the foregoing pMON13363 polypeptide.

EXAMPLE 25

Construction of pMON13364

Plasmid pMON13345 DNA was digested with restriction enzymes NsiI and EcoRV, resulting in a 4218 base pair NsiI,EcoRV fragment. The genetic elements derived from pMON13345 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-46 and 72-125 of (15-125)hIL-3. Plasmid pMON13349 DNA was digested with NsiI and EcoRV. The resulting 71 base pair NsiI, EcoRV fragment encodes amino acids 47-71 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Clones containing the correct insert contained an additional DdeI site which results in DdeI restriction fragments of 806 and 167 base pairs compared to 973 base pairs in pMON13344. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13364, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #16

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:80]

DNA sequence #21 [SEQ ID NO:117] codes for the foregoing pMON13364 polypeptide.

EXAMPLE 26

Construction of pMON13365

Plasmid pMON13346 DNA was digested with restriction enzymes NsiI and EcoRV, resulting in a 4218 base pair NsiI,EcoRV fragment. The genetic elements derived from pMON13346 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the bases encoding amino acids 15-46 and 72-125 of (15-125)hIL-3. Plasmid pMON13347 DNA was digested with NsiI and EcoRV. The resulting 71 base pair NsiI, EcoRV fragment encodes amino acids 47-71 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Clones containing the correct insert contained an additional DdeI site which results in DdeI restriction fragments of 806 and 167 base pairs compared to 973 base pairs in pMON13344. The DNA was sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13365, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #17

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:81]

DNA sequence #22 [SEQ ID NO:118] codes for the foreging pMON13365 polypeptide.

EXAMPLE 27

Construction of pMON13298

Plasmid pMON5978 DNA was digested with restriction enzymes NsiI and HindIII, resulting in a 3789 base pair NsiI,HindIII fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site, and the bases encoding amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13360 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13298, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #18

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:82]

DNA sequence #29 [SEQ ID NO:125] codes for the foregoing pMON13298 polypeptide.

EXAMPLE 28

Construction of pMON13299

Plasmid pMON5978 DNA was digested with restriction enzymes NsiI and HindIII, resulting in a 3789 base pair NsiI,HindIII fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13361 DNA was digested with NsiI and HindIII, the resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13299, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #19

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:83]

DNA sequence #30 [SEQ ID NO:126] codes for the foregoing pMON13299 polypeptide.

EXAMPLE 29

Construction of pMON13300

Plasmid pMON5978 DNA was digested with restriction enzymes NsiI and HindIII, resulting in a 3789 base pair NsiI,HindIII fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site, and the bases encoding amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13362 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 72-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid

substitutions were made. The plasmid, pMON13300, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #20

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:84]

DNA sequence #31 [SEQ ID NO:127] codes for the foregoing pMON13300 polypeptide.

EXAMPLE 30

Construction of pMON13301

Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and NsiI, resulting in a 3794 base pair NcoI,NsiI fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 72-125 of (15-125)hIL-3. Plasmid pMON13363 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-

containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13301, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #21

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:85]

DNA sequence #26 [SEQ ID NO:122] codes for the foregoing pMON13301 polypeptide.

EXAMPLE 31

Construction of pMON13302

Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and NsiI, resulting in a 3794 base pair NcoI,NsiI fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome

binding site, and the bases encoding amino acids 72-125 of (15-125)hIL-3. Plasmid pMON13364 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13302, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #22

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:86]

DNA sequence #27 [SEQ ID NO:123] codes for the foregoing pMON13302 polypeptide.

EXAMPLE 32

Construction of pMON13303

Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and NsiI, resulting in a 3794 base pair NcoI,NsiI fragment. The genetic elements derived from pMON5978 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site, and the bases encoding amino acids 72-125 of (15-125)hIL-3. Plasmid pMON13365 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N and 69E. The codons encoding amino acids 15-71 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13303, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #23

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu

Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:87]

DNA sequence #28 [SEQ ID NO:124] codes for the foregoing pMON13303 polypeptide.

EXAMPLE 33

Construction of pMON13287

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13363 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13360 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13287, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #24

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:88]

DNA sequence #1 [SEQ ID NO:97] codes for the foregoing pMON13287 polypeptide.

EXAMPLE 34

Construction of pMON13288

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13364 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoiI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13360 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32N,

37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13288, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #25

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:89]

DNA sequence #4 [SEQ ID NO:100] codes for the foregoing pMON13288 polypeptide.

EXAMPLE 35

Construction of pMON13289

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13365 DNA was digested with NcoI and NsiI. The resulting 170 base pair Ncoi, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3.

Plasmid pMON13360 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13289, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #26

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:90]

DNA sequence #7 [SEQ ID NO:103] codes for the foregoing pMON13289 polypeptide.

EXAMPLE 36

Construction of pMON13290

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13363 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13361 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13290, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #27

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:91]

DNA sequence #2 [SEQ ID NO:98] codes for the foregoing pMON13290 polypeptide.

EXAMPLE 37

Construction of pMON13292

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13365 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13361 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13292, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #28

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:92]

DNA sequence #8 [SEQ ID NO:104] codes for the foregoing pMON13292 polypeptide.

EXAMPLE 38

Construction of pMON13294

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13364 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13362 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13294, encodes the (15-

125)hIL-3 variant with the following amino acid sequence:

Peptide #29

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:93]

DNA sequence #6 [SEQ ID NO:102] codes for the foregoing pMON13294 polypeptide.

EXAMPLE 39

Construction of pMON13295

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13365 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13362 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101.

Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29V, 32A, 37S, 42S, 45M, 51R, 55L, 59L, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13295, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #30

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:94]

DNA sequence #9 [SEQ ID NO:105] codes for the foregoing pMON13295 polypeptide.

EXAMPLE 40

Construction of pMON13312

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from

pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13364 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13361 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 120Q and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13312, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #31

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:95]

DNA sequence #5 [SEQ ID NO:101] codes for the foregoing pMON13312 polypeptide.

EXAMPLE 41

Construction of pMON13313

Plasmid pMON2341 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3619 base pair NcoI,HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter and g10L ribosome binding site. Plasmid pMON13363 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON13362 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The resulting (15-125)hIL-3 variant has the following amino acid substitutions: 18I, 25H, 29R, 32A, 37P, 42A, 45V, 51R, 55L, 60S, 62V, 67N, 69E, 73G, 76A, 79R, 82V, 87S, 93S, 98T, 101A, 105Q, 109E, 116V, 117S, 120H and 123E. The codons encoding amino acids 15-125 of (15-125)hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13313, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

Peptide #32

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:96]

DNA sequence #3 [SEQ ID NO:99] codes for the foregoing pMON13313 polypeptide.

EXAMPLE 42

Construction of pMON5987

Plasmid pMON6458 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3940 base pair NcoI,HindIII fragment. The genetic elements derived from pMON6458 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site and lamB secretion leader. Plasmid pMON5978 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125)hIL-3. Plasmid pMON5976 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI,HindIII fragment encodes amino acids 72-125 of (15-125)hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and screened for the restriction sites EcoRV and NheI and DNA sequenced to confirm the correct insert.

EXAMPLE 43

Construction of pMON5988

The plasmid DNA of pMON5987 was digested with NheI and EcoRI, resulting in a 3903 base pair NheI, EcoRI fragment. The 3903 base pair NheI, EcoRI fragment was ligated to 1.0 picomoles of the following annealed oligonucleotides:

5'-CTAGCCACGGCCGCACCCACGCGACATCCAATCCATATCAA-
3'-GGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTATAGTT-

GGACGGTGACTGGAATG-3' [SEQ ID NO:131]
CCTGCCACTGACCTTACAATT-5' [SEQ ID NO:132]

The ligation reaction mixture was used to transform E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm positive clones. This plasmid was constructed to change alanine 101 to aspartic acid in the hIL-3 gene (15-125). This plasmid was designated pMON5988.

EXAMPLE 44

Construction of pMON5853 (Fig 6) which encodes [Met-(15-133)hIL-3(Arg^{129})]

Plasmid DNA of pMON5847 (Example 2) was treated with NcoI. The restriction enzyme was inactivated by heat treatment (65°C for 10 minutes). The DNA was then treated with large fragment of DNA polymerase I (Klenow) in the presence of all four nucleotide precursors. This produces DNA termini with non-overlapping ends. After 5 minutes at 37°C, the polymerase was inactivated by heat treatment at 65°C for 10 minutes. The DNA was then treated with HpaI, an enzyme which produces non-overlapping termini. The DNA was ethanol precipitated and ligated. The ligation reaction mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked and plasmid DNA was analyzed by restriction analysis. A plasmid designated pMON5853 was identified as one containing a deletion of the amino terminal 14 codons of the hIL-3 gene. The DNA sequence for the junction of the ribosome binding site to the (15-133) hIL-3 gene was determined to be the following:

5'-AAGGAGATATATCCATGAACTGCTCTAAC-3' [SEQ ID NO:133]
M N C S N [SEQ ID NO:134]

The lower line contains the one letter code for the amino acids specified by the coding sequence of the amino terminus of the 15-133 hIL-3 gene. These are methionine,

asparagine, cysteine, serine and asparagine.

When cultures of JM101 cells harboring this plasmid were induced with nalidixic acid, it was found that hIL-3 (15-133) accumulated at levels higher than hIL-3 (pMON5847).

The plasmid, pMON5853, encodes Met-(15-133) hIL-3 (Arg^{129}) which has the following amino acid sequence:

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu Arg
Leu Ala Ile Phe [SEQ ID NO:135]

EXAMPLE 45

Construction of pMON5873 which encodes [Met-(1-133)hIL-3]

The gene obtained from British Biotechnology, Ltd. specified arginine at codon position 129. The amino acid specified in the native hIL-3 cDNA is serine. To produce a protein with the native sequence at this position, the portion of the coding sequence between the EcoRI site at codons 106 and 107 and the NheI site at codons 129 and 130 was replaced. Plasmid DNA of pMON5854 (Example 3) and pMON5853 (Example 44) were treated with EcoRI and NheI. The larger fragments of each were gel purified. These were ligated to a pair of an annealed oligonucleotides with the following sequences:

5'-AATTCCGTCGTAAACTGACCTTCTATCTGAAAACC-
3'-GGCAGCATTTGACTGGAAGATAGACTTTTGG-

TTGGAGAACGCGCAGGCTCAACAGACCACTCTGTCG-3' [SEQ ID NO: 136]

AACCTCTTGCGCGTCCGAGTTGTCTGGTGAGACAGCGATC-5' [SEQ ID NO:137]

The ligation reaction mixtures were used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and grown. Plasmid DNA was isolated and screened for the presence of a new StyI recognition site present in the synthetic DNA and not in pMON5854 and pMON5853. The nucleotide sequence of the gene in the region between EcoRI and NheI was determined and found to be that of the synthetic oligonucleotides. The new plasmids were designated pMON5873 encoding [Met-(1-133)hIL-3] and pMON5872 encoding [Met-(15-133)hIL-3].

The plasmid, pMON5873, encodes Met-(1-133)hIL-3 which has the following amino acid sequence:

Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser
Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu Ser
Leu Ala Ile Phe [SEQ ID NO:128]

EXAMPLE 46

Construction of pMON6458

Plasmid pMON6525 was digested with restriction enzymes HindIII and SalI and the resulting 3172 base pair fragment was isolated from a 1% agarose gel by interception onto DEAE membrane. The genetic elements derived from pMON6525 are the beta-lactamase gene (AMP), pBR327 origin of replication, and phage f1 origin of replication as the transcription terminator. (The genetic elements derived

from plasmid pMON6525 are identical to those in plasmid pMON2341 which could also be used to construct pMON6458.) Plasmid pMON6457 was digested with restriction enzymes HindIII and SalI and the resulting 1117 base pair fragment was isolated by PAGE and crush and soak elution. The genetic elements derived from pMON6457 are the pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the (15-125) hIL-3 gene. The restriction fragments were ligated and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 15-125) contained a 345 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6458. This plasmid was constructed to eliminate an EcoRI restriction site outside the hIL-3 gene coding region in plasmid pMON6457.

EXAMPLE 47

Construction of pMON5976 which encodes [Met-(15-125)hIL-3(Ala^{101})]

The plasmid DNA of pMON5941 isolated from the dam- E. coli strain GM48 was cleaved with ClaI and NsiI and ligated to 1 picomole of an annealed assembly of six oligonucleotides encoding amino acids 20-70 of hIL-3 (FIG. 2). This synthetic fragment encodes three unique restriction sites, EcoRV, XhoI and PstI. The sequence of these oligonucleotides is shown in Figure 2.

The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated and the inserted fragment was determined to have both an EcoRV and NheI site. The nucleotide sequence of the region between ClaI

and NsiI was determined and found to be that of the synthetic oligonucleotides. At codons 86-87 of a nucleotide sequence coding for (15-125)hIL-3, an NheI site was introduced. The plasmid with this alteration was designated pMON5941. This plasmid encodes Met-(15-125)hIL-3 which is altered at position 101 by replacement of aspartate by alanine.

Plasmid pMON5976 encodes Met-(15-125)hIL-3(Ala^{101}) which has the following amino acid sequence:

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Ala Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:138]

EXAMPLE 48

Construction of pMON5917 which encodes [Met-(15-88)hIL-3]

The plasmid DNA of pMON5853 was cleaved with NsiI and HindIII and ligated to an annealed pair of oligonucleotides encoding (70-88)hIL-3 with a new NheI endonuclease restriction site at codons 86-87. The sequence of these oligonucleotides is shown in Example 18.

The ligation mixture was used to transform competent E. coli JM101 cells, and ampicillin resistant colonies were picked. Plasmid DNA isolated from individual colonies was screened for the presence of the new NheI restriction site. The nucleotide sequence of the substituted portion was determined and found to be that of the synthetic oligonucleotides. The new plasmid was designated pMON5917 encoding Met-(15-88)hIL-3 containing a new NheI site at codons 86-87.

Plasmid pMON5917 encodes Met-(15-88)hIL-3 which has the following amino acid sequence:

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala [SEQ ID NO: 139]

EXAMPLE 49

Construction of pmon5941 which encodes [Met-(15-125)hIL-3 Ala^{101}]

The plasmid DNA of pMON5917 was cleaved with NheI and HindIII and ligated to two annealed pairs of oligonucleotides which encode amino acids 86-106 and 107-125 of hIL-3. The sequences of these oligonucleotides is shown below.

NheI to EcoRI

5'-CTAGCCACGGCCGCACCCACGCGACATCCAATCCATATCAAGGCTG-
3'-GGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTATAGTTCCGAC-

GTGACTGGAATG-3' [SEQ ID NO:140]
CACTGACCTTACTTAA-5' [SEQ ID NO:141]

EcoRI to HindIII

5'-AATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGGAGAACGCGCA-
3'-GGCAGCATTTGACTGGAAGATAGACTTTTGGAACCTCTTGCGCGT-

GGCTCAACAGTAATA-3' [SEQ ID NO:142]
CCGAGTTGTCATTATTCGA-5' [SEQ ID NO:143]

The ligation mixture was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated from these cells and the size of the inserted fragment was determined to be larger by

restriction analysis with NcoI and HindIII. The Asp to Ala 101 change is encoded on the NheI to EcoRI fragment. The nucleotide sequence of the portion of the coding region between the NheI and HindIII sites was determined and found to be that of the synthetic oligonucleotides. The new plasmid was designated pMON5941.

The plasmid, pMON5941, encodes Met-(15-125)hIL-3(Ala^{101}) and contains a new NheI restriction site.

EXAMPLE 50

Construction of pMON6455

Plasmid pMON5905 was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMON5905 are the beta-lactamase gene (AMP), pBR327 origin of replication, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and phage f1 origin of replication as the transcription terminator. The following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, g10L ribosome binding site and phage f1 origin of replication as the transcription terminator, derived from plasmid pMON5905 are identical to these in plasmid pMON5594 which could also be used to construct pMON6455. The AraBAD promoter is identical to that described in pMON6235. The lamB signal peptide sequence used in pMON6455 is that shown in Figure 8 fused to hIL-3 (15-125) at the NcoI site. Plasmid pMON5887 was digested with restriction enzymes HindIII and NcoI, resulting in a 384 base pair NcoI, HindIII fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Positive clones containing the hIL-3 gene

(encoding amino acids 1-125) contained a 384 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6455.

EXAMPLE 51

Construction of pMON6456

Plasmid pMON5905 was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMON5905 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site and the lamB secretion leader. Plasmid pMON5871 was digested with restriction enzymes HindIII and NcoI, resulting in a 330 base pair NcoI, HindIII fragment. The genetic element derived from pMON5871 encompassed the bases encoding the (1-107) hIL-3 gene. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 1-107) contained a 330 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6456.

EXAMPLE 52

Construction of pMON6457

Plasmid pMON6455 DNA grown in E. coli strain GM48 (dam-)was digested with restriction enzymes NcoI and ClaI, resulting in a 4263 base pair NcoI, ClaI fragment. The restriction fragment was ligated to 1.0 picomoles of annealed oligonucleotides with the following sequence

coding for Met Ala 14-20 hIL-3:

5'-CATGGCTAACTGCTCTAACATGAT-3'[SEQ ID NO:151]
3'-CGATTGACGAGATTGTACTAGC-5'[SEQ ID NO:152]

The resulting DNA was transformed into E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes XbaI and EcoRI in double digest. Positive clones containing the hIL-3 gene (encoding aa 15-125 of hIL-3) contained a 433 base pair XbaI, EcoRI restriction fragment. This construct was designated pMON6457. This plasmid was constructed to delete the first 14 amino acids of hIL-3. The coding sequence of the resulting gene begins as follows:

5' ATG GCT AAC TGC... 3' [SEQ ID NO:153]
Met Ala Asn Cys... [SEQ ID NO:154]
15

The first two amino acids (Methionine, Alanine) create an NcoI restriction site and a signal peptidase cleavage site between the lamB signal peptide and (15-125) hIL-3. Plasmid pMON6457 encodes (15-125) hIL-3 which has the amino acid sequence designated SEQ ID NO:65.

EXAMPLE 53

Construction of pMON6235

One of the DNA fragments used to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotides, Oligo #51 [SEQ ID NO:155] and Oligo #52 [SEQ ID NO:156], were used as primers in this procedure. The template for the PCR reaction was E. coli strain W3110

chromosomal DNA, prepared as described in Maniatis (1982). The oligonucleotide primers were designed to amplify the AraBAD promoter (Greenfield et al., 1978). The resulting DNA product was digested with the restriction enzymes SacII and BglII. The reaction mixture was purified as described previously. Plasmid, pMON5594, DNA was digested with SacII and BglII, resulting in a 4416 base pair SacII,BglII restriction fragment which contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, G10L ribosome binding site, phage f1 origin of replication as the transcription terminator and the chloramphenicol acetyl transferase (cat) gene. The 4416 base pair SacII,BglII restriction fragment from pMON5594 was ligated to the PCR-generated SacII, BglII DNA fragment. The ligation mixture was used to transform E. coli K-112 strain JM101. Positive clones contained a 323 base pair SacII,BglII fragment and were DNA sequenced to confirm that the SacII,BglII fragment was the AraBAD promoter. This construct was designated pMON6235.

EXAMPLE 54

Construction of pMON5647

Plasmid pMON5585 [prepared as disclosed in EP 0241446 incorporated herein by reference in its entirety] DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3273 base pair NcoI,HindIII fragment. The genetic elements derived from pMON5585 are the pBR327 origin of replication, precA promoter, g10L ribosome binding protein, bovine somatotropin gene (bST), beta-lactamase gene (AMP) and T7 transcription terminator. Plasmid pMON3267 [prepared as disclosed in EP 0241446 incorporated herein by reference in its entirety] DNA was digested with NcoI and HindIII enzymes resulting in a 580 base pair NcoI,HindIII fragment which contains the porcine somatotropin (pST) gene. The restriction fragments were

ligated and the ligation reaction mixture was used to transform E. coli strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert.

EXAMPLE 55

Construction of pMON710

Plasmid pMON709 consists of a 1614 base pair AvaI,EcoRI fragment of transposon TN7, containing the streptomycin adenylyltransferase gene (Fling et al., 1985) and a pUC9 linker (XmaI,HindIII) cloned between the HindIII and EcoRI sites of pUC19. The streptomycin adenylyltransferase gene COnfers resistance to streptomycin and spectinomycin. Plasmid pMON709 was mutagenized by oligonucleotide site-directed mutagenesis (methods described in Zoller and Smith, 1982) to introduce an EcoRV site at the 3′ end of the streptomycin adenylyltransferase gene. The oligonucleotide, **Oligo # 53** [SEQ ID NO:157], was used in this procedure to introduce the EcoRV site. The resulting plasmid was designated pMON710.

EXAMPLE 56

Construction of pMON5723

Plasmid pMON5647 DNA was digested with restriction enzymes DraI and SspI resulting in a 2916 base pair DraI, SspI fragment. The genetic elements derived from pMON5647 are the pBR327 origin of replication, precA promoter, g10L ribosome binding protein, porcine somatotropin gene (pST) and T7 transcription terminator (Dunn and Strudier, 1983). Plasmid pMON710 DNA was digested with restriction enzymes HincII and EcoRV resulting in 940 base pair HincII,EcoRV fragment containing the streptomycin adenylyltransferase gene which infers resistance to streptomycin and spectinomycin. The restriction fragments were ligated and

GAT to GAC and ATC to ATT respectively, destroying the EcoRV recognition site. The oligonucleotide, **Oligo # 55** [SEQ ID NO:159], was used in this procedure to eliminate the EcoRV site. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to confirm the loss of the EcoRV site and sequenced to confirm the sequence of the (15-125) hIL-3 variant gene. The plasmid, pMON14058, encodes the (15-125) hIL-3 variant with the amino acid sequence of **PEPTIDE #25** [SEQ ID NO:89].
DNA sequence # 33 [SEQ ID NO:161] codes for the foregoing pMON14058 polypeptide.

EXAMPLE 59

Construction of pMON13438

Plasmid pMON5723 DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3278 NcoI,HindIII fragment. The genetic elements derived from pMON5723 are the pBR327 origin of replication, precA promoter, g10L ribosome binding protein, T7 transcription terminator and streptomycin adenylyltransferase gene. Plasmid pMON14058 DNA was digested with NcoI and HindIII resulting in a 345 base pair NcoI,HindIII fragment which contains the (15-125) hIL-3 gene with the following amino acid substitutions: 18I, 25H, 29R, 32N, 37P, 42S, 45M, 51R, 55T, 59L, 62V, 67H, 69E,73G, 76A, 79R, 83Q, 87S, 93S, 98I, 101A, 105Q, 109E, 116V, 120Q and 123E. The restriction fragments were ligated and the ligation reaction mixture was used to transform E. coli strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. The plasmid, pMON13438, encodes the (15-125) hIL-3 variant with the amino acid sequence of **PEPTIDE #25** [SEQ ID NO:89].
DNA sequence # 33 [SEQ ID NO:161] codes for the foregoing pMON13438 polypeptide.

EXAMPLE 60

Construction of pMON13285

Plasmid pMON13252 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 3669 base pair NcoI,EcoRV fragment contains the following genetic elements; streptomycin adenyltransferase gene, pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 47-125 of (15-125) hIL-3 with the following amino acid substitution, 50D. The 3669 base pair NcoI,EcoRV restriction fragment from pMON13252 was ligated to the following annealed complementary oligonucleotides.

Oligo #165 [SEQ ID NO:162]
Oligo #166 [SEQ ID NO:163]

Oligo #167 [SEQ ID NO:164]
Oligo #168 [SEQ ID NO:165]

Oligo #169 [SEQ ID NO:166]
Oligo #170 [SEQ ID NO:167]

When assembled, the oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125) hIL-3 with the following amino acid substitutions; 42D, 45M and 46S. The codons encoding amino acids 15-46 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13285, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide #A3 [SEQ ID NO:258]

DNA sequence #A3 pMON13285 42D, 45M 46S, 50D

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA
GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGAC GAAGACATGT
CTATCCTGAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC
CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA
AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC
CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC
TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG
[SEQ ID NO:398]

EXAMPLE 61

Construction of pMON13286

Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 3865 base pair NcoI,EcoRV fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 47-125 of (15-125) hIL-3. The 3865 base pair NcoI,EcoRV restriction fragment from pMON5978 was ligated to the following annealed complementary oligonucleotides.

Oligo #165 [SEQ ID NO:162]
Oligo #166 [SEQ ID NO:163]
Oligo #167 [SEQ ID NO:164]
Oligo #168 [SEQ ID NO:165]

Oligo #169 [SEQ ID NO:166]
Oligo #170 [SEQ ID NO:167]

When assembled, the oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125) hIL-3 with the following amino acid substitutions; 42D, 45M and 46S. The codons encoding amino acids 15-46 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13286, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide #A4 [SEQ ID NO:259]

DNA sequence #A4 pMON13286 42D, 45M, 46S

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGAC GAAGACATGT CTATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG
[SEQ ID NO:399]

EXAMPLE 62

Construction of pMON13325

The 3704 base pair EcoRI, HindIII DNA fragment from plasmid pMON13286 is ligated to the 64 base pair EcoRI, HindIII DNA fragment from plasmid pMON13215. The following genetic elements are derived from pMON13286; beta-lactamase gene (AMP), pBR327 origin of replication, phage F1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 15-105 of the (15-125) hIL-3 gene with the following changes, 42D, 45M, and 46S.

The bases encoding amino acids 106-125 of the (15-125) gene with the following change, 116W, are derived from pMON13215. The resulting plasmid, pMON13325, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide # A5 [SEQ ID NO:261]

EXAMPLE 63

Construction of pMON13326

The 3683 base pair NcoI, EcoRI DNA fragment from plasmid pMON13215 is ligated to the 281 base pair NcoI, EcoRI DNA fragment from plasmid pMON13285. The following genetic elements are derived from pMON13215; beta-lactamase gene (AMP), pBR327 origin of replication, phage F1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 106-125 of the (15-125) hIL-3 gene with the following change, 116W. The bases encoding amino acids 15-105 of the (15-125) gene with the following change, 42D, 45M, 46S and 50D derived from pMON13285. The resulting plasmid, pMON13326, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide # A6 [SEQ ID NO:262]

EXAMPLE 64

Construction of pMON13332

Plasmid pMON13326 DNA is digested with restriction enzymes NsiI and EcoRI and the resulting 3853 base pair NsiI,EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator,

recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-71 and 106-125 of (15-125) hIL-3 gene with the following changes 42D, 45M, 46S, 50D and 116W. The 3853 base pair NsiI,EcoRI restriction fragment from pMON13326 is ligated to the following annealed complementary oligonucleotides.

Oligo #15(A) [SEQ ID NO:168]

Oligo #16(A) [SEQ ID NO:169]

In the resulting plasmid the 111 bases between the NsiI and EcoRI restriction sites in the (15-125) hIL-3 gene are replaced with 24 bases from the above mentioned oligonucleotides. This linker also creates a NdeI recognition sequence.

EXAMPLE 65

Construction of pMON13330

The 3846 base pair PstI, EcoRI DNA fragment from plasmid pMON13332 is ligated to the 118 base pair PstI, EcoRI DNA fragment from plasmid pMON13305. The following genetic elements are derived from pMON13332; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of the (15-125) hIL-3 gene with the following change, 42D, 45M, 46S, 50D and 116W. The bases encoding amino acids 70-105 of the (15-125) gene with the following change, 95R, 98I and 100R are derived from pMON13305. The resulting plasmid, pMON13330, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide # A7 [SEQ ID NO:263]

EXAMPLE 66

Construction of pMON13329

The 3846 base pair PstI, EcoRI DNA fragment from plasmid pMON13332 is ligated to the 118 base pair PstI, EcoRI DNA fragment from plasmid pMON13304. The following genetic elements are derived from pMON13332; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of the (15-125) hIL-3 gene with the following change, 42D, 45M, 46S, and 116W. The bases encoding amino acids 70-105 of the (15-125) gene with the following change, 98I and 100R are derived from pMON13304. The resulting plasmid, pMON13329, encodes the (15-125) hIL-3 variant with the following amino acid sequence:

Peptide # A8 [SEQ ID NO:406]

EXAMPLE 67

Construction of pMON5853 (Fig 6) which encodes [Met-(15-133)hIL-3(Arg^{129})]

Plasmid DNA of pMON5847 (Example 2) was treated with NcoI. The restriction enzyme was inactivated by heat treatment (65°C for 10 minutes). The DNA was then treated with large fragment of DNA polymerase I (Klenow) in the presence of all four nucleotide precursors. This produces DNA termini with non-overlapping ends. After 5 minutes at 37°C, the polymerase was inactivated by heat treatment at 65°C for 10 minutes. The DNA was then treated with HpaI, an enzyme which produces non-overlapping termini. The DNA was ethanol precipitated and ligated. The ligation

reaction mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked and plasmid DNA was analyzed by restriction analysis. A plasmid designated pMON5853 was identified as one containing a deletion of the amino terminal 14 codons of the hIL-3 gene. The DNA sequence for the junction of the ribosome binding site to the (15-133) hIL-3 gene was determined to be the following:

5'-AAGGAGATATATCCATGAACTGCTCTAAC-3' [SEQ ID NO:400]
M N C S N [SEQ ID NO:401]

The lower line contains the one-letter code for the amino acids specified by the coding sequence of the amino terminus of the 15-133 hIL-3 gene. These are methionine, asparagine, cysteine, serine and asparagine.

When cultures of JM101 cells harboring this plasmid were induced with nalidixic acid, it was found that hIL-3 (15-133) accumulated at levels higher than hIL-3 (pMON5847).

The plasmid, pMON5853, encodes Met-(15-133) hIL-3 (Arg^{129}) which has the following amino acid sequence:

Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu Arg
Leu Ala Ile Phe [SEQ ID NO:402]

EXAMPLE 68

Construction of pMON13252

Plasmid, pMON2341, DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3619 base pair NcoI/HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication F1 phage origin of replication as the transcription terminator, precA, g10L ribosome binding site. The plasmid encoding the hIL-3 (15-125) $Asp^{(50)}$ variant, was digested with NcoI and HindIII resulting in a 345 base pair NcoI/HindIII fragment. This 345 Base pair NcoI/HindIII fragment was ligated with the 3619 base pair fragment from pMON2341 and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. Plasmid DNA was isolated and screened by restriction analysis using NcoI and HindIII. Positive clones contained a 345 base pair NcoI/HindIII fragment. This construct was designated pMON13252. The plasmid, pMON13252, encodes the (15-125)hIL-3 variant with the following amino acid sequence:

PEPTIDE A10; (15-125)HIL-3 $Asp^{(50)}$ pMON13252

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
15 20 25
Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 35 40
Glu Asp Gln Asp Ile Leu Met Asp Asn Asn Leu Arg Arg Pro Asn
45 50 55
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
60 65 70
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
75 80 85
Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
90 95 100

Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
105 110 115
Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:407]
120 125

DNA sequence #A10 pMON13252 50D

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA
GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG
ATATCCTGAT GGAACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC
CGTGCTGTCA ACTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA
AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC
CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC
TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG
[SEQ ID NO:408]

Examples 69-76

The variants in Table 5 were constructed by cassette mutagenesis using methods described in the Materials and Methods and the Examples contained herein, particularly Examples 54-58 . Parental plasmid DNA (Table 5), digested with the appropriate restriction enzymes (Table 5), was ligated with the indicated annealed pairs of complementary oligonucleotides (Table 5). The assembled oligonucleotides create appropriate restriction ends and a portion of the (15-125) hIL-3 gene sequence (pMON13288 [SEQ ID NO:100]). Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The oligonucleotides create change(s) in the (15-125) hIL-3 gene which encode the corresponding amino acid substitution(s) in the variant polypeptide (Table 5). The amino acids substitutions in addition to and/or different from those in polypeptide # 25 [SEQ ID NO:89] are indicated in Table 5. The table also shows the plasmid designation (pMON number), DNA sequence identification number for the mutated hIL-3 gene and the identification

number for the the resulting variant polypeptide. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 5 is shown in Table 1.

Examples 77-82

The variants in Table 6 were constructed by methods described in the Materials and Methods and the Examples contained herein, particularly in Examples 60 and 61. Parental plasmid DNA (Table 6), digested with the appropriate restriction enzymes (Table 6), was ligated with the indicated restriction fragment (Table 6). Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The resulting mutated (15-125) hIL-3 genes encode the corresponding amino acid substitutions in the variant polypeptides (Table 6). The amino acids substitutions in addition to and/or different from those in polypeptide # 25 [SEQ ID NO:89] are indicated in Table 6. The table also shows the plasmid designation (pMON number), DNA sequence identification number for the mutated hIL-3 gene and the identification number for the the resulting variant polypeptide. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 6 is shown in Table 1.

Example 83

Construction of pMON13368

One of the DNA fragments to construct the plasmid, pMON13368, was generated by site-directed mutagenesis employing PCR techniques described in the Materials and Methods and the Examples contained herein, particularly Example 53. The template for the PCR reaction was plasmid,

pMON13289, DNA using the oligonucleotides, Oligo #B13 18I23A25H [SEQ ID NO: 182] and Oligo #B14 2341HIN3 [SEQ ID NO:183], as primers. The resulting DNA product was digested with the restriction enzymes NcoI and HindIII. Upon completion, the digest was heated at 70°C for 15 minutes to inactivate the enzymes. The restriction fragment was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH4OAc. The oligonucleotide, Oligo #B13 18I23A25H [SEQ ID NO:182], changes the codon at position 23 of (15-125) hIL-3 variant gene pMON13289 [SEQ ID NO:103] from 'ATT' to 'GCA' (Ile to Ala). The 3619 base pair NcoI, HindIII restriction fragment from pMON2341 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The plasmid, pMON13368, contains the (15-125) hIL-3 variant gene (DNA sequence #B15 [SEQ ID NO:346]) which encodes the (15-125) hIL-3 variant polypeptide with the following amino acid sequence:

Polypeptide #B15 [SEQ ID NO.:278]

Example 84

Construction of pMON13380

Plasmid, pMON13368, DNA was digested with restriction enzymes EcoRI and HindIII. The resulting 3900 base pair EcoRI,HindIII fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage F1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the DNA sequence encoding amino acids 15-105 of the variant pMON13368. The 3900 base pair EcoRI,HindIII restriction fragment from pMON13368 was

ligated to the following annealed complementary oligonucleotides.

Oligo # B48	9E12Q6V1	[SEQ ID NO:217]
Oligo # B49	9E12Q6V3	[SEQ ID NO:218]
Oligo #49	120Q123E2	[SEQ ID NO:63]
Oligo #50	120Q123E4	[SEQ ID NO:64]

When assembled, the oligonucleotides create EcoRI and HindIII restriction ends and the DNA sequence that encodes amino acids 106-125 of (15-125) hIL-3 with the following amino acid substitution; 109E, 112Q, 116V, 120Q and 123E. The codons used in the (15-125) hIL-3 gene are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The plasmid, pMON13380, contains the (15-125) hIL-3 variant gene (DNA sequence #B16 [SEQ ID NO:347]) which encodes the (15-125) hIL-3 variant polypeptide with the following amino acid sequence:

Polypeptide #B16 [SEQ ID NO.:279]

Example 85

Construction of pMON13476

One of the DNA fragments to construct the plasmid, pMON13476, was generated by site-directed mutagenesis employing PCR techniques described in the Materials and Methods and the Examples contained herein, particularly Example 54. The template for the PCR reaction was plasmid, pMON13287, DNA using the oligonucleotides, Oligo #B13 18I23A25H [SEQ ID NO:182] and Oligo #B14 2341HIN3 [SEQ ID NO.:183] as primers. The resulting DNA product was

digested with the restriction enzymes NcoI and HindIII. Upon completion, the digest was heated at 70°C for 15 minutes to inactivate the enzymes. The restriction fragment was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH4OAc. The oligonucleotide, Oligo #B13 18I23A25H [SEQ ID NO.:182], changes the codon at position 23 of (15-125) hIL-3 variant gene, pMON13287, [SEQ ID NO:97] from 'ATT' to 'GCA' (Ile to Ala). The 3619 base pair NcoI, HindIII restriction fragment from pMON2341 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The resulting clone also contained a change, that was not designed in the mutagenic oligonucleotide, which changed the codon at position -1 from 'GCT' to 'GAT' which changes the amino acid from Alanine to Aspartic Acid. The plasmid, pMON13476, contains the (15-125) hIL-3 variant gene (DNA sequence #B52 [SEQ ID NO:303]) which encodes the (15-125) hIL-3 variant polypeptide with the following amino acid sequence:

Polypeptide #B52 [SEQ ID NO.:314]

Examples 86-92

The variants in Table 7 were constructed by PCR techniques using methods described in the Materials and Methods and the Example contained herein, particularly Example 51. Two sequential PCR reactions were used to create the variants. In the first PCR reaction pMON13287 plasmid DNA served as the template and the two oligonucleotides indicated in Table 7 served as the primers. Following the PCR extension reaction, the PCR product was partially purified to remove primer that was not extended. In the second PCR reaction pMON13287 plasmid

DNA served as the template, the purified PCR product from the first PCR reaction served as one of the primers and the Oligo #B14 2341Hin3 [SEQ ID NO:183] as the second primer. The product from the second PCR reaction was partially purified and digested with restriction enzymes NcoI and HindIII and ligated with the 3619 base pair NcoI,HindIII fragment from pMON2341. Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The amino acids substitutions in addition to and/or different from those in polypeptide # 24 [SEQ ID NO:88] are indicated in Table 7. The table also shows the plasmid designation (pMON number), DNA sequence identification number for the mutated hIL-3 gene and the identification number for the the resulting variant polypeptide. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 7 is shown in Table 1.

Examples 93-120

The variants in Table 8 were constructed by cassette mutagenesis using methods described in the Materials and Methods and the Examples contained here, particularly Examples 54-58. Parental plasmid DNA (Table 8), digested with the appropriate restriction enzymes (Table 8), was ligated with the indicated annealed pairs of complementary oligonucleotides (Table 8). The assembled oligonucleotides create the appropriate restriction ends and a portion of (15-125) hIL-3 gene (pMON13288 [SEQ ID NO:100]) sequence. The oligonucleotides create change(s) in the (15-125) hIL-3 variant gene which encode the corresponding amino acid substitution(s); and/or deletions from the C-terminus of the variant polypeptide (Table 8). Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The amino acids substitutions in addition to and/or different from those in polypeptide #

25 [SEQ ID NO:88] are indicated in Table 8. The table also shows the plasmid designation (pMON number), DNA sequence identification number for the mutated hIL-3 gene and the identification number for the the resulting variant polypeptide. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 5 is shown in Table 1.

Example 121

Construction of pMON13446

Plasmid, pMON13287, DNA (purified from the E. coli strain GM48 {dam-}) was digested with restriction enzymes NcoI and ClaI. The resulting 3942 base pair NcoI,ClaI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage F1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the DNA sequence encoding amino acids 21-125 of the (15-125) hIL-3 variant pMON13287. The 3942 base pair NcoI,ClaI restriction fragment from pMON13368 was ligated to the following annealed complementary oligonucleotides.

Oligo #B57	338UP	[SEQ ID NO:226]
Oligo #B56	338DOWN	[SEQ ID NO:225]

When assembled, the oligonucleotides create NcoI and ClaI restriction ends and the DNA sequence that encodes the following 14 amino acid sequence; Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys [SEQ ID NO:403] and the DNA sequence which encodes amino acids 15-20 of the (15-125) hIL-3 variant gene, pMON13287 [SEQ ID NO:97]. The resulting variant polypeptide has a 14 amino acid N-terminal extension fused to the (15-125) hIL-3 variant polypeptide, pMON13288 [SEQ ID NO: 88]. The plasmid, pMON13446, contains the (15-125) hIL-3 variant gene (DNA sequence #B53 [SEQ ID NO:404]) which encodes the (15-125) hIL-3 variant polypeptide with the following amino acid

sequence:

Polypeptide #B53 [SEQ ID NO.:315]

Example B54

Construction of pMON13390

Plasmid, pMON13288, DNA (purified from the E. coli strain GM48 {dam-}) was digested with restriction enzymes NcoI and ClaI. The resulting 3942 base pair NcoI,ClaI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage F1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the DNA sequence encoding amino acids 21-125 of the (15-125) hIL-3 variant pMON13288. The 3942 base pair NcoI,ClaI restriction fragment from pMON13288 was ligated to the following annealed complementary oligonucleotides.

Oligo #B57	338UP	[SEQ ID NO:226]
Oligo #B56	338DOWN	[SEQ ID NO:225]

When assembled, the oligonucleotides create NcoI and ClaI restriction ends and the DNA sequence which encodes the following 14 amino acid sequence; Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys [SEQ ID NO:403] and the DNA sequence which encodes amino acids 15-20 of the (15-125) hIL-3 variant gene pMON13288 [SEQ ID NO:100]. The resulting variant has a 14 amino acid N-terminal extension fused to the (15-125) hIL-3 variant polypeptide, pMON13288 [SEQ ID NO:88]. The plasmid, pMON13390, containes the (15-125) hIL-3 variant gene (DNA sequence #B54 [SEQ ID NO.:405] which encodes the (15-125) hIL-3 variant polypeptide with the following amino acid sequence:

Polypeptide #B54 [SEQ ID NO:316]

Examples 133-136

The variants in Table 10 were constructed by methods described in Materials and Methods and in Examples contained herein, particularly Examples 54-58. Parental plasmid DNA (Table 10), digested with the appropriate restriction enzymes (Table 10) was ligated with the indicated restriction fragment containing the changes listed (Table 10). The resulting mutated (15-125) IL-3 genes encode the corresponding amino acid substitutions in the variant polypeptides (Table 10). The amino acid substitutions in addition to and/or different from those in polypeptide #25 [SEQ ID NO: 89] are indicated in Table 10. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 10 is shown in Table 1.

Examples 123-132

The variants in Table 9 were constructed by cassett mutagenesis using methods described in Materials and Methods and in Examples 54-58 contained herein. Parental plasmid DNA (Table 9), digested with the appropriate restriction enzymes (Table 9), was ligated with the indicated annealed pairs of complementry oligonucleoties (Table 9). The assembled oligonucleotides create the appropriate restriction fragment which was inserted into the (15-125) hIL-3 gene (pMON13288 [SEQ ID NO:100] between these restriction sites. The deletions or substitutions encoded by the oligonucleotide in the (15-125) IL-3 gene correspond to the amino acid deletions or substitutions in the variant polypeptide (Table 9). The amino acid substitutions or deletions, in addition to and/or different from those in the polypeptide #25 [SEQ ID NO:89] are indicated in Table 9. The biological activity (growth promoting activity in AML 193 cells) for some of the variants in Table 9 is shown in Table 1.

Formula XI shown below is a representation of a [(15-125)hIL-3 mutein] with numbers in bold type added above the amino acids to represent the position at which the amino acid below the bolded number appears in native (1-133)hIL-3 [e. g. the amino acid at position 1 of Formula XI corresponds to the Asn which appears at position 15 in native (1-133)hIL-3]. The number shown in bold indicates the amino acids that correspond to the native IL-3(1-133). The non-bold members below the amino acids sequences are for Seq Id reference numbers. When the muteins are expressed the initial amino acid may be preceded by Met- or Met-Ala-.

15 **20** **25**
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln
1 5 10 15

30 **35** **40**
Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp
20 25 30

45 **50** **55**
Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu
35 40 45

60 **65** **70**
Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile
50 55 60

75 **80** **85**
Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr
65 70 75

90 **95** **100**
Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp
80 85 90

105 **110** **115**
Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu
95 100 105

120 **125**
Asn Ala Gln Ala Gln Gln [SEQ ID NO:23]
110

Table 5

Example	pMON number	Parental plasmid/ restriction digest	oligo pair 1,4	oligo pair 2,5	oligo pair 3,6	amino acid changes	resulting polypeptide
Example 69	pMON13406 SEQ ID NO:332	pMON13288/ NcoI, EcoRV	19Ala1 OLIGO# B1 SEQ ID NO:170 19Ala4 OLIGO# B2 SEQ ID NO:171	29R32N37P2 OLIGO# 5 SEQ ID NO:19 29R32N37P5 OLIGO#6 SEQ ID NO:20	42S45M3 OLIGO# 11 SEQ ID NO:25 42S45M6 OLIGO# 12 SEQ ID NO:26	19Ala	polypeptide B1 SEQ ID NO:264
Example 70	pMON13414 SEQ ID NO:333	pMON13288/ NcoI, EcoRV	19Ile1 OLIGO# B3 SEQ ID NO:172 19Ile4 OLIGO# B4 SEQ ID NO:173	29R32N37P2 OLIGO# 5 SEQ ID NO:19 29R32N37P5 OLIGO#6 SEQ ID NO:20	42S45M3 OLIGO# 11 SEQ ID NO:25 42S45M6 OLIGO# 12 SEQ ID NO:26	19Ile	polypeptide B2 SEQ ID NO:265
Example 71	pMON13407 SEQ ID NO:334	pMON13288/ NcoI, EcoRV	18I25H1 OLIGO# 1 SEQ ID NO:15 18I25H4 OLIGO# 2 SEQ ID NO:16	29R32N37P2 OLIGO# 5 SEQ ID NO:19 29R32N37P5 OLIGO#6 SEQ ID NO:20	42S45V3 OLIGO#B11 SEQ ID NO:180 42S45V6 OLIGO#B12 SEQ ID NO:181	45Val	polypeptide B3 SEQ ID NO:266
Example 72	pMON13405 SEQ ID NO:335	pMON13288/ NcoI, EcoRV	19Ala1 OLIGO# B1 SEQ ID NO:170 19Ala4 OLIGO# B2 SEQ ID NO:171	29R32N37P2 OLIGO# 5 SEQ ID NO:19 29R32N37P5 OLIGO#6 SEQ ID NO:20	42S45V3 OLIGO#B11 SEQ ID NO:180 42S45V6 OLIGO#B12 SEQ ID NO:181	19Ala,45Val	polypeptide B4 SEQ ID NO:267
Example 73	pMON13415 SEQ ID NO:336	pMON13288/ NcoI, EcoRV	19Ile1 OLIGO# B3 SEQ ID NO:172 19Ile4 OLIGO# B4 SEQ ID NO:173	29R32N37P2 OLIGO# 5 SEQ ID NO:19 29R32N37P5 OLIGO#6 SEQ ID NO:20	42S45V3 OLIGO#B11 SEQ ID NO:180 42S45V6 OLIGO#B12 SEQ ID NO:181	19Ile,45Val	polypeptide B5 SEQ ID NO:268
Example 74	pMON13408 SEQ ID NO:337	pMON13288/ EcoRV, NsiI	49Ile1 OLIGO# B7 SEQ ID NO:176 49Ile4 OLIGO# B8 SEQ ID NO:177	59L62V2 OLIGO# 25 SEQ ID NO:39 59L62V5 OLIGO# 26 SEQ ID NO:40	67H69E3 OLIGO# 29 SEQ ID NO:43 67H69E6 OLIGO# 30 SEQ ID NO:44	49Ile	polypeptide B6 SEQ ID NO:269

Table 5 cont

Example 75	pMON13409 SEQ ID NO:338	pMON13288/ EcoRV, NsiI	49Leu1 SEQ ID NO:178 OLIGO# B9 49Leu4 OLIGO# B10 SEQ ID NO:179	59L62V2 OLIGO# 25 SEQ ID NO:39 59L62V5 OLIGO# 26 SEQ ID NO:40	67H69E3 OLIGO# 29 SEQ ID NO:43 67H69E6 OLIGO# 30 SEQ ID NO:44	49Leu	polypeptide B7 SEQ ID NO:270
Example 76	pMON13410 SEQ ID NO:339	pMON13288/ EcoRV, NsiI	49Asp1 OLIGO# B5 SEQ ID NO:174 49Asp4 OLIGO# B6 SEQ ID NO:175	59L62V2 OLIGO# 25 SEQ ID NO:39 59L62V5 OLIGO# 26 SEQ ID NO:40	67H69E3 OLIGO# 29 SEQ ID NO:43 67H69E6 OLIGO# 30 SEQ ID NO:44	49Asp	polypeptide B8 SEQ ID NO:271

Table 6

Example No	plasmid pMON number	Parental plasmid/ restriction digest	restriction fragment	amino acid substitutions	resulting polypeptide
Example 77	pMON13422 SEQ ID NO:340	pMON13408/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13405	19Ala, 45Val, 49Ile	polypeptide B9 SEQ ID NO:272
Example 78	pMON13423 SEQ ID NO:341	pMON13408/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13415	19Ile, 45Val, 49Ile	polypeptide B10 SEQ ID NO:273
Example 79	pMON13424 SEQ ID NO:342	pMON13409/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13405	19Ala, 45Val, 49Leu	polypeptide B11 SEQ ID NO:274
Example 80	pMON13425 SEQ ID NO:343	pMON13409/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13415	19Ile, 45Val, 49Leu	polypeptide B12 SEQ ID NO:275
Example 81	pMON13426 SEQ ID NO:344	pMON13410/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13405	19Ala, 45Val, 49Asp	polypeptide B13 SEQ ID NO:276
Example 82	pMON13429 SEQ ID NO:345	pMON13410/ NcoI, EcoRV	99 base pair NcoI, EcoRV fragment from pMON13415	19Ile, 45Val, 49Asp	polypeptide B14 SEQ ID NO:277

Table 7

Example	pMON number	template	Step one PCR primer1	Step one PCR primer2	Step two PCR primer1	Step two PCR primer2	Amino Acid Substitutions	Polypeptide
Example 86	pMON13475 SEQ ID NO:348	pMON13287	18123A25H OLIGO# B13 SEQ ID NO:182	42D45V46S50D OLIGO# B19 SEQ ID NO:188	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	42D,46S,50D	Polypeptide # B17 SEQ ID NO 280
Example 87	pMON13366 SEQ ID NO:349	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42D45V46S50D OLIGO# B19 SEQ ID NO:188	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	42N,46S,50D	Polypeptide # B18 SEQ ID NO 281
Example 88	pMON13367 SEQ ID NO:350	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42A45V46S50D OLIGO# B17 SEQ ID NO:186	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	46S,50D	Polypeptide # B19 SEQ ID NO 282
Example 89	pMON13369 SEQ ID NO:351	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42D45V46S50D OLIGO# B21 SEQ ID NO:190	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	42D,46S,50D	Polypeptide # B20 SEQ ID NO 283
Example 90	pMON13370 SEQ ID NO:352	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42A45M46S50D OLIGO# B16 SEQ ID NO:185	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	45M,46S,50D	Polypeptide # B21 SEQ ID NO 284
Example 91	pMON13373 SEQ ID NO:353	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42D45M46S50D OLIGO# B18 SEQ ID NO:187	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	42D,45M,46S 50D	Polypeptide # B22 SEQ ID NO 285
Example 92	pMON13374 SEQ ID NO:354	pMON13287	2341NCO OLIGO# B15 SEQ ID NO:184	42S45M46S50D OLIGO# B20 SEQ ID NO:189	product from step one	2341HIN3 OLIGO# B14 SEQ ID NO:183	42S,45M46S 50D	Polypeptide # B23 SEQ ID NO 286

Table 8

Example	plasmid	parental plasmid	oligo pair	oligo pair	oligo pair	resulting amino acid sub(s).	polypeptide
Example 93	pMON13375 SEQ ID NO:355	pMON13287/ EcoR1,H1ndIII	S09E16V1 OLIGO# B50 SEQ ID NO:219 S09E16V3 OLIGO# B51 SEQ ID NO:220	S116VD31 OLIGO# B52 SEQ ID NO:221 SECR1D33 OLIGO# B53 SEQ ID NO:222		15-119	polypeptide B24 SEQ ID NO:287
Example 94	pMON13376 SEQ ID NO:356	pMON13476/ EcoR1,H1ndIII	S9E2Q6V1 OLIGO# B54 SEQ ID NO:223 S9E2Q6V3 OLIGO# B55 SEQ ID NO:224	S116VD31 OLIGO# B52 SEQ ID NO:221 SECR1D33 OLIGO# B53 SEQ ID NO:222		15-119,23A,112Q	polypeptide B25 SEQ ID NO:288
Example 95	pMON13377 SEQ ID NO:357	pMON13475/ EcoR1,H1ndIII	S9E2Q6V1 OLIGO# B54 SEQ ID NO:223 S9E2Q6V3 OLIGO# B55 SEQ ID NO:224	S116VD31 OLIGO# B52 SEQ ID NO:221 SECR1D33 OLIGO# B53 SEQ ID NO:222		15-119,23A,42D, 46S,50D,112Q	polypeptide B26 SEQ ID NO:289
Example 96	pMON13378 SEQ ID NO:358	pMON13365/ EcoR1,H1ndIII	S09E16V1 OLIGO# B50 SEQ ID NO:219 S09E16V3 OLIGO# B51 SEQ ID NO:220	S116VD31 OLIGO# B52 SEQ ID NO:221 SECR1D33 OLIGO# B53 SEQ ID NO:222		15-119,23A	polypeptide B27 SEQ ID NO:290
Example 97	pMON13379 SEQ ID NO:359	pMON13367/ EcoR1,H1ndIII	9E12Q6V1 OLIGO# B48 SEQ ID NO:217 9E12Q6V3 OLIGO# B49 SEQ ID NO:218	120Q123E2 OLIGO# 49 SED ID NO:63 120Q123E4 OLIGO# 50 SED ID NO:64		46S,50D,112Q	polypeptide B28 SEQ ID NO:291
Example 98	pMON13385 SEQ ID NO:360	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29V32R34S2 OLIGO# B28 SED ID NO:197 29V32R34S5 OLIGO# B29 SED ID NO:198	42A45V3 OLIGO# 9 SEQ ID NO:23 42A45V6 OLIGO# 10 SEQ ID NO:24	29V,32R,34S	polypeptide B29 SEQ ID NO:292
Example 99	pMON13381 SEQ ID NO:361	pMON13287/ NsiI,EcoRI	73G76A1 OLIGO# 41 SEQ ID NO:55 73G76A4 OLIGO# 42 SEQ ID NO:56	82TRP2 OLIGO# B44 SEQ ID NO:213 82TRP5 OLIGO# B45 SEQ ID NO:214	87S93S98I3 OLIGO# 35 SEQ ID NO:49 87S93S98I7 OLIGO# 36 SEQ ID NO:50	82W 101A105Q4 OLIGO# 43 SEQ ID NO:57 101A105Q8 OLIGO# 44 SEQ ID NO:58	polypeptide B30 SEQ ID NO:293

Table 8 cont

Example 100	pMON13383 SEQ ID NO:362	pMON13475/ EcoR1,HindIII	9E12Q6V1 OLIGO# B48 SEQ ID NO:217 9E12Q6V5 OLIGO# B49 SEQ ID NO:218	120Q123E2 OLIGO# 49 SED ID NO:63 120Q123E4 OLIGO# 50 SED ID NO:64			23A,42D,46S,50D 112Q	polypeptide B31 SEQ ID NO:294
Example 101	pMON13384 SEQ ID NO:363	pMON13287/ EcoR1,HindIII	9E12Q6V1 OLIGO# B48 SEQ ID NO:217 9E12Q6V5 OLIGO# B49 SEQ ID NO:218	120Q123E2 OLIGO# 49 SED ID NO:63 120Q123E4 OLIGO#50 SED ID NO:64			112Q	polypeptide B32 SEQ ID NO:295
Example 102	pMON13388 SEQ ID NO:364	pMON13287/ EcoRV,NsiI	50D56S1 OLIGO# B42 SEQ ID NO:211 50ASP4 OLIGO# B41 SEQ ID NO:210	60S62V2 OLIGO# 27 SEQ ID NO:41 56SER5 OLIGO# B43 SEQ ID NO:212	67N69E3 OLIGO# 31 SEQ ID NO:45 67N69E6 OLIGO# 32 SEQ ID NO:46		50D,56S	polypeptide B33 SEQ ID NO:296
Example 103	pMON13389 SEQ ID NO:365	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45M3 OLIGO# B32 SEQ ID NO:201 42D45M6 OLIGO# B33 SEQ ID NO:202		42D,45M	polypeptide B34 SEQ ID NO:297
Example 104	pMON13391 SEQ ID NO:366	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	34SER1 OLIGO# B30 SEQ ID NO:199 34SER5 OLIGO# B31 SEQ ID NO:200	42A45V3 OLIGO# 9 SEQ ID NO:23 42A45V6 OLIGO# 10 SEQ ID NO:24		34S	polypeptide B35 SEQ ID NO:298
Example 105	pMON13392 SEQ ID NO:367	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45V3 OLIGO# B34 SEQ ID NO:203 42D45V6 OLIGO# B35 SEQ ID NO:204		42D	polypeptide B36 SEQ ID NO:299
Example 106	pMON13393 SEQ ID NO:368	pMON13287/ NcoI,EcoRV	23AlA1 OLIGO# B26 SEQ ID NO:195 23AlA4 OLIGO# B27 SEQ ID NO:196	34SER1 OLIGO# B30 SEQ ID NO:199 34SER5 OLIGO# B31 SEQ ID NO:200	42D45M46S3 OLIGO# B36 SEQ ID NO:205 42D45M46S6 OLIGO# B37 SEQ ID NO:206		23A,34S,42D,45M 46S	polypeptide B37 SEQ ID NO:300

Table 8 cont

Example 107	pMON13394 SEQ ID NO:369	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45M46S3 OLIGO# B36 SEQ ID NO:205 42D45M46S6 OLIGO# B37 SEQ ID NO:206		42D,45M,46S	polypeptide B38 SEQ ID NO:301
Example 108	pMON13395 SEQ ID NO:370	pMON13287/ NcoI,EcoRV	23ALA1 OLIGO# B26 SEQ ID NO:195 23ALA4 OLIGO# B27 SEQ ID NO:196	29V32R34S2 OLIGO# B28 SED ID NO:197 29V32R34S5 OLIGO# B29 SED ID NO:198	42D45V46S3 OLIGO# B38 SEQ ID NO:207 42D45V46S6 OLIGO# B39 SEQ ID NO:208		23A,29V,32R,34S 42D,46S	polypeptide B39 SEQ ID NO:302
Example 109	pMON13396 SEQ ID NO:371	pMON13287/ NsiI,EcoRI	73G76A1 OLIGO# 41 SEQ ID NO:55 73G76A4 OLIGO# 42 SEQ ID NO:56	79R82Q2 OLIGO# 39 SEQ ID NO:53 79R82Q5 OLIGO# 40 SEQ ID NO:54	100ARG3 SEQ ID NO: 87S93S98I7 OLIGO# 36 SEQ ID NO:50	100MET4 OLIGO# B24 SEQ ID NO:193 10R01M8 OLIGO# B25 SEQ ID NO:194	100R,101M	polypeptide B40 SEQ ID NO:303
Example 110	pMON13397 SEQ ID NO:372	pMON13287/ NsiI,EcoRI	73G76A1 OLIGO# 41 SEQ ID NO:55 73G76A4 OLIGO# 42 SEQ ID NO:56	82TRP2 OLIGO# B44 SEQ ID NO:213 82TRP5 OLIGO# B45 SEQ ID NO:214	100ARG3 OLIGO# B22 SEQ ID NO:191 87S93S98I7 OLIGO# 36 SEQ ID NO:50	100MET4 OLIGO# B24 SEQ ID NO:193 10R01M8 OLIGO# B25 SEQ ID NO:194	82W,100R,101M	polypeptide B41 SEQ ID NO:304
Example 111	pMON13398 SEQ ID NO:373	pMON13287/ NcoI,EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45V46S3 OLIGO# B38 SEQ ID NO:207 42D45V46S6 OLIGO# B39 SEQ ID NO:208		42D,46S	polypeptide B42 SEQ ID NO:305
Example 112	pMON13399 SEQ ID NO:374	pMON13388/ NcoI,EcoRV	23ALA1 OLIGO# B26 SEQ ID NO:195 23ALA4 OLIGO# B27 SEQ ID NO:196	29V32R34S2 OLIGO# B28 SED ID NO:197 29V32R34S5 OLIGO# B29 SED ID NO:198	42D45V46S3 OLIGO# B38 SEQ ID NO:207 42D45V46S6 OLIGO# B39 SEQ ID NO:208		23A,29V,32R,34S 42D,46S	polypeptide B43 SEQ ID NO:306
Example 113	pMON13404 SEQ ID NO:375	pMON13287/ EcoRI,HindIII	S9E2Q6V1 OLIGO# B54 SEQ ID NO:223 S9E2Q6V3 OLIGO# B55 SEQ ID NO:224	S116VD31 OLIGO# B52 SEQ ID NO:221 SECR1D33 OLIGO# 53 SEQ ID NO:222			15-119 112Q	polypeptide B44 SEQ ID NO:307

Table 8 cont

Example 114	pMON13387 SEQ ID NO:376	pMON13287/ EcoRV,NsiI	50ASP1 OLIGO# B40 SEQ ID NO:209 50ASP4 OLIGO# B41 SEQ ID NO:210	60S62V2 OLIGO# 27 SEQ ID NO:41 60S62V5 OLIGO# 28 SEQ ID NO:42	67N69E3 OLIGO# 31 SEQ ID NO:45 67N69E6 OLIGO# 32 SEQ ID NO:46		50D	polypeptide B45 SEQ ID NO:308
Example 115	pMON13416 SEQ ID NO:377	pMON13387/ NcoI/EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45V46S3 OLIGO# B38 SEQ ID NO:207 42D45V46S6 OLIGO# B39 SEQ ID NO:208		42D,46S, 50D	polypeptide B46 SEQ ID NO:309
Example 116	pMON13417 SEQ ID NO:378	pMON13387/ NcoI/EcoRV	18I25H1 OLIGO#1 SEQ ID NO:15 18I25H4 OLIGO#2 SEQ ID NO:16	29R32A37P2 OLIGO# 3 SEQ ID NO:17 29R32A37P5 OLIGO# 4 SEQ ID NO:18	42D45M46S3 OLIGO# B36 SEQ ID NO:205 42D45M46S6 OLIGO# B37 SEQ ID NO:206		42D,45M,46S, 50D	polypeptide B47 SEQ ID NO:310
Example 117	pMON13420 SEQ ID NO:379	pMON13388/ NcoI,EcoRV	23A1A1 OLIGO# B26 SEQ ID NO:195 23A1A4 OLIGO# B27 SEQ ID NO:196	34SER1 OLIGO# B30 SEQ ID NO:199 34SER5 OLIGO# B31 SEQ ID NO:200	42D45V46S3 OLIGO# B38 SEQ ID NO:207 42D45V46S6 OLIGO# B39 SEQ ID NO:208		23A,34S,42D,46S 50D,56S	polypeptide B48 SEQ ID NO:311
Example 118	pMON13421 SEQ ID NO:380	pMON13388/ NcoI,EcoRV	23A1A1 OLIGO# B26 SEQ ID NO:195 23A1A4 OLIGO# B27 SEQ ID NO:196	34SER1 OLIGO# B30 SEQ ID NO:199 34SER5 OLIGO# B31 SEQ ID NO:200	42D45M46S3 OLIGO# B36 SEQ ID NO:205 42D45M46S6 OLIGO# B37 SEQ ID NO:206		23A,34S,42D,45M 46S,50D,56S	polypeptide B49 SEQ ID NO:331
Example 119	pMON13432 SEQ ID NO:381	pMON13387/ NcoI,EcoRV	23A1A1 OLIGO# B26 SEQ ID NO:195 23A1A4 OLIGO# B27 SEQ ID NO:196	34SER1 OLIGO# B30 SEQ ID NO:199 34SER5 OLIGO# B31 SEQ ID NO:200	42D45M46S3 OLIGO# B36 SEQ ID NO:205 42D45M46S6 OLIGO# B37 SEQ ID NO:206		23A,34S,42D,45M 46S,50D	polypeptide B50 SEQ ID NO:312
Example 120	pMON13382 SEQ ID NO:382	pMON13287/ EcoRI,HindIII	9E1206W1 OLIGO# B46 SEQ ID NO:215 9E1Q16W3 OLIGO# B47 SEQ ID NO:216	120Q123E2 OLIGO# 49 SED ID NO:63 120Q123E4 OLIGO# 50 SED ID NO:64			112Q,116W	polypeptide B51 SEQ ID NO:313

TABLE 9

Example No.	Plasmid	Parental Plasmid/ Restriction Digest	Oligo pair	Oligo pair	Oligo pair	Oligo pair	Amino acid changes	Polypeptide
Example 124	pMON13400 SEQ ID NO:384	pMON13288 Restriction NcoI-EcoRV	20P23A1 SEQ ID NO:232 20P23A4 SEQ ID NO:233	29I4S7S2 SEQ ID NO:236 29I4S7S5 SEQ ID NO:237	38A5V6S3 SEQ ID NO:238 38A5V6S3 SEQ ID NO:239		20P 23A 29I 34S 37S 38A 45V 46S	Polypeptide C-2 SEQ ID NO:317
Example 125	pMON13402 SEQ ID NO:385	pMON13288 Restriction NcoI-EcoRV	23L1 SEQ ID NO:234 23L4 SEQ ID NO:235	29I4S7S2 SEQ ID NO:236 29I4S7S5 SEQ ID NO:237	38A5V6S3 SEQ ID NO:238 38A5V6S3 SEQ ID NO:239		23L 29I 34S 37S 38A 45V 46S	Polypeptide C-3 SEQ ID NO:318
Example 131	pMON13440 SEQ ID NO:386	pMON13288 Restriction NcoI-EcoRV	18I3A5H1 SEQ ID NO:195 18I3A5H4 SEQ ID NO:196	29I4S7S2 SEQ ID NO:236 29I4S7S5 SEQ ID NO:237	38A5V6S3 SEQ ID NO:238 38A5V6S3 SEQ ID NO:239		18I 23A 25H 29I 34S 37S 38A 45V 46S	Polypeptide C-10 SEQ ID NO:319
Example 132	pMON13451 SEQ ID NO:387	pMON13288 Restriction NcoI-EcoRV	19I0L3A1 SEQ ID NO:230 19I0L3A4 SEQ ID NO:231	29I4S7S2 SEQ ID NO:236 29I4S7S5 SEQ ID NO:237	38A5V6S3 SEQ ID NO:238 38A5V6S3 SEQ ID NO:239		19I 20L 23A 29I 34S 37S 38A 45V 46S	Polypeptide C-11 SEQ ID NO:320
Example 130	pMON13419 SEQ ID NO:389	pMON13288 Restriction EcoRV-NsiI	50D51S1 SEQ ID NO:240 50D51S4 SEQ ID NO:241	62P3H5S2 SEQ ID NO:244 62P3H5 SEQ ID NO:246	67Q3 SEQ ID NO:248 65S67Q6 SEQ ID NO:247		50D 51S 62P 63H 65S 67Q	Polypeptide C-8 SEQ ID NO:325
Example 126	pMON13403 SEQ ID NO:388	pMON13288 Restriction EcoRV-NsiI	50D51S1 SEQ ID NO:240 50D51S4 SEQ ID NO:241	62P3H2 SEQ ID NO:245 62P3H5 SEQ ID NO:246	67Q3 SEQ ID NO:248 67Q6 SEQ ID NO:249		50D 51S 62P 63H 67Q	Polypeptide C-4 SEQ ID NO:321

TABLE 9

Example 123	pMON13418 SEQ ID NO:393	pMON13288 Restriction NsiI-EcoRI	76P1 SEQ ID NO:250 76P5 SEQ ID NO:251	79S2 SEQ ID NO:252 79S6 SEQ ID NO:253	5VYWPTT3 SEQ ID NO:242 5VYWPTT7 SEQ ID NO:243	101A105Q4 SEQ ID NO:57 101A105Q8 SEQ ID NO:58	76P 79S 85V 87Y 88W 91P 95T 98T	Polypeptide C-1 SEQ ID NO:326
Example 127	pMON13411 SEQ ID NO:390	pMON13288 Restriction EcoRI-HindIII	09L2Q6S1 Seq ID NO:227 09L2Q6S3 SEQ ID NO:228	120Q123E2 SEQ ID NO:63 120Q123E4 SEQ ID NO:64			109L 112Q 116S	Polypeptide C-5 SEQ ID NO:322
Example 128	pMON13412 SEQ ID NO:391	pMON13288 Restriction EcoRI-HindIII	9LQS1181 Seq ID NO:255 9LQS1183 SEQ ID NO:256				15-118 109L 112Q 116S	Polypeptide C-6 SEQ ID NO:323
Example 129	pMON13413 SEQ ID NO:392	pMON13288 Restriction EcoRI-HindIII	09L2Q6S1 Seq ID NO:227 09L2Q6S3 SEQ ID NO :228	117S2 SEQ ID NO:229 120Q123E4 SEQ ID NO:64			109L 112Q 116S 117S	Polypeptide C-7 SEQ ID NO:324

TABLE 10

Example No	Plasmid	Parental plasmid/ Restriction digest	Restriction fragment	Amino Acid changes	Polypeptide
Example 133	pMON13428 SEQ ID NO:394	pMON13411 NsiI-EcoRI	102 bp NsiI-EcoRI fragment from pMON13418	76P 79S 85V 87Y 91P 95T 98T 109L 112Q 116S	Polypeptide C-9 SEQ ID NO:327
Example 134	pMON13459 SEQ ID NO:395	pMON13428 NcoI-NsiI	170 bp NcoI-NsiI fragment from pMON13402	23L 29I 34S 37S 38A 45V 46S 76P 79S 85V 87Y 91P 95T 98T 109L 112Q 116S	Polypeptide C-12 SEQ ID NO:328
Example 135	pMON13467 SEQ ID NO:396	pMON13413 NcoI-NsiI	170 bp NcoI-NsiI fragment from pMON13402	23L 29I 34S 37S 38A 45V 46S 109L 112Q 116S 109L 112Q 116S 117S	Polypeptide C-13 SEQ ID NO:329
Example136	pMON13492 SEQ ID NO:397	pMON13418 NcoI-NsiI	170 bp NcoI-NsiI fragment from pMON13402	23L 29I 34S 37S 38A 45V 46S 76P 79S 85V 87Y 91P 95T 98T	Polypeptide C-14 SEQ ID NO:330

WHAT IS CLAIMED IS:

1. A human interleukin-3 mutant polypeptide Formula I:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID
125 130

NO:15]

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or
Val;
Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or
Gly;
Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;
Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe,
Ile or Met;
Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp, Leu, or Val;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn, or Ala;
Xaa at position 40 is Leu, Trp, or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe,
Tyr, Ile, Met or Ala;
Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr,
Gly or Ser;
Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln,

Ala or Pro;
Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn,
Arg, Ser, Ala, Ile, Glu or His;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala,
Tyr, Ile, Val or Gly;
Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala,
Met, Val or Asn;
Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,
His, Phe, Met or Gln;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;
Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;
Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;
Xaa at position 57 is Asn or Gly;
Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;
Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;
Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, Asp, or Ile;
Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;
Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;
Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;

Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser,
Ala, Trp, Phe, Ile, or Tyr;
Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;
Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;
Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr,
Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,
Gly, Ser, Phe, or His;
Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln,
or Pro;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,
Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;
Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
Xaa at position 103 is Asp, or Ser;
Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,
Gln, Lys, Ala, Phe, or Gly;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,
Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser,
Ala or
Pro;
Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;
Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu,
Ser, Ala,
or Trp;
Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,
Lys, Leu, Ile, Val or Asn;
Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,
Trp, or Met;
Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,
Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;
Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.

2. A human interleukin-3 mutant polypeptide of the Formula II:

Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa
35 40 45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa
80 85 90

Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa
95 100 105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa
110 115 120
Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:16]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 20 is Ile or Pro;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Phe, Gly, Arg, or Ala;
Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 29 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp or Leu;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn or Ala;
Xaa at position 41 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu,

His, Ile, Lys, Tyr, Val or Gly;
Xaa at position 47 is Ile, Val, or His;
Xaa at position 49 is Met, Asn, or Asp;
Xaa at position 50 is Glu, Thr, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 52 is Asn or Gly;
Xaa at position 53 is Leu, Met, or Phe;
Xaa at position 54 is Arg, Ala, or Ser;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu,
Thr, Val or Lys;
Xaa at position 59 is Glu, Tyr, His, Leu, or Arg;
Xaa at position 60 is Ala, Ser, Asn, or Thr;
Xaa at position 61 is Phe or Ser;
Xaa at position 62 is Asn, Val, Pro, Thr, or Ile;
Xaa at position 63 is Arg, Tyr, Lys, Ser, His, or Val;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val, Thr, Leu, or Ser;
Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 67 is Ser, Phe, Val, Gly, Asn, Ile, or His;
Xaa at position 68 is Leu, Val, Ile, Phe, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 70 is Asn or Pro;
Xaa at position 71 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;
Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;
Xaa at position 74 is Ile or Met;
Xaa at position 75 is Glu, Gly, Asp, Ser, or Gln;
Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;
Xaa at position 77 is Ile, Ser, or Leu;
Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 80 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 81 is Leu, or Val;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, or Met;

Xaa at position 85 is Leu or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala, Arg, or Trp;

Xaa at position 89 is Thr, Asp, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Asp, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;

Xaa at position 92 is Pro or Ser;

Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;

Xaa at position 96 is Pro or Tyr;

Xaa at position 97 is Ile, Val, or Ala;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Leu, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 99 is Ile, Leu, Val, or Phe;

Xaa at position 100 is Lys, Leu, His, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;

Xaa at position 102 is Gly, Glu, Lys, or Ser;

Xaa at position 104 is Trp, Val, Tyr, Met, or Leu;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, or Gly;

Xaa at position 108 is Arg, Ala, Gln, Ser or Lys;

Xaa at position 109 is Arg, Thr, Glu, Leu, Ser, or Gly;

Xaa at position 112 is Thr, Val, Gln, Glu, His, or Ser;

Xaa at position 114 is Tyr or Trp;

Xaa at position 115 is Leu or Ala;

Xaa at position 116 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;

Xaa at position 117 is Thr, Ser, or Asn;

Xaa at position 119 is Glu, Ser, Pro, Leu, Thr, or Tyr;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.

3. A human interleukin-3 mutant polypeptide according to claim 2 of the Formula III:

```
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1           5   10                  15

Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa
             20  25                  30

Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa
             35  40                  45

Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa
             50  55                  60

Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu
             65  70                  75

Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala
             80  85                  90

Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa
             95 100                 105
```

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:17]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 19 is Met or Ile;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, or Leu;
Xaa at position 25 is Thr, His, Gln, or Ala;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln, Asn, or Val;
Xaa at position 30 is Pro, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 37 is Phe, Ser, Pro, or Trp;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 54 is Arg or Ala;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;

Xaa at position 60 is Ala or Ser;

Xaa at position 62 is Asn, Pro, Thr, or Ile;

Xaa at position 63 is Arg or Lys;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val or Thr;

Xaa at position 66 is Lys or Arg;

Xaa at position 67 is Ser, Phe, or His;

Xaa at position 68 is Leu, Ile, Phe, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 71 is Ala, Pro, or Arg;

Xaa at position 72 is Ser, Glu, Arg, or Asp;

Xaa at position 73 is Ala or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;

Xaa at position 77 is Ile or Leu;

Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;

Xaa at position 80 is Asn, Gly, Glu, or Arg;

Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 83 is Pro or Thr;

Xaa at position 85 is Leu or Val;

Xaa at position 87 is Leu or Ser;

Xaa at position 88 is Ala or Trp;

Xaa at position 91 is Ala or Pro;

Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;

Xaa at position 96 is Pro or Tyr;

Xaa at position 97 is Ile or Val;

Xaa at position 98 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, Met, Ser, Tyr, Val or Pro;

Xaa at position 99 is Ile, Leu, or Val;

Xaa at position 100 is Lys, Arg, Ile, Gln, Pro, or Ser;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu or Tyr;

Xaa at position 104 is Trp or Leu;
Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu or Gly;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr, Val, or Gln;
Xaa at position 114 is Tyr or Trp;
Xaa at position 115 is Leu or Ala;
Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 35 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3.

4. A human interleukin-3 mutant polypeptide according to Claim 3 of the Formula IV:

```
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1           5   10                  15

Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa
                20  25                  30

Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa
                35  40                  45
```

Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala
50 55 60

Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu
65 70 75

Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala
80 85 90

Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa
95 100 105

Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa
110 115 120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:18]
125 130

wherein
Xaa at position 17 is Ser, Gly, Asp, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 25 is Thr, His, or Gln;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln or Asn;
Xaa at position 30 is Pro or Gly;
Xaa at position 32 is Leu, Arg, Asn, or Ala;
Xaa at position 34 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met;
Xaa at position 35 is Leu, Ala, Asn, or Pro;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 45 is Gln, Val, Met, Leu, Ala, Asn, Glu, or Lys;
Xaa at position 46 is Asp, Phe, Ser, Gln, Glu, His, Val or Thr;
Xaa at position 50 is Glu Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Pro, Thr, or His;

Xaa at position 55 is Arg, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 62 is Asn, Pro, or Thr;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 67 is Ser or Phe;
Xaa at position 68 is Leu or Phe;
Xaa at position 69 is Gln, Ala, Glu, or Arg;
Xaa at position 76 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Gly, Asn, Met, Arg, Ile, or Gly;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, or Ala;
Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 98 is His, Ile, Asn, Ala, Thr, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 99 is Ile or Leu;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 105 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr or Gln;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 122 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 123 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- preceding the amino acid in

position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3.

5. The human interleukin-3 mutant polypeptide of claim 1 wherein 1-15 amino acids are deleted from the C-terminus and/or 1-14 amino acids are deleted from the N-terminus.

6. The human interleukin-3 mutant polypeptide of claim 1 wherein;

Xaa at position 42 is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala;
Xaa at position 45 is Gln, Val, Met or Asn;
Xaa at position 46 is Asp, Ser, Gln, His or Val;
Xaa at position 50 is Glu or Asp;
Xaa at position 51 is Asn, Pro or Thr;
Xaa at position 62 is Asn or Pro;
Xaa at position 76 is Ser, or Pro;
Xaa at position 82 is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr;
Xaa at position 95 is His, Arg, Thr, Asn or Ser;
Xaa at position 98 is His, Ile, Leu, Ala, Gln, Lys, Met, Ser, Tyr or Val;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, His, Asn, Ile or Leu;
Xaa at position 105 is Asn, or Pro;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, or Tyr;
Xaa at position 121 is Ala, or Ile;
Xaa at position 122 is Gln, or Ile; and
Xaa at position 123 is Ala, Met or Glu.

7. A (15-125)human interleukin-3 mutant polypeptide of the Formula V:

Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:19]
110

wherein
Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
Xaa at position 6 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;
Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, or Gly;
Xaa at position 9 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;
Xaa at position 10 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 13 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 14 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 15 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;
Xaa at position 21 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 22 is Asp, Leu, or Val;
Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 24 is Asn, or Ala;
Xaa at position 26 is Leu, Trp, or Arg;
Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met, Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, Phe, Tyr, Ile or Met;
Xaa at position 29 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;
Xaa at position 30 is Asp, Ser, Leu, Arg, Lys, Thr,Met, Trp, Glu, Asn, Gln, Ala or Pro;
Xaa at position 31 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, Ser, Ala, Ile, Glu, His or Trp;
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;
Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 34 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 39 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, Met, or;
Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn,

Lys, His, Ala or Leu;
Xaa at position 41 is Arg, Thr, Val, Ser, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;
Xaa at position 43 is Asn or Gly;
Xaa at position 44 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
Xaa at position 45 is Glu Tyr, His, Leu, Pro, or Arg;
Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn, or Thr;
Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;
Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
Xaa at position 50 is Ala, Asn, Pro, Ser, or Lys;
Xaa at position 51 is Val, Thr, Pro, His, Leu, Phe, or Ser;
Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
Xaa at position 54 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;
Xaa at position 56 is Asn, Leu, Val, Trp, Pro, or Ala;
Xaa at position 57 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;
Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
Xaa at position 60 is Ile, Met, Thr, Pro, Arg, Gly, Ala;
Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;
Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
Xaa at position 63 is Ile, Ser, Arg, Thr, or Leu;
Xaa at position 64 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 67 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;
Xaa at position 68 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

Xaa at position 69 is Pro, Ala, Thr, Trp, Arg, or Met;
Xaa at position 70 is Cys, Glu, Gly, Arg, Met, or Val;
Xaa at position 71 is Leu, Asn, Val, or Gln;
Xaa at position 72 is Pro, Cys, Arg, Ala, or Lys;
Xaa at position 73 is Leu, Ser, Trp, or Gly;
Xaa at position 74 is Ala, Lys, Arg, Val, or Trp;
Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;
Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;
Xaa at position 79 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;
Xaa at position 80 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro;
Xaa at position 81 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile or Tyr;
Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile, or Thr;
Xaa at position 83 is Ile, Val, Lys, Ala, or Asn;
Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;
Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, Pro;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu or Gln;
Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
Xaa at position 89 is Asp, or Ser;
Xaa at position 90 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro;
Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 96 is Lys, Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala or Trp;
Xaa at position 97 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 98 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;
Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 101 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;
Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;
Xaa at position 103 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 104 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;
Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 106 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding native amino acids of (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

8. A (15-125)human interleukin-3 mutant polypeptide of the Formula VI:

```
Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa
 1           5   10                  15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa
                20  25                  30
```

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa
65 70 75

Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:20]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 6 is Ile or Pro;
Xaa at position 7 is Asp, or Glu;
Xaa at position 9 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Phe, Gly, Arg, or Ala;
Xaa at position 14 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 15 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;

Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 22 is Asp or Leu;
Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 24 is Asn or Ala;
Xaa at position 27 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg;
Xaa at position 30 is Asp, or Glu;
Xaa at position 31 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn Glu, Ser or Trp;
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;
Xaa at position 33 is Ile, Val, or His;
Xaa at position 35 is Met, Asn, or Asp;
Xaa at position 36 is Glu, Thr, Ala, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 38 is Asn or Gly;
Xaa at position 39 is Leu, Met, or Phe;
Xaa at position 40 is Arg, Ala or Ser;
Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;
Xaa at position 45 is Glu, Tyr, His, Leu, or Arg;
Xaa at position 46 is Ala, Ser, Asn, or Thr;
Xaa at position 47 is Phe or Ser;
Xaa at position 48 is Asn, Val, Pro, Thr, or Ile;
Xaa at position 49 is Arg, Tyr, Lys, Ser, His, or Val;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val, Thr, Leu, or Ser;
Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 53 is Ser, Phe, Val, Gly, Asn, Ile, or His;
Xaa at position 54 is Leu, Val, Ile, Phe, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 56 is Asn or Pro;
Xaa at position 57 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;
Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or

Pro;
Xaa at position 60 is Ile or Met;
Xaa at position 61 is Glu, Gly, Asp, Ser, or Gln;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;
Xaa at position 63 is Ile, Ser, or Leu;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
Xaa at position 66 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 67 is Leu, or Val;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro, Ala, Thr, Trp, or Met;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala, Arg, or Trp;
Xaa at position 75 is Thr, Asp, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Asp, or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
Xaa at position 78 is Pro or Ser;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is Ile, Val, or Ala;
Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, Val, or Phe;
Xaa at position 86 is Lys, Leu, His, Arg, Ile, Gln, Pro or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;
Xaa at position 88 is Gly, Glu, Lys, or Ser;
Xaa at position 90 is Trp, Val, Tyr, Met, or Leu;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, Ser, Ala, or Gly;

Xaa at position 94 is Arg, Ala, Gln, Ser or Lys;
Xaa at position 95 is Arg, Thr, Glu, Leu, Ser, or Gly;
Xaa at position 98 is Thr, Val, Gln, Glu, His, or Ser;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr, Ser, or Asn;
Xaa at position 105 is Glu, Ser, Pro, Leu, Thr, or Tyr;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

9. A (15-125)human interleukin-3 mutant polypeptide according to Claim 7 of the Formula VII:

Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa
20 25 30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu
35 40 45

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile
50 55 60

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr
65 70 75

Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa
80 85 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:21]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 5 is Met or Ile;
Xaa at position 7 is Asp or Glu;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, or Leu;
Xaa at position 11 is Thr, His, Gln, or Ala;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln, Asn, or Val;
Xaa at position 16 is Pro, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg,
Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 23 is Phe, Ser, Pro, or Trp;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile,
Leu, Met Tyr or Arg;
Xaa at position 30 is Asp or Glu;
Xaa at position 31 is Gln, Val, Met, Leu, Thr, Ala, Asn,

Glu, Ser or Lys;
Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 40 is Arg or Ala;
Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;
Xaa at position 46 is Ala or Ser;
Xaa at position 48 is Asn, Pro, Thr, or Ile;
Xaa at position 49 is Arg or Lys;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 52 is Lys or Arg;
Xaa at position 53 is Ser, Phe, or His;
Xaa at position 54 is Leu, Ile, Phe, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 57 is Ala, Pro, or Arg;
Xaa at position 58 is Ser, Glu, Arg, or Asp;
Xaa at position 59 is Ala or Leu;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro or Thr;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;

Xaa at position 83 is Ile or Val;
Xaa at position 84 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, or Val;
Xaa at position 86 is Lys, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu or Tyr;
Xaa at position 90 is Trp or Leu;
Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, or Gly;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr, Val, or Gln;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 35 of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3.

10. A (15-125)human interleukin-3 mutant polypeptide according to Claim 7 of the Formula VIII:

Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa
1 5 10 15

Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp

20 25 30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu
35 40 45

Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile
50 55 60

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr
65 70 75

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp
80 85 90

Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu
95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:22]
110

wherein
Xaa at position 3 is Ser, Gly, Asp, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 11 is Thr, His, or Gln;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln or Asn;
Xaa at position 16 is Pro or Gly;
Xaa at position 18 is Leu, Arg, Asn, or Ala;
Xaa at position 20 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, or Pro;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 31 is Gln, Val, Met, Leu, Ala, Asn, Glu or Lys;
Xaa at position 32 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;

Xaa at position 36 is Glu, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Pro, Thr, or His;
Xaa at position 41 is Arg, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 48 is Asn, Pro, or Thr;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 53 is Ser or Phe;
Xaa at position 54 is Leu or Phe;
Xaa at position 55 is Gln, Ala, Glu, or Arg;
Xaa at position 62 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Asn, Met, Arg, Ile, or Gly;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, or Ala;
Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 84 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 85 is Ile or Leu;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 91 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr or Gln;
Xaa at position 102 is Lys, Val, Trp, or Ile;
Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 108 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 109 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 26 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

11. A (15-125) human interleukin-3 mutant polypeptide of claim 7 wherein:

Xaa at position 17 is Ser, Lys, Asp, Met, Gln, or Arg;
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Arg, Gly, Ala, or Cys;
Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, or Val;
Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, or Gly;
Xaa at position 23 is Ile, Ala, Gly, Trp, Lys, Leu, Ser, or Arg;
Xaa at position 24 is Ile, Gly, Arg, or Ser;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Ala, or Trp;
Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 29 is Gln, Asn, Loh, Pro, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 31 is Pro, Asp, Gly, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Thr, or Glu;
Xaa at position 34 is Leu, Gly, Ser, or Lys;
Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, or Gln;
Xaa at position 36 is Asp, Leu, or Val;
Xaa at position 37 is Phe, Ser, or Pro;
Xaa at position 38 is Asn, or Ala;
Xaa at position 40 is Leu, Trp, or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, or Ala;

Xaa at position 42 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, or Trp;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, or Gly;

Xaa at position 47 is Ile, Gly, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, His, Phe, or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, or Tyr;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or;

Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Ser, Pro, or Val;

Xaa at position 64 is Ala, Asn, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Thr, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Arg, Glu, Thr, Gln, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is Ile, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is Ile, Ser, Arg, or Thr;

Xaa at position 78 is Leu, Ala, Ser, Glu, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Ile, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, or Arg;

Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, or Asp;

Xaa at position 83 is Pro, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, or Gln;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, or Asn;

Xaa at position 90 is Ala, Ser, Asp, Ile, or Met;

Xaa at position 91 is Ala, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, or Pro;

Xaa at position 95 is His, Gln, Pro, Val, Leu, Thr or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, or Pro;

Xaa at position 99 is Ile, Arg, Asp, Pro, Gln, Gly, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Ile, Ser, Gln, or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 108 is Arg, Asp, Leu, Thr, Ile, or Pro;
Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly.

12. The human interleukin-3 mutant polypetide of claim 7:

wherein;

Xaa at position 28 is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala;
Xaa at position 31 is Gln, Val, Met or Asn;
Xaa at position 32 is Asp, Ser, Ala, Gln, His or Val;
Xaa at position 36 is Glu or Asp;
Xaa at position 37 is Asn, Pro or Thr;
Xaa at position 48 is Asn or Pro;
Xaa at position 62 is Ser, or Pro;
Xaa at position 68 is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr;
Xaa at position 81 is His, Arg, Thr, Asn or Ser;
Xaa at position 84 is His, Ile, Leu, Ala, Arg, Gln, Lys, Met, Ser, Tyr or Val;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Pro, His, Asn, Ile or Leu;
Xaa at position 91 is Asn, or Pro;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 102 is Lys, Val, Trp, Ala, His, Phe, or Tyr;
Xaa at position 107 is Ala, or Ile;
Xaa at position 108 is Gln, or Ile; and
Xaa at position 109 is Ala, Met or Glu.

13. A polypeptide of the formula

```
          1               5                  10
(Met)m-Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr
                15                  20
Ser Trp Val Asn Cys Ser Xaa Xaa Xaa Asp Glu Ile Ile
25                  30                  35
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa
      40                  45                  50
```

Xaa Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Xaa Glu
55 60
Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa
65 70 75
Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
80 85
Ile Leu Xaa Asn Leu Xaa Pro Cys Xaa Pro Xaa Xaa Thr
90 95 100
Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly
105 110 115
Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu
120 125
Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu
130
Ser Leu Ala Ile Phe [SEQ ID NO:129]

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile; Xaa at position 19 is Met, Ala or Ile; Xaa at position 20 is Ile, Pro or Ile; Xaa at position 23 is Ile, Ala or Leu; Xaa at position 25 is Thr or His; Xaa at position 29 is Gln, Arg, Val or Ile; Xaa at position 32 is Leu, Ala, Asn or Arg; Xaa at position 34 is Leu or Ser; Xaa at position 37 is Phe, Pro, or Ser; Xaa at position 38 is Asn or Ala; Xaa at position 42 is Gly, Ala, Ser, Asp or Asn; Xaa at position 45 is Gln, Val, or Met; Xaa at position 46 is Asp or Ser; Xaa at position 49 is Met, Ile, Leu or Asp; Xaa at position 50 is Glu or Asp; Xaa at position 51 is Asn Arg or Ser; Xaa at position 55 is Arg, Leu, or Thr; Xaa at position 56 is Pro or Ser; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn, Val or Pro; Xaa at position 63 is Arg or His; Xaa at position 65 is Val or Ser; Xaa at position 67 is Ser, Asn, His or Gln; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser, Ala or Pro; Xaa at position 79 is Lys, Arg or Ser; Xaa at position 82 is Leu, Glu, Val or Trp; Xaa at position 85 is Leu or Val; Xaa at position 87 is Leu, Ser, Tyr; Xaa at position 88

is Ala or Trp; Xaa at position 91 is Ala or Pro; Xaa at position 93 is Pro or Ser; Xaa at position 95 is His or Thr; Xaa at position 98 is His, Ile, or Thr; Xaa at position 100 is Lys or Arg; Xaa at position 101 is Asp, Ala or Met; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg, Glu or Leu; Xaa at position 112 is Thr or Gln; Xaa at position 116 is Lys, Val, Trp or Ser; Xaa at position 117 is Thr or Ser; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; with the proviso that from four to forty-four of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

14. A polypeptide according to Claim 13 wherein Xaa at position 18 is Ile; Xaa at position 19 is Ala, or Ile; Xaa at position 20 is Pro, or Leu; Xaa at position 23 is Ala, or Leu; Xaa at position 25 is His; Xaa at position 29 is Arg, Val, or Ile; Xaa at position 32 is Ala, Asn or Arg; Xaa at position 34 is Ser; Xaa at position 37 is Pro or Ser; Xaa at position 38 is Ala; Xaa at position 42 is Ala, Ser, Asp, or Asn; and Xaa at position 45 is Val or Met; Xaa at position 46 is Ser.

15. A polypeptide according to Claim 13 wherein Xaa at position 49 is Ile, or Leu, or Asp; Xaa at position 50 is Asp; Xaa at position 51 is Arg or Ser; Xaa at position 55 is Leu or Thr; Xaa at position 56 is Ser; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Val, or Pro; Xaa at position 63 is His; Xaa at position 65 is Ser; Xaa at position 67 is Asn, or His, or Gln; and Xaa at position 69 is Glu.

16. A polypeptide according to Claim 13

wherein Xaa at position 73 is Gly; Xaa at position 76 is Ala, or Pro; Xaa at position 79 is Arg, or Ser; Xaa at position 82 is Gln or Val, or Trp; Xaa at position 85 is Val; Xaa at position 87 is Ser, or Tyr; Xaa at position 88 is Trp; Xaa at position 91 is Pro; Xaa at position 93 is Ser; Xaa at position 95 is Thr; Xaa at position 98 is Ile or Thr; Xaa at position 100 is Arg; Xaa at position 101 is Ala, or Met; and Xaa at position 105 is Glu.

17. A polypeptide according to Claim 13 wherein Xaa at position 109 is Glu, or Leu; Xaa at position 112 is Gln; Xaa at position 116 is Val, or Trp, or Ser; Xaa at position 117 is Ser; Xaa at position 120 is Glu or His; and Xaa at position 123 is Glu.

18. A polypeptide according to Claim 13 wherein Xaa at position 18 is Ile; Xaa at position 19 is Ala, or Ile; Xaa at position 20 is Pro, or Leu; Xaa at position 23 is Ala, or Leu; Xaa at position 25 is His; Xaa at position 29 is Arg or Val, or Ile; Xaa at position 32 is Ala or Asn, or Arg; Xaa at position 34 is Ser; Xaa at position 37 is Pro or Ser; Xaa at position 38 is Ala; Xaa at position 42 is Ala or Ser, Asp or Asn; Xaa at position 45 is Val or Met; Xaa at position 46 is Ser; Xaa at position 49 is Ile, or Leu, or Asp; Xaa at position 50 is Asp; Xaa at position 51 is Arg, or Ser; Xaa at position 55 is Leu or Thr; Xaa at position 56 is Ser; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Val, or Pro; Xaa at position 63 is His; Xaa at position 65 is Ser; Xaa at position 67 is Asn, or His, or Gln; and Xaa at position 69 is Glu.

19. A polypeptide according to Claim 13 wherein Xaa at position 73 is Gly; Xaa at position 76 is Ala, or Pro; Xaa at position 79 is Arg, or Ser; Xaa at position 82 is Gln or Val, or Trp; Xaa at position 85 is Val; Xaa at position 87 is Ser, or Tyr; Xaa at position 88 is Trp; Xaa at position 91 is Pro; Xaa at position 93 is Ser; Xaa at position 95 is Thr; Xaa at position 98 is Ile or Thr; Xaa at position 100 is Arg; Xaa at position 101 is Ala, or Met; Xaa at position 105 is Glu; Xaa at position 109 is Glu, or Leu; Xaa at position 112 is Gln; Xaa at position 116 is Val, or Trp, or Ser; Xaa at position 117 is Ser; Xaa at position 120 is Glu or His; and Xaa at position 123 is Glu.

20. A polypeptide of the formula

1 5 10

$(Met_m\text{-}Ala_n)_p$-Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa Ile

15 20

Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa

25 30 35

Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu Xaa Glu

40 45

Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa

50 55 60

Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa

65 70 75

Ile Leu Xaa Asn Xaa Xaa Pro Cys Xaa Pro Xaa Ala Thr

80 85

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly

90 95 100

Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu

105 110

Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln [SEQ ID NO:130]

wherein m is 0 or 1; n is 0 or 1; p is 0 or 1; Xaa at position 4 is Asn or Ile; Xaa at position 5 is Met, Ala or Ile: Xaa at position 6 is Ile, Pro or Leu; Xaa at position 9 is Ile, Ala or Leu; Xaa at position 11 is Thr or His; Xaa at position 15 is Gln, Arg, Val or Ile; Xaa at position 18 is Leu, Ala, Asn or Arg; Xaa at position 20 is Leu or Ser; Xaa at position 23 is Phe, Pro, or Ser; Xaa at position 24 is Asn or Ala; Xaa at position 28 is Gly, Ala, Ser, Asp or Asn; Xaa at position 31 is Gln, Val, or Met; Xaa at position 32 is Asp or Ser; Xaa at position 35 is Met, Ile or Asp; Xaa at position 36 is Glu or Asp; Xaa at position 37 is Asn, Arg or Ser; Xaa at position 41 is Arg, Leu, or Thr; Xaa at position 42 is Pro or Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Asn, Val

or Pro; Xaa at position 49 is Arg or His; Xaa at position 51 is Val or Ser; Xaa at position 53 is Ser, Asn, His or Gln; Xaa at position 55 is Gln or Glu; Xaa at position 59 is Ala or Gly; Xaa at position 62 is Ser, Ala or Pro; Xaa at position 65 is Lys, Arg or Ser; Xaa at position 67 is Leu, Glu, or Val; Xaa at position 68 is Leu, Glu, Val or Trp; Xaa at position 71 is Leu or Val; Xaa at position 73 is Leu, Ser or Tyr; Xaa at position 74 is Ala or Trp; Xaa at position 77 is Ala or Pro; Xaa at position 79 is Pro or Ser; Xaa at position 81 is His or Thr; Xaa at position 84 is His, Ile, or Thr; Xaa at position 86 is Lys or Arg; Xaa at position 87 is Asp, Ala or Met; Xaa at position 91 is Asn or Glu; Xaa at position 95 is Arg, Glu, Leu; Xaa at position 98 Thr or Gln; Xaa at position 102 is Lys, Val, Trp or Ser; Xaa at position 103 is Thr or Ser; Xaa at position 106 is Asn, Gln, or His; Xaa at position 109 is Ala or Glu; with the proviso that from four to forty-four of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

21. A polypeptide according to Claim 20 wherein Xaa at position 4 is Ile; Xaa at position 5 is Ala, or Ile; Xaa at position 6 is Pro, or Leu; Xaa at position 9 is Ala, or Leu; Xaa at position 11 is His; Xaa at position 15 is Arg or Val, or Ile; Xaa at position 18 is Ala or Asn, or Arg; Xaa at position 20 is Ser; Xaa at position 23 is Pro or Ser; Xaa at position 24 is Ala; Xaa at position 28 is Ala or Ser, or Asp, or Asn; Xaa at position 31 is Val or Met; and Xaa at position 32 is Ser.

22. A polypeptide according to Claim 20 wherein Xaa at position 35 is Ile, or Leu, or Asp; Xaa at position 36 is Asp; Xaa at position 37 is Arg, or Ser; Xaa at position 41 is Leu or Thr; Xaa at position 42 is

Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Val, or Pro; Xaa at position 49 is His; Xaa at position 51 is Ser; Xaa at position 53 is Asn, or His, or Gln; and Xaa at position 55 is Glu.

23. A polypeptide according to Claim 20 wherein Xaa at position 59 is Gly; Xaa at position 62 is Ala, or Pro; Xaa at position 65 is Arg, or Ser; Xaa at position 67 is Gln or Val; Xaa at position 68 is Glu, or Val, or Trp; Xaa at position 71 is Val; Xaa at position 73 is Ser, or Tyr; Xaa at position 74 is Trp; Xaa at position 77 is Pro; Xaa at position 79 is Ser; Xaa at position 81 is Thr; Xaa at position 84 is Ile or Thr; Xaa at position 86 is Arg; Xaa at position 87 is Ala, or Met; and Xaa at position 91 is Glu.

24. A polypeptide according to Claim 20 wherein Xaa at position 95 is Glu, or Leu; Xaa at position 98 ia Gln; Xaa at position 102 is Val, or Trp, or Ser; Xaa at position 103 is Ser; Xaa at position 106 is Glu or His; and Xaa at position 109 is Glu.

25. A polypeptide according to Claim 20 wherein Xaa at position 4 is Ile; Xaa at position 5 is Ala, or Ile; Xaa at position 6 is Pro, or Leu; Xaa at position 9 is Ala, or Leu; Xaa at position 11 is His; Xaa at position 15 is Arg or Val, or Ile; Xaa at position 18 is Ala or Asn, or Arg; Xaa at position 20 is Ser; Xaa at position 23 is Pro or Ser; Xaa at position 24 is Ala; Xaa at position 28 is Ala or Ser, or Asp, or Asn; Xaa at position 31 is Val or Met; Xaa at position 32 is Ser; Xaa at position 35 is Ile, or Leu, or Asp; Xaa at position 36 is Asp; Xaa at position 37 is Arg, or Ser; Xaa at position 41 is Leu or Thr; Xaa at position 42 is Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Val, or Pro; Xaa at

position 49 is His; Xaa at position 51 is Ser; Xaa at position 53 is Asn, or His, or Gln; and Xaa at position 55 is Glu.

26. A polypeptide according to Claim 20 wherein Xaa at position 59 is Gly; Xaa at position 62 is Ala, or Pro; Xaa at position 65 is Arg, or Ser; Xaa at position 67 is Gln or Val; Xaa at position 68 is Glu, or Val, or Trp; Xaa at position 71 is Val; Xaa at position 73 is Ser, or Tyr; Xaa at position 74 is Trp; Xaa at position 77 is Pro; Xaa at position 79 is Ser; Xaa at position 81 is Thr; Xaa at position 84 is Ile or Thr; Xaa at position 86 is Arg; Xaa at position 87 is Ala, or Met; Xaa at position 91 is Glu; Xaa at position 95 is Glu, or Lue; Xaa at position 98 is Gln; Xaa at position 102 is Val, or Trp, or Ser; Xaa at position 103 is Ser; Xaa at position 106 is Glu or His; and Xaa at position 109 is Glu.

27. A polypeptide according to Claim 20 which is selected from

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
Glu Asp Val Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:66];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys
Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu
Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:67];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys
Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
Glu
Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:68];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu

Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:69];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu
Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:70];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu
Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:71];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly
Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala
Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp
Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:72];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly
Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala
Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp
Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:73];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu
Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:74];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser Leu
Glu His Ala Gln Glu Gln Gln [SEQ ID NO:75];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly
Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala
Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp
Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu
Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:76];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly
Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala
Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp
Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu
Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:77];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu
Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly
Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala

Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly Asp
Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser Leu
Glu His Ala Gln Glu Gln Gln [SEQ ID NO:78];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys
Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu
Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu
Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:79];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys
Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu
Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu
Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:80];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys
Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu
Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu
Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:81];

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:82];

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:83];

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:84];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro

Leu
Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
Gly
Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr
Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:85];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro
Leu
Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
Gly
Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr
Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:86];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu
Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn
Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro
Leu
Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
Gly
Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:87];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:88];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:89];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn

Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn
Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:90];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ala
Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn
Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:91];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu
Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn
Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:92];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:93];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:94];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:95]; and

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:96].

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn

Ala

Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Ser Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 296]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His Leu

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn Asp

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 300]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 301]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala

Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 308]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 309]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 310]

Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys Asn

Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val

Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu

Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala

Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln

Ala Gln Glu Gln Gln [SEQ ID NO.: 315]

Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys Asn

Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro

Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala

Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu

Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala

Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln

Ala Gln Glu Gln Gln [SEQ ID NO.: 316]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His Leu

Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn Ser

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn

Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 318]

28. A pharmaceutical composition for the treatment of hematopoietic cell deficiencies comprising a therapeutically effective amount of a mutant human

interleukin-3 polypeptide selected from the group consisting of a polypeptide of claim 1, a polypeptide of claim 2, a polypeptide of claim 3, a polypeptide of claim 4, a polypeptide of claim 5, a polypeptide of claim 6, a polypeptide of claim 7, a polypeptide of claim 8, a polypeptide of claim 9, a polypeptide of claim 10, a polypeptide of claim 11, a polypeptide of claim 12, a polypeptide of claim 13, a polypeptide of claim 14, a polypeptide of claim 15, a polypeptide of claim 16, a polypeptide of claim 17; a polypeptide of claim 18, a polypeptide of claim 19, a polypeptide of claim 20, a polypeptide of claim 21, a polypeptide of claim 22, a polypeptide of claim 23, a polypeptide of claim 24, a polypeptide of claim 25, a polypeptide of claim 26 and a polypeptide of claim 27, and a pharmaceutically acceptable carrier..

29. A pharmaceutical composition according to Claim 28 for the treatment of hematopoietic cell deficiencies comprising a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88 and a pharmaceutically acceptable carrier.

30. A pharmaceutical composition according to Claim 28 for the treatment of hematopoietic cell deficiencies comprising a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:89 and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition according to Claim 28 for the treatment of hematopoietic cell deficiencies comprising a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:90 and a pharmaceutically

acceptable carrier.

32. A pharmaceutical composition according to Claim 28 for the treatment of hematopoietic cell deficiencies comprising a therapeutically effective amount of a polypeptide selected from the group consisting of

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:66;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:67;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:68;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:69;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:70;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:71;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:72;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:73;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:74;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:75;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:76;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:77;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:78;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:79;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:80;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:81;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:82;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:83;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:84;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:85;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:86;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:87;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:91;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:92;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:93;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:94;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:95;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:96;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:258;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:259;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:260;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:261;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:262;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:263;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:278;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:279;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:314;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:315;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:316;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:264;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:265;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:266;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:267;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:268;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:269;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:270;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:271;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:272;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:273;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:274;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:275;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:276;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:277;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:280;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:281;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:282;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:283;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:284;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:285;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:286;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:287;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:288;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:289;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:299;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:300;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:301;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:302;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:303;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:304;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:305;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:306;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:307;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:308;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:309;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:310;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:311;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:312;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:313;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:314;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:317;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:318;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:319;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:320;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:321;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:322;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:323;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:324;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:325;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:326;

and a pharmaceutically acceptable carrier.

33. A method of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a mutant human interleukin-3 polypeptide selected from the group consisting of a polypeptide of claim 1, a polypeptide of claim 2, a polypeptide of claim 3, a polypeptide of claim 4, a polypeptide of claim 5, a polypeptide of claim 6, a polypeptide of claim 7, a polypeptide of claim 8, a polypeptide of claim 9, a polypeptide of claim 10, a polypeptide of claim 11, a polypeptide of claim 12, a polypeptide of claim 13, a polypeptide of claim 14, a polypeptide of claim 15, a polypeptide of claim 16, a polypeptide of claim 17; a polypeptide of claim 18, a polypeptide of claim 19, a polypeptide of claim 20, a polypeptide of claim 21, a polypeptide of claim 22, a polypeptide of claim 23, a polypeptide of claim 24, a polypeptide of claim 25, a polypeptide of claim 26, a polypeptide of claim 27, to a patient in need of such treatment.

34. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88.

35. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:89.

36. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective

amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:90.

37. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide selected from the group consisting of

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:66;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:67;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:68;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:69;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:70;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:71;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:72;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:73;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:74;

a polypeptide having an amino acid sequence corresponding to

SEQ ID NO:75;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:76;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:77;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:78;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:79;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:80;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:81;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:82;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:83;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:84;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:85;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:86;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:87;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:91;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:92;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:93;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:94;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:95;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:96;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:258;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:259;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:260;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:261;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:262;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:263;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:278;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:279;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:314;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:315;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:316;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:264;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:265;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:266;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:267;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:268;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:269;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:270;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:271;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:272;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:273;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:274;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:275;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:276;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:277;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:280;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:281;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:282;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:283;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:284;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:285;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:286;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:287;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:288;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:289;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:299;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:300;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:301;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:302;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:303;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:304;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:305;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:306;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:307;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:308;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:309;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:310;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:311;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:312;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:313;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:314;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:317;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:318;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:319;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:320;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:321;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:322;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:323;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:324;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:325;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:326;

to a patient in need of such treatment.

38. A recombinant DNA sequence comprising vector DNA and a DNA that encodes a polypeptide selected from the group consisting of a polypeptide of claim 1, a polypeptide of claim 2, a polypeptide of claim 3, a polypeptide of claim 4, a polypeptide of claim 5, a polypeptide of claim 6, a polypeptide of claim 7, a polypeptide of claim 8, a polypeptide of claim 9, a polypeptide of claim 10, a polypeptide of claim 11, a polypeptide of claim 12, a polypeptide of claim 13, a polypeptide of claim 14, a polypeptide of claim 15, a polypeptide of claim 16, a polypeptide of claim 17; a polypeptide of claim 18, a polypeptide of claim 19, a polypeptide of claim 20, a polypeptide of claim 21, a polypeptide of claim 22, a polypeptide of claim 23, a polypeptide of claim 24, a polypeptide of claim 25, a polypeptide of claim 26, or a

polypeptide of claim 27,.

39. A recombinant DNA sequence according to Claim 38 comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:97.

40. A recombinant DNA sequence according to Claim 38 comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:100 or 103.

41. A recombinant DNA sequence according to Claim 38 comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161.

42. A recombinant DNA sequence according to Claim 38 comprising vector DNA and a DNA selected from

a DNA having a nucleotide sequence corresponding to SEQ ID NO:98;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:99;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:101;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:102;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:104;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:105;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:106;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:107;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:108;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:109;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:110;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:111;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:112;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:113;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:114;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:115;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:116;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:117;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:118;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:119;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:120;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:121;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:122;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:123;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:124;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:125;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:126;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:127;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:160;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:161;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:398;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:399;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:346;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:347

a DNA having a nucleotide sequence corresponding to SEQ ID NO:303

a DNA having a nucleotide sequence corresponding to SEQ ID NO:404

a DNA having a nucleotide sequence corresponding to SEQ ID NO:405

a DNA having a nucleotide sequence corresponding to SEQ ID NO:332

a DNA having a nucleotide sequence corresponding to SEQ ID NO:333

a DNA having a nucleotide sequence corresponding to SEQ ID NO:334

a DNA having a nucleotide sequence corresponding to SEQ ID NO:335

a DNA having a nucleotide sequence corresponding to SEQ ID NO:336

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:337

a DNA having a nucleotide sequence corresponding to SEQ ID NO:338

a DNA having a nucleotide sequence corresponding to SEQ ID NO:339

a DNA having a nucleotide sequence corresponding to SEQ ID NO:340

a DNA having a nucleotide sequence corresponding to SEQ ID NO:341

a DNA having a nucleotide sequence corresponding to SEQ ID NO:342

a DNA having a nucleotide sequence corresponding to SEQ ID NO:343

a DNA having a nucleotide sequence corresponding to SEQ ID NO:344

a DNA having a nucleotide sequence corresponding to SEQ ID NO:345

a DNA having a nucleotide sequence corresponding to SEQ ID NO:348

a DNA having a nucleotide sequence corresponding to SEQ ID NO:349

a DNA having a nucleotide sequence corresponding to SEQ ID NO:350

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:352

a DNA having a nucleotide sequence corresponding to SEQ ID NO:353

a DNA having a nucleotide sequence corresponding to SEQ ID NO:354

a DNA having a nucleotide sequence corresponding to SEQ ID NO:355

a DNA having a nucleotide sequence corresponding to SEQ ID NO:356

a DNA having a nucleotide sequence corresponding to SEQ ID NO:357

a DNA having a nucleotide sequence corresponding to SEQ ID NO:358

a DNA having a nucleotide sequence corresponding to SEQ ID NO:359

a DNA having a nucleotide sequence corresponding to SEQ ID NO:360

a DNA having a nucleotide sequence corresponding to SEQ ID NO:361

a DNA having a nucleotide sequence corresponding to SEQ ID NO:362

a DNA having a nucleotide sequence corresponding to SEQ ID NO:363

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:364

a DNA having a nucleotide sequence corresponding to SEQ ID NO:365

a DNA having a nucleotide sequence corresponding to SEQ ID NO:366

a DNA having a nucleotide sequence corresponding to SEQ ID NO:367

a DNA having a nucleotide sequence corresponding to SEQ ID NO:368

a DNA having a nucleotide sequence corresponding to SEQ ID NO:369

a DNA having a nucleotide sequence corresponding to SEQ ID NO:370

a DNA having a nucleotide sequence corresponding to SEQ ID NO:371

a DNA having a nucleotide sequence corresponding to SEQ ID NO:372

a DNA having a nucleotide sequence corresponding to SEQ ID NO:373

a DNA having a nucleotide sequence corresponding to SEQ ID NO:374

a DNA having a nucleotide sequence corresponding to SEQ ID NO:375

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:376

a DNA having a nucleotide sequence corresponding to SEQ ID NO:377

a DNA having a nucleotide sequence corresponding to SEQ ID NO:378

a DNA having a nucleotide sequence corresponding to SEQ ID NO:379

a DNA having a nucleotide sequence corresponding to SEQ ID NO:380

a DNA having a nucleotide sequence corresponding to SEQ ID NO:381

a DNA having a nucleotide sequence corresponding to SEQ ID NO:382

a DNA having a nucleotide sequence corresponding to SEQ ID NO:384

a DNA having a nucleotide sequence corresponding to SEQ ID NO:385

a DNA having a nucleotide sequence corresponding to SEQ ID NO:386

a DNA having a nucleotide sequence corresponding to SEQ ID NO:387

a DNA having a nucleotide sequence corresponding to SEQ ID NO:388

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:389

a DNA having a nucleotide sequence corresponding to SEQ ID NO:390

a DNA having a nucleotide sequence corresponding to SEQ ID NO:391

a DNA having a nucleotide sequence corresponding to SEQ ID NO:392

43. A host cell containing a recombinant DNA sequence of claim 38 and capable of expressing the encoded polypeptide.

44. A host cell of claim 43 containing a recombinant DNA vector comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:97 and capable of expressing the encoded polypeptide.

45. A host cell of claim 43 containing a recombinant DNA vector comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:100 or 103 and capable of expressing the encoded polypeptide.

46. A host cell of claim 43 containing a recombinant DNA vector comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161 and capable of expressing the encoded polypeptide.

47. A method of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant

DNA sequence comprising vector DNA and a DNA sequence of Claim 38 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

48. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:97 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

49. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:100 or 103 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

50. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

51. A vector containing a gene having a DNA sequence selected from the group consisting of:

a DNA having a nucleotide sequence corresponding to SEQ ID NO:97;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:100;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:103;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:160;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:161;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:404;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:405;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:364;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:368;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:369;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:376;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:377;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:378;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:385;

52. A recombinant DNA vector comprising a promoter, a ribosome binding site, and a signal peptide directly linked to a DNA sequence encoding a polypeptide selected from the group consisting of

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88;

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:89; and

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:90;

said vector being capable of directing expression of said mutant human interleukin-3 polypeptide.

53. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD.

54. A recombinant DNA vector according to Claim 51 wherein the ribosome binding site is g10-L.

55. A recombinant DNA vector according to Claim 51 wherein the signal peptide is a lamB signal peptide.

56. A recombinant DNA vector according to Claim 51 wherein the signal peptide is the lamB signal peptide depicted in Figure 8.

57. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD and the ribosome binding site is g10-L.

58. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD, the ribosome binding site is g10-L, and the signal peptide is a lamB signal peptide.

59. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD, the ribosome binding site is g10-L, and the signal peptide is the lamB signal peptide depicted in Figure 8.

60. A recombinant bacterial host which comprises the vector of Claim 51 wherein said host secretes a mutant human interleukin-3 polypeptide selected from the group consisting of

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88;

a polypeptide having an amino acid sequence

corresponding to SEQ ID NO:89; and

a polypeptide having an amino acid sequence corresponding to SEQ ID NO:90.

61. A polypeptide of the formula

1 5 10
(Met)$_m$-Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr

15 20
Ser Trp Val Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile
25 30 35
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa
40 45 50
Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu
55 60
Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg
65 70 75
Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
80 85
Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr
90 95 100
Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly
105 110 115
Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu
120 125
Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu
130
Ser Leu Ala Ile Phe [SEQ ID NO:129]

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile; Xaa at position 25 is Thr or His; Xaa at position 29 is Gln, Arg, or Val; Xaa at position 32 is Leu, Ala, or Asn; Xaa at position 37 is Phe, Pro, or Ser; Xaa at position 42 is Glu, Ala, or Ser; Xaa at position 45 is Gln, Val, or Met; Xaa at position 51 is Asn or Arg; Xaa at position 55 is Arg, Leu, or Thr; Xaa at position 59 is Glu or Leu;

Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn or Val; Xaa at position 67 is Ser, Asn, or His; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser or Ala; Xaa at position 79 is Lys or Arg; Xaa at position 82 is Leu, Glu, or Val; Xaa at position 87 is Leu or Ser; Xaa at position 93 is Pro or Ser; Xaa at position 98 is His, Ile, or Thr; Xaa at position 101 is Asp or Ala; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg or Glu; Xaa at position 116 is Lys or Val; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; with the proviso that from four to twenty-seven of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3 and wherein from 1 to 14 of amino acids 1 to 14 has been deleted from the N-terminus and/or from 1 to 15 of amino acids 119 to 133 has been deleted from the C-terminus of the polypeptide; or a polypeptide having substantially the same structure and substantially the same biological activity.

62. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:160 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

63. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

64. A host cell containing a recombinant DNA vector comprising vector DNA and a DNA sequence selected from the group consisting of:

a DNA having a nucleotide sequence corresponding to SEQ ID NO:160; and

a DNA having a nucleotide sequence corresponding to SEQ ID NO:161;

and capable of expressing the encoded polypeptide.

65. A polypeptide according to Claim 27 which is:

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:89].

```
    1                   5                  10
ATG GCT CCA ATG ACT CAG ACT ACT TCT CTT AAG ACT TCT
Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser

        15                  20                  25
TGG GTT AAC TGC TCT AAC ATG ATC GAT GAA ATT ATA ACA
Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr

                30                  35
CAC TTA AAG CAG CCA CCT TTG CCT TTG CTG GAC TTC AAC
His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn

    40                  45                  50
AAC CTC AAT GGG GAA GAC CAA GAC ATT CTG ATG GAA AAT
Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn

            55                  60
AAC CTT CGA AGG CCA AAC CTG GAG GCA TTC AAC AGG GCT
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala

65                  70                  75
GTC AAG AGT TTA CAG AAT GCA TCA GCA ATT GAG AGC ATT
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile

        80                  85                  90
CTT AAA AAT CTC CTG CCA TGT CTG CCC CTG GCC ACG GCC
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala

                95                  100
GCA CCC ACG CGA CAT CCA ATC CAT ATC AAG GAC GGT GAC
Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp

    105                 110                 115
TGG AAT GAA TTC CGT CGT AAA CTG ACC TTC TAT CTG AAA
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys

            120                 125
ACC TTG GAG AAC GCG CAG GCT CAA CAG ACC ACT CTG TCG
Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu Ser

130
CTA GCG ATC TTT TAA TAA  [SEQ ID NO:144]
Leu Ala Ile Phe END END  [SEQ ID NO:128]
```


FIG. 1



FIG. 2: ClaI to NsiI Replacement Fragment

FIG. 2

SUBSTITUTE SHEET (RULE 26)


NcoI
HpaI
CCATGGCTCCAATGACTCAGACTACTTCTCTTAAGACTTCTTGGGTTAACTGCTCTAACA
GGTACCGAGGTTACTGAGTCTGATGAAGAGAATTCTGAAGAACCCAATTGACGAGATTGT
MetAlaProMetThrGlnThrThrSerLeuLysThrSerTrpValAsnCysSerAsnMet
ClaI
TGATCGATGAAATTATAACACACTTAAAGCAGCCACCTTTGCCTTTGCTGGACTTCAACA
ACTAGCTACTTTAATATTGTGTGAATTTCGTCGGTGGAAACGGAAACGACCTGAAGTTGT
IleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsn
ACCTCAATGGGGAAGACCAAGACATTCTGATGGAAAATAACCTTCGAAGGCCAAACCTGG
TGGAGTTACCCCTTCTGGTTCTGTAAGACTACCTTTTATTGGAAGCTTCCGGTTTGGACC
LeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGlu
NsiI
AGGCATTCAACAGGGCTGTCAAGAGTTTACAGAATGCATCAGCAATTGAGAGCATTCTTA
TCCGTAAGTTGTCCCGACAGTTCTCAAATGTCTTACGTAGTCGTTAACTCTCGTAAGAAT
AlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLys
AAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGCACCCACGCGACATCCAATCCATA
TTTTAGAGGACGGTACAGACGGGGACCGGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTAT
AsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIle
1
61
121
181
241
60
120
180
240
300

FIG. 3


EcoRI
TCAAGGACGGTGACTGGAATGAATTCCGTCGTAAACTGACCTTCTATCTGAAAACCTTGG
301
AGTTCCTGCCACTGACCTTACTTAAGGCAGCATTTGACTGGAAGATAGACTTTTGGAACC
360
LysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGlu
HindIII
NheI
AGAACGCGCAGGCTCAACAGACCACTCTGTCGCTAGCGATCTTTTAATAAGCTT
361
TCTTGCGCGTCCGAGTTGTCTGGTGAGACAGCGATCGCTAGAAAATTATTCGAA
414
AsnAlaGlnAlaGlnGlnThrThrLeuSerLeuAlaIlePheEndEnd

FIG. 4


NheI
BamHI
EcoRI
hIL-3
NcoI
HindIII
pPO518
Amp
Ori
Synthetic
Oligonucleotide
NheI HindIII BamHI
Cleave with NheI and BamHI
Mix with annealed oligonucleotides
Ligate
Transform E. coli JM101 cells
Select for ampicillin resistant colonies
HindIII
NheI
BamHI
EcoRI
hIL-3
NcoI
HindIII
pMON5846
Amp
Ori

FIG. 5


HindIII
NcoI
BglII
BamHI
cat
ori
f1
g10-L
precA
pMON2341
Amp
pBR327
Ori
HindIII
NheI
BamHI
EcoRI
NcoI
HindIII
hIL-3
pMON5846
Amp
Ori
Cleave with NcoI and HindIII Isolate vector fragment
Cleave with NcoI and HindIII Isolate hIL-3 fragment
Mix isolated fragments
Ligate
Transform E. coli JM101 cells
Select ampicillin R colonies
HindIII
NcoI
g10-L
BglII
precA
BamHI
hIL-3
ori
f1
pMON5847
Amp
pBR327
Ori

FIG. 6


HindIII
HpaI
NcoI
ori
f1
hIL-3
1-133
g10-L
precA
pMON5847
Amp
pBR327
Ori
Cleave with NcoI and HpaI.
Klenow fill the NcoI end to
render it blunt.
Ligate the blunt ends.
Transform E. coli JM101
to ampicillin resistance
HindIII
ori
f1
IL-3
15-133
g10-L
precA
pMON5853
Amp
pBR327
Ori

FIG. 7


HindIII
Hpai
NcoI
hIL-3
1-133
ori
f1
g10-L
precA
pMON5847
Amp
pBR327
Ori
Synthetic
Oligonucieotides
NcoI
Hpai
Cleave with NcoI and Hpai.
Mix cleaved plasmid
with oligonucieotides.
Transform E. coli JM101
cells to ampicillin resistance.
HindIII
Hpai
NcoI
IL-3
1-133
ori
f1
g10-L
precA
pMON5854
Amp
pBR327
Ori

FIG. 8

```
   ATGATGATTACTCTGCGCAAACTTCCTCTGGCGGTTGCCGTCGCAGCGGGCGTAATGTCT
1  ------------------------------------------------------------ 60
   TACTACTAATGAGACGCGTTTGAAGGAGACCGCCAACGGCAGCGTCGCCCGCATTACAGA

   MetMetIleThrLeuArgLysLeuProLeuAlaValAlaValAlaAlaGlyValMetSer

         N
         c
         o
         I
   GCTCAGGCCATGGCTAACTGC      [SEQ ID NO: 149]
61 ---------+---------- 81
   CGAGTCCGGTACCGATTGACG      [SEQ ID NO: 150]

   AlaGlnAlaMetAlaAsnCys      [SEQ ID NO: 14]
                    ↑
```

lamB Signal Peptide

FIG. 9



ClaI to NsiI Replacement Fragment (FIG. 2)

Digested with ClaI and NsiI

Ligated fragments

Transformed into JM101



FIG 10


HindIII
EcoRI
NheI
NsiI
PstI
XhoI
EcoRV
ClaI
NcoI
F1 ori
hIL3
MA15-125
Amp
pMON5987
A101
lamB
327 ori
G10L
pAraBad
SalI
Synthetic oligonucleotides
NheRIUP.req [SEQ ID NO:131]
NheRILO.req [SEQ ID NO:132]
Digested with NheI and EcoRI
Ligated fragments
Transformed into JM101
HindIII
EcoRI
NheI
NsiI
PstI
XhoI
EcoRV
ClaI
NcoI
F1 Ori
hIL3
MA15-125
Amp
pMON5988
lamB
327 Ori
G10L
pAraBAD
SalI

FIG. 11


NheI
EcoRI
HindIII
HpaI
NcoI
ori
f1
hIL-3
1-133
g10-L
precA
pMON5854
Amp
pBR327
Ori
Synthetic
Oligonucleotides
EcoRI
HindIII
DNA sequence terminate
hIL-3 coding sequence
after codon 125
Cleave with EcoRI and HindIII.
Mix cleaved vector
with oligonucleotides.
Transform E. coli JM101
cells to ampicillin resistance.
EcoRI
HindIII
HpaI
NcoI
ori
f1
hIL-3
1-125
g10-L
precA
pMON5887
Amp
pBR327
Ori

FIG. 12


5'CATGGCTAACTGCTCTAACATGAT 3'
SEQ ID NO:151
3' CGATTGACGAGATTGTACTAGC 5'
SEQ ID NO:152
Annealed oligonucleotides
Ligated fragments
Transformed into JM101
Digested with NcoI andClaI
Gel purified 4263 bp fragment
EcoRI
HindIII
EcoRI
F1 Ori
hIL3 1-125
Amp
pMON8455
ClaI
NcoI
lamB
327 Ori
G10L
pAraBAD
SalI
EcoRI
HindIII
EcoRI
F1 Ori
hIL3 15-125
Amp
pMON8457
ClaI
NcoI
lamB
327 Ori
G10L
pAraBAD
SalI

FIG. 13


HindIII
EcoRI
F1 Ori
Amp
pMON6525
NcoI
G10L
327 Ori
pRecA
SalI
EcoRI
HindIII
EcoRI
F1 Ori
hIL3
15-125
Amp
pMON6457
NcoI
lamB
327 Ori
G10L
pAraBAD
SalI
Digested with SalI and HindIII
Gel purified 3172 bp fragment
Digested with SalI and HindIII
Gel purified 1117 bp fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
hIL3
15-125
Amp
pMON6458
NcoI
lamB
327 Ori
G10L
pAraBAD
SalI

FIG. 14



OLIGO #17 [SEQ ID NO:31]

AATTCGAACCATATGTCAGA

GCTTGGTATACAGTCTTCGA

OLIGO #18 [SEQ ID NO:32]

Annealed complementary oligonucleotide pair

Digested pMON5988 with HindIII and EcoRI and isolated the 4225 base pair fragment

Ligated annealed oligonucleotide pair and 4225 base pair HindIII/EcoRI fragment from pMON5988

Transformed into JM101



FIG. 15


HindIII
EcoRI
NsiI
EcoRV
NcoI
SalI
pAraBAD
lamB
G10L
hIL-3
15-125
Δ106-125
F1 Ori
327 Ori
Amp
pMON13359
Digested pMON13359 with HindIII and EcoRI and isolated the 4225 base pair fragment
Ligated annealed oligonucleotide pairs and 4225 base pair HindIII/EcoRI fragment from pMON13359
Transformed into JM101
Annealed complementary oligonucleotide pairs
OLIGO #45 [SEQ ID NO:59]
OLIGO #46 [SEQ ID NO:60]
OLIGO #49 [SEQ ID NO:63]
5' TCCCTTGAGCAAGCGCAGGAACAACAGTAATA 3'
3' TTCGCGTCCTTGTTGTCATTATTCGA 5'
OLIGO #50 [SEQ ID NO:64]

FIG. 16


HindIII
EcoRI
NsiI
EcoRV
NcoI
SalI
F1 Ori
hIL-3
15-125
Amp
pMON13352
lamB
G10L
327 Ori
pAraBAD
pMON13350
Digested pMON13352 with NsiI and EcoRI and isolated the 4178 base pair fragment
Digested pMON13350 with NsiI and EcoRI and isolated the 111 base pair fragment
Ligated fragments
Transformed into JM101
pMON13360

FIG. 17


HindIII
EcoRI
NsiI
EcoRV
NcoI
SalI
F1 Ori
hIL-3
15-125
Amp
pMON13344
lamB
G10L
327 Ori
pAraBAD
pMON13348
Digested pMON13344 with NsiI and EcoRV and isolated the 4218 base pair fragment
Digested pMON13348 with NsiI and EcoRV and isolated the 71 base pair fragment
Ligated fragments
Transformed into JM101
pMON13363

FIG. 18


HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13345
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
Digested pMON13345 with NsiI and EcoRV and isolated the 4218 base pair fragment
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13349
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
Digested pMON13349 with NsiI and EcoRV and isolated the 71 base pair fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13364
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI

FIG. 19


HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13346
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13347
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
Digested pMON13346 with NsiI and EcoRV and isolated the 4218 base pair fragment
Digested pMON13347 with NsiI and EcoRV and isolated the 71 base pair fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13365
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI

FIG. 20


HindIII
F1 Ori
CAT
Amp
pMON2341
NcoI
G10L
327 Ori
pRecA
SalI
HindIII
EcoRI
NsiI
F1 Ori
hIL-3
15-125
EcoRV
Amp
pMON13360
lamB
NcoI
G10L
327 Ori
pAraBAD
SalI
Digested pMON2341 with NcoI and HindIII and isolated the resulting 3619 base pair fragment
Digested pMON13360 with NsiI and HindIII and isolated the resulting 175 base pair fragment
Digested pMON13363 with NcoI and NsiI and isolated the resulting 170 base pair fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13363
lamB
NcoI
G10L
327 Ori
pAraBAD
SalI
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13287
NcoI
G10L
pRecA
327 Ori
SalI

FIG. 21


HindIII
F1 Ori
CAT
Amp
pMON2341
NcoI
G10L
327 Ori
pRecA
SalI
HindIII
EcoRI
NsiI
F1 Ori
hIL-3
15-125
EcoRV
Amp
pMON13360
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
Digested pMON2341 with NcoI and HindIII and isolated the resulting 3619 base pair fragment
Digested pMON13360 with NsiI and HindIII and isolated the resulting 175 base pair fragment
Digested pMON13364 with NcoI and NsiI and isolated the resulting 170 base pair fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13364
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13288
NcoI
G10L
pRecA
327 Ori
SalI

FIG. 22


HindIII
F1 Ori
CAT
Amp
pMON2341
NcoI
G10L
327 Ori
pRecA
SalI
HindIII
EcoRI
NsiI
F1 Ori
hIL-3
15-125
EcoRV
Amp
pMON13360
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
Digested pMON2341 with NcoI and HindIII and isolated the resulting 3619 base pair fragment
Digested pMON13360 with NsiI and HindIII and isolated the resulting 175 base pair fragment
Digested pMON13365 with NcoI and NsiI and isolated the resulting 170 base pair fragment
Ligated fragments
Transformed into JM101
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13365
NcoI
lamB
G10L
327 Ori
pAraBAD
SalI
HindIII
EcoRI
F1 Ori
NsiI
hIL-3
15-125
EcoRV
Amp
pMON13289
NcoI
G10L
327 Ori
pRecA
SalI

FIG. 23

24/25


HindIII
T7 term
bST
Amp
pMON5585
G10L
NcoI
327 Ori
pRecA
SalI
1. Digested pMON5585 with NcoI and HindIII
2. Isolated 3273 base pair vector fragment
3. Ligated fragments
4. Transformed
HindIII
pST
pMON3267
NcoI
1. Digested pMON3267 with NcoI and HindIII
2. Isolated 580 base pair fragment containing the pST gene
SspI
HindIII
T7 term
pST
Amp
pMON5647
G10L
NcoI
327 Ori
DraI
pRecA
SalI
pMON710
EcoRV
Spec
HincII
5. Digested pMON5647 with DraI and SspI
6. Isolated 2916 base pair vector fragment
7. Ligated fragments
8. Transformed
5. Digested pMON710 with HincII and EcoRV
6. Isolated 940 base pair fragment containing the streptomycin adenyiyitransferase gene
HindIII
T7 term
pST
Spec
pMON5723
NcoI
G10L
pRecA
327 Ori
SalI

FIG. 24


HindIII
1. Site-directed mutagenesis to remove NsiI site using oligo #54 (SEQ ID NO:158)
NsiI
EcoRV
NcoI
SalI
f1 Ori
hIL-3
Amp
pMON13473
G10L
327 Ori
pRecA
2. Site-directed mutagenesis to remove EcoRV site using oligo #55 (SEQ ID NO:159)
pMON14058
3. Digested pMON14058 with NcoI and HindIII
4. Isolated 345 base pair NcoI.HindIII fragment containing the hIL-3 gene
5. Ligated fragments
6. Transformed
T7 term
pST
Spec
pMON5723
3. Digested pMON5723 with NcoI and HindIII
4. Isolated 3278 base pair NcoI.HindIII vector fragment
pMON13438

FIG. 25